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Abstract
Understanding the properties of protein-protein interactions (PPIs) is necessary to
deconvolute the processes inside living organisms. As such, research in this regard
has significant implications for gaining insight into cancers and other diseases.
Once understood, drugs can be designed to target these diseases. In these chapters
we focus on the network of interactions of WD40 repeat protein 5 (WDR5), a
known hub protein. Several of its interactions are significant for regulation of
histone methylation and consequently epigenetic regulation. These interacting
partners include the SET1 family of proteins and retinoblastoma binding protein-5
(RbBP5). In this work we used multiple ensemble measurement based bulk-phase
techniques to

characterize WDR5’s interactions.

We utilized biolayer

interferometry (BLI) and surface plasmon resonance (SPR) to calculate the
association and dissociation rate constants. Furthermore, we used fluorescence
polarization (FP) to calculate the equilibrium dissociation constants. After
characterizing these PPIs under wild-type conditions we quantified the impact of
key WDR5 cancer mutants on these interactions. These mutants can impact
downstream gene expression, which ultimately controls various cellular processes.
Therefore, evaluating their modification of WDR5’s kinetics is key to
understanding their potential impact on tumor development. Additionally, by using
different tether conditions, we have explored the role of surface-tethering in
modulating the kinetics of these PPIs. The work shows the impact of tethering on
tethered ligand-receptor complexes that are common in biological signaling and

cellular adhesion. Moreover, it shows how surface-tethering can be used to
modulate a typical PPI. We also characterized the role of the N-terminal
intrinsically disordered region (IDR) of WDR5. Our work explores the selfassociation behavior catalyzed by this IDR and the potential ramifications of this
self-association on WDR5’s role inside the nucleus.
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Chapter 1: Introduction
Protein-protein interactions (PPIs) form the backbone of various cellular processes.
Understanding these interactions is key to parsing and disentangling the complex
mechanisms inside living organisms. PPIs have a range of properties that can be
studied through different techniques. The focus of my thesis is on the binding
affinities and kinetics of sets of PPIs obtained through well-established ensemble
measurement based bulk-phase techniques. In this work, we explored a known hubprotein, and its network of interactions with a range of different binding partners.

1.1 Protein System
1.1.1

WDR5

WD40 repeat protein 5 (WDR5) is a nuclear hub whose interactions have
significant implications for epigenetic regulations.1-8 Moreover, WDR5 is
overexpressed under various oncogenic conditions and its upregulation catalyzes
cancer development.9 Its repertoire of known binding partners includes the SET1
family, retinoblastoma binding protein-5 (RbBP5), MYC, 3-phosphoinositidedependent protein kinase 1 (PDPK1) as well as a host of different proteins10-14.
This 334 residue protein is formed by a seven-bladed, WD40 repeat-based β
propeller structure, surrounding a central cavity. Its interactions are regulated
through two known sites: WDR5 interaction (Win) site and WDR5 binding motif
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(WBM) site (fig.1).15 Win site interactions require the presence of the Win motif,
shown in Table 1, on the binding partner. Additionally, this motif has a crucial
Arginine residue, conserved across all Win site binders, that inserts into the central
cavity and forms several stabilizing hydrogen bonds and cation-pi interactions.10,11
This motif also displays interactions with the surface residues around the cavity.
On the other hand, WBM site interactions require the presence of the WBM motif
on the binding partner. For example, RbBP5 has the WBM motif EEVDVT.
Bindings to this site consist of primarily surface interactions dominated by
electrostatic and hydrophobic contributions13,15.

WBM site
180⁰

22 Å

19 Å

42 Å

14
Å
17
Å

Win site

42 Å

Figure 1: WDR5 binding sites. Surface-representation cartoon of the Win and
WBM binding sites of WDR5. Orientations of WDR5 in the two cartoon are 180
with respect to each other. Representations were made using pdb entry 4ERY.11
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1.1.2 SET1 Proteins
The SET1 family of proteins’ interactions with WDR5, through the Win site, have
regulatory implications for histone 3 lysine (H3K4) mono-, di- and tri-methylation.
These proteins have the evolutionarily conserved SET domain which is required
for lysine methylation.29 There are 6 known SET1 family members: MLL1, MLL2,
MLL3, MLL4, SETd1A and SETd1B.16-18 Because these proteins are hundreds of
kDa in size it is not feasible to express and purify them. Therefore, for in-vitro
studies of the SET1 family, only regions of interest are produced and employed.
Particularly, for my work, I used 14 residues sequences, containing the Win motif,
from each SET1 protein to create peptides that emulate the interaction of these
proteins with WDR5.11 Previous work has shown that these peptides are sufficient
to model the interactions of larger regions of these proteins with WDR5. The design
of the peptides is shown in the table below.10

SET1Win Peptide Sequence
MLL1
MLL2
MLL3
MLL4

3758-3771

L N P H G S A R A E V H L S*

5333-5346

I N P T G C A R S E P K I L

4703-4716

V N P T G C A R S E P K M S

2504-2517

L N P H G A A R A E V Y L S*

1488-1501

E H Q T G S A R S E G Y Y P

1698-1711

E H V T G C A R S E G F Y T

SETd1A
SETd1B

Table 1: Design of the SET1Win peptides. The table of peptide sequences
chosen to represent the different SET1 proteins. The part of the sequence in blue
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represents the Win motif on each protein.*For MLL1 and MLL4 the last residues
was changes from Arginine to Serine to prevent any artifacts from the C-terminus
free Arginine inserting into the Win site cavity.

The extent of the impact of SET1-WDR5 interactions on H3K4 methylation has
been studied before. The MLL1-WDR5 interaction is crucial for the assembly of
the MLL1 complex with RbBP5 and ASH2L and therefore for the methylation
behavior of this complex. On the other hand, the MLL3 complex with RbBP5 and
ASH2L is unaffected by the lack of WDR5 or the inhibition of the Win site. The
peptides.18,27 SET1 proteins are also seen frequently mutated in certain cancers, for
example, MLL3 is one of the top 10 proteins seen mutated in breast cancers.30
Therefore, studying their interactions can help us disentangle the different
contributions to those cancers.

1.1.3 RbBP5
RbBP5 is a member of the SET1 family core complex, along with WDR5, ASH2L
and DPY-30.16 It is a 538 residue protein that interacts with WDR5 through the
WBM site13. RbBP5 is an integral part of the complex, and its presence has been
established to be crucial to the methylation function of the SET1 proteins.18 The
RbBP5-ASH2L hetero-dimer is an essential sub-unit that allows for the SET1
complex to come together.28
This is one of the interactions stabilizing the SET1 complex and consequently
important for their function.13,15,18 Therefore, studying the RbBP5-WDR5

4

interaction allows us to better understand the assembly and function of the SET1
complexes.
1.2 Theoretical Overview
All protein-protein interactions can be broken down into association rates and
dissociation rates. A simple 1:1 binding can be represented as follows:
𝑘on

𝐴+𝐵 →
𝐴𝐵 →

𝑘off

𝐴𝐵

(1)

𝐴+𝐵

(2)

Here A and B represent the binding partners while AB represents their complex.1921

The first equation shows the forward reaction which is controlled by the

association rate constant kon. The second equation represents the corresponding
reverse reaction controlled by the dissociation rate constant koff. These constants
are collectively known as the kinetics of the interaction. Using the notation for
concentrations, we see that the rate of complex formation is given by:
𝑑[𝐴𝐵]
𝑑𝑡

= 𝑘on [𝐴][𝐵] − 𝑘off [𝐴𝐵]

(3)

At equilibrium the forward and backward rates are equal; the rate of complex
formation is 0. This gives us:

𝑘on [𝐴][𝐵] = 𝑘off [𝐴𝐵]

(4)

Some rearrangement here can give us the equilibrium dissociation constant, KD as
shown below:
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𝐾𝐷 =

𝑘off
𝑘on

=

[𝐴][𝐵]

(5)

[𝐴𝐵]

The derivation shows that we can obtain the KD by taking a ratio of the dissociation
rate constant and the association rate constant.19 KD can be used as a measure of the
strength of the interaction. The smaller the value, the stronger the interaction.

1.3 Bulk-phase Techniques
There are several well established bulk-phase techniques that are used, by academic
labs and pharmaceutical companies alike, to characterize PPIs. All techniques have
their own advantages and disadvantages. This work uses biolayer interferometry
(BLI), surface plasmon resonance (SPR) and fluorescence polarization (FP). BLI
and SPR allow the characterization of kinetics while FP directly obtains the
equilibrium dissociation constant.

1.3.1 Biolayer Interferometry
BLI is an optics based sensing method. It uses the interference of light to quantify
the protein bound to a biosensor. White light passes through the sensor and gets
reflected by two different interfaces. The first interface is a part of the sensor while
the second interface is formed by the bound molecules. The interference of these
two reflected lights gives us an absorbance spectrum. This spectrum experiences a
shift when more molecules bind to the sensor surface and plotting this shift against
time gives us a BLI sensorgram.22
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Figure 2: A BLI sensorgram. This BLI sensorgram shows us the association and
dissociation phases of an interaction.

For a simple 1:1 binding, the BLI association and dissociation curves look like
those shown in fig. 2. To see how these results can be analyzed, we can look at the
differential equation underlying the process. The response (R) seen by the biosensor
is directly proportional to the amount of complex and the maximum R possible
(Rmax). If B is the immobilized ligand, then we can say that Rmax is directly
proportional to the concentration of B. This simplification gives us:
𝑑𝑅
𝑑𝑡

= 𝑘on [𝐴](𝑅max − 𝑅) − 𝑘off 𝑅

(6)

.23 For the association and dissociation phases we get the analytical solutions:

𝑅 = (𝑅max − 𝑅0 )𝑒 −(𝑘on[𝐴]+𝑘off )𝑡 + 𝑅0

(7)

𝑅 = (𝑅max − 𝑅0 )𝑒 −𝑘off 𝑡 + 𝑅0

(8)
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. Here R0 is the response seen after B is immobilized onto the surface but no
complex has formed. Fitting the BLI sensorgrams with these equations gives us the
association and dissociation rates.

1.3.2 Surface Plasmon Resonance
SPR is another technique for measuring association and dissociation rates. It is also
an optical technique however its measurement principle is based on the SPR angle
of reflected light. In this case, an incident light is bounced off a sensor chip and the
SPR angle is measured. Presence of proteins on the other side chip shifts the critical
angle. This shift in the SPR angle when plotted against time gives us a SPR
sensorgram.24
The data obtained from SPR is very similar to that obtained from the BLI and is
analyzed the same way. It can provide kinetics of an interaction which can then be
used to calculate the equilibrium dissociation constant as well.22,23

1.3.3 Steady-state Fluorescence Polarization
Steady-state Fluorescence Polarization (FP) can be used to measure the KD of an
interaction. The method looks at the polarization of light emitted by a rotating
fluorophore-labelled ligand after excitation. The anisotropy, r, of the emitted light
is calculated using the following equation.

𝑟=

𝐼|| −𝐺𝐼⊥

(9)

𝐼|| +𝐺2𝐼⊥
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Here 𝐼|| represents the intensity of the emitted light parallel to the polarization of
the light used for excitation, 𝐼⊥ represents the intensity of the light perpendicular to
the polarization and G is a calibration factor.19,25 When the ligand binds to an
analyte, the rotational rate slows down and it increases the anisotropy of the emitted
light. By mapping out the anisotropy values of the ligand population when exposed
to a range of concentrations of analyte we can calculate the fractional occupancy α
of the ligand. This number represent the proportion of the ligand that is bound to
the analyte. At α equals 0.5, half the ligand population is bound, and the
corresponding analyte concentration gives us the KD of the interaction.26

1.4 Thesis Outline
WDR5’s interactions with other binding partners have been studied before. While
previous studies have focused on the mechanisms of the interaction using crystal
structures and binding affinities of the interactions using ITC or FP, a thorough
exploration of the kinetics of these interactions has not yet been performed. This
gap in knowledge is what we sought to fill with this work.
In chapter 2, we look at the kinetics of wild-type WDR5’s interaction with SET1
proteins. Using BLI and SPR, we examined these PPIs and looked at the
contributions of the association and dissociation rates towards the strengths of the
interactions. Additionally, for further validation we obtained KD values for these
interactions using FP. These values were then compared to those KD values
indirectly calculated from the kinetics obtained through BLI and SPR. Our work
allowed us to look at the impact of restrictions on these interactions. Ranging from
9

most restricted for the BLI to least restricted for the FP. Furthermore, having
multiple bulk-phase methods allows us to account for any biases introduced from
one. The agreement of our results across multiple techniques strengthens our
conclusions.
In chapter 3, we dive into deviations from wild-type behavior of WDR5 induced by
oncogenic mutations. We looked at the mutations in WDR5 seen in tumors and
quantified the impact of those mutations on WDR5-SET1 interactions. First, we
used computational clustering techniques to identify a region of interest. Then we
selectively isolated mutations in that region for further in vitro study. These WDR5
mutants were expressed and purified. The kinetics of their interactions with SET1
were then studied using BLI. Not only did we measure the impact of these
mutations on the strengths of the interactions, but we were also able to break down
the impact in terms of effects on association and dissociation rates. Moreover, by
extracting KD via FP, we were able to validate our findings and perform an accurate
determination of the impact of the oncogenic mutations. These results allow us to
understand the possible consequences of the mutations on H3K4 methylation.
In chapter 4, we look at the effect of surface tethering on PPIs. Surface-tethered
ligand-receptor complexes are important elements in biological signaling and
adhesion. We explored the impact of tethers, of different lengths, on the kinetics of
different PPIs. Our work with WDR5 (Wild-type and mutants) and SET1 proteins
gave us a range of PPIs with varying binding strengths. Leveraging that, we
observed these interactions under short-tether, long-tether, and no-tether
conditions. For the design of this study, the SET1Win peptides were tethered.
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Moreover, we used WDR5 wild-type and 3 mutants to establish the impact of the
tethers. Additionally, we used the interactions of a 4th mutant to test how effectively
we can predict the effect of the tether. The work shows that this tethering can
separately modulate the association and dissociation rates of the interactions.
In chapter 5, we shift focus on to the WBM site of WDR5. We looked at the
interaction of WDR5 with RbBP5 through WBM site. However, in this case we
noticed a deviation from expected behavior. Through a hypothesis-based design
approach we explored likely possibilities and identified that this divergence was
caused by the N-terminal intrinsically disordered region (IDR) of WDR5.
Additionally, using orthogonal experiments, we further confirmed the role of this
IDR in affecting our measurements of WDR5-RbBP5 binding. We discuss the
relevance of our results for future explorations of WBM interactions as well as for
understanding the role of WDR5 inside the cell.
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2.1 Abstract
Recent advances in quantitative proteomics show that WD40 proteins play a pivotal
role in numerous cellular networks. Yet, they have been fairly unexplored and their
physical associations with other proteins are ambiguous. A quantitative
understanding of these interactions has wide-ranging significance. WD40 repeat
protein 5 (WDR5) interacts with all members of human SET1/MLL
methyltransferases, which regulate methylation of the histone 3 lysine 4 (H3K4).
Here, using real-time binding measurements in a high-throughput setting, we
identified the kinetic fingerprint of transient associations between WDR5 and 14residue WDR5 interaction (Win) motif peptides of each SET1 protein (SET1Win).
Our results reveal that the high-affinity WDR5-SET1Win interactions feature slow
association kinetics. This finding is likely due to the requirement of SET1Win to
insert into the narrow WDR5 cavity, also named the Win binding site. Furthermore,
our explorations indicate fairly slow dissociation kinetics. This conclusion is in
accordance with the primary role of WDR5 in maintaining the functional integrity
of a large multisubunit complex, which regulates the histone methylation. Because
the Win binding site is considered a key therapeutic target, the immediate outcomes
of this study could form the basis for accelerated developments in medical
biotechnology.
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2.2 Introduction
WD40 repeat protein 5 (WDR5) is a conserved chromatin-associated protein
that is involvedin a number of transient protein-protein interactions [1]. However,
WDR5 is notoriously known for its regulatory role in multisubunit epigenetic
complexes, such as Suppressor of Variegation, Enhancer of Zeste, and Trithorax 1
(SET1) lysine methyltransferases (KMT) of histones [2-8]. There are six SET1
family members in humans: MLL1, MLL2, MLL3, MLL4, SETd1A, and SETd1B.
Each member forms a large multisubunit complex with functions that appear to
have diverged in target gene localization and product specificity. However, features
common among the complexes are a C-terminal catalytic SET domain that is
regulated by interaction with a conserved subcomplex consisting of WDR5,
retinoblastoma binding protein-5 (RbBP5), absent-small-homeotic-2-like protein
(Ash2L), and dumpy-30 (DPY-30) (WRAD2) [7, 9-20]. WDR5 functions to bridge
the interaction between the SET domain and other WRAD2 subunits by the
recognition of an evolutionarily conserved WDR5-interaction (Win) motif found in
all SET1 family members [21-25]. Formation of this core complex is required for
optimal methyltransferase activity [9, 11, 26]. Therefore, small molecules targeting
the Win motif-WDR5 protein-protein interaction show promise as anticancer
therapeutic candidates.

Interestingly, recent studies have revealed that WDR5 is involved in numerous
interactions with other proteins [27-29], including the transcription factor MYC
oncoprotein [30-35], 3- phosphoinositide-dependent protein kinase 1 (PDPK1)
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[36], and interacting partners involved in phosphatidylinositol 3-kinase (PI3K)
signaling [36]. Moreover, WDR5 is implicated in nongenomic activities, such as
regulatory mechanisms of cellular shape, polarity, and migration [37, 38].
Therefore, WDR5 is a multitasking protein with diverse roles in cellular processes
[36, 39, 40]. Its highly conserved sequence across multiple organisms suggests the
fundamental significance of its multiple roles [40].

An essential structural archetype of WDR5 is its internal cavity that hosts a
high-affinity binding pocket for an evolutionarily conserved Arg-containing
peptide segment of the six SET1 proteins [21-23]. Interestingly, this binding cavity
of WDR5, here named the Win binding site, is the same [21, 23] as that previously
suggested to bind histone H3 [41-46]. Yet, the WDR5-SET1 interaction is required
for the stability and functional operation of the C-terminal catalytic SET domain
[11, 21, 22]. Moreover, it has only recently been identified that the Win binding
site is implicated in transient protein-protein interactions with dozens of proteins,
including those involved in PI3K signaling [36]. Given that WDR5 is
overexpressed under various oncogenic conditions [47-49], the Win binding site
has become a key therapeutic target for different cancers [24, 25, 50-59]. Therefore,
a better mechanistic and quantitative understanding of the interactions of the Win
binding site with other Win motif partners has fundamental and clinical significance
[60-64].

Several research groups have previously examined interactions of WDR5
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protein with Win motif SET1 (SET1Win) peptides using a variety of approaches,
such as analytical ultracentrifugation (AUC) [22], isothermal titration calorimetry
(ITC) [21, 24, 65], surface plasmon resonance (SPR) [23], and X-ray
crystallography [21, 23, 24, 65]. These explorations have confirmed the high
affinity of the Win binding site for different Win motif interaction partners [24, 65].
In this study, we determined the kinetic fingerprint and affinities of these
interactions using high-throughput optical and fluorescence approaches, which
included biolayer interferometry (BLI), SPR, and steady-state fluorescence
polarization (state-state FP).
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Figure 1: Structure of the binary WDR5-MLL1Win complex. (A) The insertion
of MLL1Win into the WDR5 cavity is shown from the top. (B) The same interaction
is shown fromthe side. These graphic representations were made using the pdb code
4ESG.63
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Table 1: Alignment of the amino acid sequence of SET1Win motifs.
Peptide

P-7 P-6 P-5 P-4 P-3 P-2 P-1 P0 P1 P2 P3 P4 P5 P6 Charge

MLL1Win: MLL13758-3771

L N P

H G S A R A E V H L S*

0

MLL2Win: MLL25333-5346

I N P

T G C A R S E P K I L

+1

MLL3Win: MLL34703-4716

V N P

T G C A R S E P K M S

+1

MLL4Win: MLL42504-2517

L N P

H G A A R A E V Y L S*

0

SETd1AWin: SETd1A1488-1501

E H Q

T G S A R S E G Y Y P

-1

SETd1BWin: SETd1B1698-1711

E H V

T G C A R S E G F Y T

-1

S* This is a R3771S substituted MLL1Win peptide.
S* This is a R2517S substituted MLL4Win peptide.
WDR5 is a 334-residue protein that has a 7-bladed, WD-40 repeat-based 
propeller structure surrounding a central cavity (Figure 1A) [29, 66-68]. Each blade
contains four anti-parallel  strands. A segment of the central cavity serves as the
high-affinity Win binding site for the SET1Win peptides (Figure 1B;
Supplementary Figures S1-S2) [21, 23, 24, 65]. Here, we performed a systematic
kinetic analysis of the interactions of WDR5 with six 14-residue SET1Win peptides,
which include an evolutionarily conserved Arg residue at P0 (Table 1). Moreover,
this Arg residue has been shown to be critical to WDR5-SET1Win interactions
(Supplementary Table S1, Figure S3) [22, 26, 69, 70]. In addition, SET1Win
sequences contain a highly conserved 6-residue Win motif peptide, at positions P-3
through P2, along with 8 residues on their flanking sides, at positions P-7 through P-
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4

and P3 through P6. These flanking residues diverge among SET1 family members,

accounting for differences in the binding affinity of WDR5-SET1Win interactions
[24, 65]. The highly conserved 6-residue Win motif peptide has to insert into the
WDR5 binding cavity to facilitate these highly specific WDR5-SET1Win
interactions [24, 65]. Therefore, the choice of a 14-residue length of SET1Win was
based on the requirement of the minimal 6-residue Win motif sequence, along with
four residues on each flanking side. This also facilitated the interpretation of our
results in light of a prior crystallographic study [24], which was conducted with an
identical SET1Win length.

Here, we employed multiple techniques to probe the effect of the surface
immobilization on the kinetic fingerprint of WDR5-SET1Win interactions as well as
to establish the efficacy of each technique for the measurement of the kinetic rate
constants and binding affinities. We provide a critical analysis of each approach
with respect to the kinetics of the Win binding site. BLI and SPR require surface
immobilization, while steady-state FP does not. On the other hand, steady-state FP
is free from this limitation, but is unable to provide real-time kinetic measurements.
Furthermore, the use of multiple approaches allowed us to provide quantitative and
qualitative validations of our conclusions and to obtain more generalizable
outcomes that were not restrained by any one approach. Finally, we also show that
distinctions in the kinetic rate constants of these interactions are correlated with
unique sequences on the SET1Win peptides' flanking sides.
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2.3 Materials and Methods
Protein Expression and Purification
Human WDR5 (UniProtKB - P61964; WDR5_HUMAN) was expressed and
purified, as follows. pET3aTr vectors containing the 6×His-TEV-WDR5 sequence
were transformed into Rosetta™ 2 BL21(DE3)pLysS (Novagen, Cat #71403)
competent E. coli cells. Rosetta™ 2 BL21(DE3)pLysS (Novagen, Cat #71403)
competent E. coli cells were

grown overnight on Luria-Bertani (LB) agar

carbenecillin/chloramphenicol selection plates at 37oC. 50 mL LB broth starter
cultures (one per 10 L bioreactor growth) containing 50 µg/mL each of
carbenecillin and chloramphenicol were inoculated with 5 colonies and grown for
3-5 hours until turbid at 37°C. 10 L Luria broth bioreactors (Eppendorf BioFlo,
Enfield, CT) containing 50 µg/mL each of carbenecillin and chloramphenicol, in
addition to Antifoam 204 (Sigma-Aldrich, St. Louis, MO), were then inoculated at
37C and 800 rpm with the entire turbid starter culture. When the culture attained
OD600 = 0.8, agitation was decreased to 600 rpm and the temperature was rapidly
dropped to 18oC. Induction of target proteins was initiated with 100 µM Isopropylβ-d-1-thiogalactopyranoside (IPTG; Goldbio, St. Louis, MO) at 18oC. After 12-24
hours post-induction at 18°C, cells were pelleted by centrifugation at 4,465g using
a J6-MI centrifuge (Beckman Coulter, Brea, CA) for 30 minutes at 4°C. The pellet
was resuspended in 50 mM Tris-HCl (pH 7.4), 300 mM NaCl, 10 mM βME, and
20 mM imidazole. The resuspended cells were frozen on dry ice and stored at -80oC
until purification.
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Cell pellets were lysed with a Qsonica Sonicator Q700 (FisherBrand, Pittsburg,
PA) on ice. 5 L of thawed, resuspended pellets were resuspended in 160 mL of 50
mM Tris-HCl (pH 7.4), 300 mM NaCl, 3 mM DTT, and 30 mM imidazole
(lysis/Ni-NTA Buffer A/dialysis buffer) containing an additional 200 µL of
phenylmethylsulfonyl fluoride (PMSF; Sigma-Aldrich) and two Pierce™ Protease
Inhibitor Mini Tablets (EDTA-free; Thermo Fisher Scientific, Waltham, MA). The
cell suspensions were stirred at 4oC for 15 minutes until homogeneous and then
sonicated for 10 minutes at 90% power (2 seconds on, 4 seconds off). Lysate was
then centrifuged for 1 hour at 4,465g and 4°C, and the supernatant was stored at
2-8°C for purification. A Ni-NTA purification process was followed. A Kontes 25
x 200 mm column with 30-40 mL Ni-NTA resin (Qiagen, Hilden, Germany) was
equilibrated with at least 10 resin-bed volumes (RBVs) of 0.22 µm filtered deionized (DI) H2O to remove ethanol, and then at least 5 RBVs of Ni-NTA Buffer
A (above). After equilibration, lysate was added to the column and washed with 510 RBVs of Ni-NTA Buffer A. Sample was eluted using at least 5 RBVs of NiNTA Buffer B (50 mM Tris-HCl (pH 7.4), 300 mM NaCl, 3 mM DTT, and 500
mM imidazole). 5 mL fractions were collected, analyzed via SDS-PAGE, and
pooled. Then, sample was dialyzed, as follows. WDR5-containing fractions were
pooled into 12-14 kDa MWCO dialysis tubing (Repligen, Waltham, MA), then 2.5
mg of GST-6H-TEV protease (per 5 L of culture; expressed and purified in-house)
was added to cleave the His-tag, and the solution was dialyzed against 4 L of
dialysis buffer (above) overnight for 12-18 hours at 2-8°C. Dialyzed protein was
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analyzed via SDS-PAGE to ensure complete cleavage. A negative Ni-NTA was
then conducted. The resulting cleaved WDR5 solution was passed through a BioRad Ni-NTA IMAC cartridge (Bio-Rad, Hercules, CA) using a Bio-Rad NGC
chromatography system (Bio-Rad) to remove the cleaved His-tag and GST-6HTEV protease. The flowthrough was collected, analyzed via SDS-PAGE and UVVis, and concentrated for size-exclusion chromatography (SEC) purification. As a
final polish, the WDR5 proteins were purified via SEC using a HiLoad® 26/600
Superdex® 200 pg column (GE Healthcare, Chicago, IL) into 20 mM Tris-HCl (pH
7.5), 300 mM NaCl, 1 µM ZnCl2, 1 mM TCEP. Fractions of interest were analyzed
via SDS-PAGE and UV-Vis, pooled, concentrated where necessary, aliquoted to 1
mL, flash-frozen in liquid nitrogen, and stored at -80oC.

Peptide

synthesis,

labeling,

purification,

and

analysis

for

BLI

measurements
All peptides for biolayer interferometry measurements were synthesized by
GenScript (Piscataway, NJ). The peptides werepurified to ≥ 95% purity. Amino
acid analysis, purity confirmation, and solubility testing were provided by
GenScript. All peptides were biotinylated at the N terminus. Their C terminus was
amidated.

Peptide synthesis, labeling, purification, and analysis for SPR and FP
measurements
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For Fmoc-SPPS, peptides were synthesized at theoretical 100 µmol scale using
the standard double coupling workflow pre-programmed on the Biotage Syro I
peptide synthesizer (Biotage, Charlotte, NC). 278 mg of Rink Amide AM Resin LL
(100-200 mesh, 0.36 mmol/g functionalization; Novabiochem (EMD Millipore))
was loaded into each 10 mL reactor vial, corresponding to the 100 µmol synthesis
scale. Each resin aliquot was swelled with DMF for 30 minutes, followed by an
initial resin deprotection step using 40% piperidine in DMF. Each double coupling
cycle was comprised of two independent, 45-minute coupling sub-steps that
differed in the choice of activation reagents: 1) DIC/Oxyma (1:2 ratio with respect
to Fmoc-[AA]), followed by 2) HBTU/DIPEA (0.95:2 ratio with respect to Fmoc[AA]). For each coupling sub-step, four molar equivalents of each respective 0.5
M Fmoc-[AA] stock was added to each vial. Each coupling cycle terminated with
a double Fmoc deprotection step using 40% piperidine in DMF. Coupling reactions
proceeded with interspersed vortexing of the vials and under an air atmosphere at
ambient temperature. Following the conclusion of peptide synthesis, resins were
washed with three successive aliquots of DCM, followed by three minutes under
vacuum to dry.

Each peptidyl-resin aliquot was swelled with DMF for 30 minutes and drained.
DMF (1,200 µL) was added to each aliquot, followed by 300 µL of DIPEA in NMP
(6 molar equivalents, 600 µmol), then followed by 600 µL of Lissamine Rhodamine
B sulfonyl chloride in DMF (3 molar equivalents, 300 µmol). The mixture was
shielded from light and allowed to react with intermittent vortexing overnight at
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ambient temperature. Following conjugation, the resin bed was drained, washed
successively with DMF until no further change in the color of the flowthrough was
observed (faint pink), washed successively with DCM, and then held under vacuum
for three minutes to dry.

Cleavage cocktail containing 90% TFA, 5% TIS, 2.5% DODT, and 2.5% H2O
was freshly prepared. 4 mL of cleavage cocktail was added to each peptidyl-resin
aliquot, sealed, and placed on a rocking platform to react for 4 hours at ambient
temperature. After incubation, the contents of each reactor vial were plunged into
separate 50 mL conical tubes. The resin was then treated with an additional 2 mL
of cleavage cocktail and allowed to react on the rocking platform for 30 minutes at
ambient temperature. Following the second incubation, the contents of each reactor
vial were pooled into their respective 50 mL conical tubes and the resin containing
reactor vials were discarded. Cleavage aliquots were triturated by the fast addition
of ~45 mL cold (-80°C) diethyl ether. Precipitate was compacted by centrifugation
at 1,000×g for 10 minutes at 0°C using an Allegra X-22R centrifuge (Beckman
Coulter, Brea, CA). The supernatant was discarded, and the peptide pellets were
washed with a second ~30 mL aliquot of cold diethyl ether, centrifuged, and
decanted as before. The resulting peptide pellets were flash frozen in liquid nitrogen
and lyophilized using a FreeZone 2.5L lyophilizer (Labcono, Kansas City, MO)
overnight to remove residual solvents. The crude lyophilized peptide was stored at
-80°C until purification.
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Crude peptide aliquots were purified using reversed-phase chromatography
through two stages: 1) Flash chromatography using a Biotage Isolera One (Biotage
AB, Uppsala, Sweden), 2) Semi-preparative HPLC using a Waters 2695
separations module equipped with a Waters 2996 photodiode array detector (PDA).
1) Biotage Isolera One purifications: Each crude peptide aliquot was solubilized in
2.5 mL total of either DMSO or DMF (DMF only if the peptide contained
oxidizable Cys or Met residues) and loaded onto a Biotage Sfär C18 Samplet for 25
g Column (Biotage, Uppsala, Sweden) with the aid of a vacuum. Each samplet was
placed in a Biotage Sfär Bio C18 D Duo (300 Å, 20 µm) 25 g column (Biotage).
Peptides were eluted using a 15-column volume (CV) gradient of 9-90% MeCN in
H2O containing 0.1% TFA at a flowrate of 30 mL/min. The collection threshold
was 75 mAU for λ = 200-400 nm, with monitoring at λ = 215 nm and 355 nm
(rhodamine). Rhodamine labeled fractions were pooled and MeCN was removed
using a rotary evaporator for 30 minutes at 25oC. Samples were flash-frozen in
liquid nitrogen and lyophilized using a FreeZone 2.5L lyophilizer (Labcono) for
three days. The semi-pure lyophilized peptide was stored at -80°C until further
purification. 2) Semi-preparative HPLC: Peptide samples were resuspended in 5080 µL aliquots of DMSO or 1:2 DMSO/H2O. Aliquots were injected onto a Waters
XBridge Peptide BEH C18 OBD Prep Column (5 µm, 300 Å, 10 mm x 150 mm). A
gradient of 10-50% MeCN containing 0.1% (v/v) TFA in H2O containing 0.1%
(v/v) TFA was applied over 40 minutes (Δ1%/min.) at a flow rate of 4.73 mL/min.
at ambient temperature using a Waters 2695 separations module. Sample detection
occurred at 215 nm, 280 nm, 355 nm (rhodamine), and 560 nm (rhodamine) using
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a Waters 2996 photodiode array detector (PDA). Sample purity was determined by
baseline integration using Waters Empower 3 software (>90% purity in all cases).
Rhodamine containing fractions were analyzed by MALDI-TOF mass
spectroscopy for the identity and purity confirmatory tests. Target fractions were
flash-frozen in liquid nitrogen and lyophilized using a FreeZone 2.5L lyophilizer
(Labcono) for three days. The resulting purified, lyophilized peptides were
reconstituted as concentrated stocks in ultrapure water, aliquoted, flash-frozen in
liquid nitrogen, and stored at -80°C until use.

For MALDI-TOF mass spectroscopy of the purified peptides, 1 µL of peptide
stock in H2O (1-100 µM) was mixed with 9 µL spotting matrix (10 mg/mL α-cyano4-hydroxycinnamic acid (CHCA) in 50:50 MeCN/0.1% (v/v) TFA in H2O). 2 µL
of each peptide spotting solution was spotted onto a Bruker MTP 384 Target Plate,
which was calibrated using Anaspec Peptide Mass Standard Kit, and allowed to dry
at room temperature for at least 30 minutes prior to analysis. Samples were
analyzed on a Bruker Autoflex iii Mass Spectrometer as an average of 1200 shots
using 35% laser power, an m/z range from 840-6000 Da with suppression <400 Da
in linear mode, 3.6x detector gain, 2.00 sample rate, and medium gating strength.

Biolayer interferometry (BLI)
Octet RED384 (FortéBio, Fremont, CA) was used for the BLI studies [71-73].
Streptavidin (SA) sensors were presoaked in buffer for ~30 minutes. The buffer
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solution contained 150 mM NaCl, 20 mM Tris-HCl, 1 mM TCEP, 1 mg/mL bovine
serumalbumin (BSA), pH 7.5. 5 nM tagged peptide was then loaded onto sensors
for 15 minutes. Sensors were then dipped in buffer again for 5 minutes to wash off
unbound peptides from the surface. A 3-fold serial dilution of WDR5 was
conducted ranging from 0.1 µM to 9 µM for the association process and then placed
into the buffer solution for the dissociation process. The association and
dissociation processes were ~200 and ~600 seconds long, respectively. For all
WDR5 concentrations, unloaded sensors were run concurrently as controls and
were used to subtract the baseline and the drift in the sensorgrams to extract the
binding curves. The BLI experiments were performed at 24ºC. All reagents were
prepared in the above- mentioned buffer and were loaded into 96-well flat bottom
black plates for the sensorgram recordings. The binding curves were fitted using
the Octet Data Analysis software (FortéBio). The curves of the association process,
which were recorded for various analyte concentrations, [C], were fitted using the
following equation [74]:
𝑌 = 𝑌∞ − (𝑌∞ − 𝑌0 )𝑒 −𝑘obs 𝑡
(1)
Here, Y0 and Y are the BLI response signals at time zero and infinity, respectively,
of the association process. t denotes the cumulative time of the association reaction.
kobs is the apparentfirst-order reaction rate constant of the association process. The
curves of the dissociation process were fitted using the following equation:
𝑌 = 𝑌∞ + (𝑌0 − 𝑌 )𝑒 −𝑘off 𝑡
(2)
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Here, Y0 and Y are the BLI response signals at time zero and infinity, respectively,
of the dissociation process. koff indicates the dissociation rate constant. Finally, the
association rateconstant, kon, was determined using the slope of the linear curve [75,
76]:
𝑘obs = 𝑘on [𝐶] + 𝑘off
(3)
Global fitting, which was conducted using several analyte concentrations, provided
the corresponding kon and koff values. The dissociation constant, KD, were indirectly
determined using the kon and koff values. Three distinct BLI measurements were
conducted for all inspected interactions.

Surface plasmon resonance (SPR)
All SPR experiments [77-79] were conducted on a Cytiva Biacore 8K (Cytiva
Life Sciences, Marlborough, MA). All buffers and dilutions were freshly made inhouse using ultrapure water obtained from an IQ 7000 Milli-Q system (MilliporeSigma, Burlington, MA). WDR5 protein was immobilized onto the active flow cell
of each channel of a Cytiva Series S Sensor Chip CM5 (Cytiva Life Sciences)
according to the following parameters and protocol. A CM5 chip was inserted into
the instrument and equilibrated for 1 h at 25oC in PBS-P+ running buffer (PBS-P+
Buffer 10×, Cytiva Life Sciences). The chip surface was activated using an
injection

of

1:1

N-

hydroxysuccinimide

(NHS)/1-ethyl-3-(3-

dimethylaminopropyl)carbodiimide (EDC) (Cytiva Amine Coupling Kit, Cytiva
Life Sciences) for 420 seconds at 10 µL/min across both active and reference flow
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cells. This activation process was followed by a wash of the microfluidics with 1
M ethanolamine-HCl (pH 8). Following activation, wild-type WDR5 (1.75-2.50
µg/mL; analyte dependent) in 50 mM sodium phosphate (pH 6.5), 50 mM NaCl
was then injected across the active flow cell for 150 seconds at 10 µL/min.
Following ligand immobilization, both active and passive flow cells were
chemically deactivated with an injection of 1 M ethanolamine-HCl (pH 8) for 420
seconds at 10 µL/min. SET1Win peptide dilutions were freshly prepared from
HPLC- purified peptide stocks in ultrapure water; the peptides were identical to
those used in the steady-state FP experiments and contained an N-terminal
sulforhodamine B and a C-terminal amide. Titrations of each labeled SET1Win
peptide analyte were conducted to span an approximate range of 0.1-10 × KD
(approximately 1 nM to 7 µM; 40 µM for MLL1). Each SET1Win peptide was
analyzed in a separate channel. Multicycle kinetic analyses were conducted at a
flow cell temperature of 25oC and a sample compartment temperature of 20oC in a
running buffer composed of 20 mM Tris- HCl (pH 7.5), 150 mM NaCl, 1 mM
TCEP, 0.05% Tween 20. Each analysis cycle consisted of the following steps: 1)
SET1Win

peptide

analyte

injection:

120-second

association,

360-second

dissociation, 30 µL/min.; 2) regeneration injection with 100% ethylene glycol for
15 seconds at 10 µL/min. (high viscosity setting); 3) wash of the microfluidics
system with running buffer; 4) regeneration injection with 1 µM ZnCl2 for 30
second at 10 µL/min. Prior to curve fitting, all data generated from the active flow
cell of each channel are double referenced to both the appropriate buffer blanks
(first/last) and the reference flow cell. For MLL2Win, MLL3Win, MLL4Win,
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SETd1AWin, and SETd1BWin, the affinity constants, KD, were calculated indirectly
using KD = koff/kon. For MLL1Win, a plot of relative response versus the MLL1Win
analyte concentration was constructed and data were fitted using a four-parameter
logistic regression to obtain the KD. Therefore, an affinity analysis (relative
response vs. concentration dose- response curve) was used to calculate the KD, in
this instance due to kinetic rate constants falling outside of the instrument detection
range. All interactions were independently determined in triplicate (e.g., separate
ligand immobilizations). Experimental data and fits were plotted using GraphPad
Prism 8 (GraphPad Software).

Steady-state fluorescence polarization (steady-state FP) measurements
All steady-state fluorescence polarization (FP) measurements were recorded
using a SpectraMax i3x plate reader (Molecular Devices, San Jose, CA).[80, 81]
HPLC-purified peptides, which contained an N-terminal sulforhodamine B and a
C-terminal amide, were reconstituted as concentrated stocks in ultrapure water and
used in all subsequent experiments. All steady-state FP assays were conducted in a
buffer containing 20 mM Tris-HCl (pH 7.5), 150mM NaCl, 1 mM TCEP, 0.005%
Tween 20 and plated in black untreated 96-well polystyrene microplates (Corning
Inc., Corning, NY). Steady-state FP assays were conducted in triplicate, 24-point
serial dilution for each of the six SET1Win peptides against WDR5. 200 µL of
WDR5 stock solutions, ranged from 21.6 to 131 µM, were added to each well on
the first column of one of two adjacent black 96-well dilution plates, and 100 µL
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of the assay buffer was added to wells A2-H24 over the two plates. WDR5 variants
were then diluted down the two plates by transferring 100 µL from each well to the
next, for a total of 24, 2-fold dilutions which range from low µM to low pM (variant
specific). Following dilutions, 100 µL of the appropriate 20 nM labeled SET1Win
peptide, which was dissolved in the assay buffer, was added to each well on each
set of plates at a final concentration of 10 nM. The steady-state FP anisotropy was
measured on the plates after a 1 h incubation at room temperature in the dark. The
resulting dose-response data were averaged and fitted using a four-parameter
logistic regression to obtain the binding affinity (KD) for each interaction. Data were
plotted and analyzed using GraphPad Prism 8 (GraphPad Software, San Diego,
CA).
Molecular graphics
All cartoons showing molecular graphics were prepared using the PyMOL
Molecular Graphics System (Version 2.4.0 Schrödinger, LLC).
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2.4 Results and Discussion
The kinetic fingerprint of WDR5 – SET1Win interactions
We first explored the association (kon) and dissociation (koff) rate constants of
WDR5-SET1Win interactions using BLI measurements [71, 72]. This technology
probes ligand-receptor interactions that lead to accumulations of bimolecular
complexes at the surface of the BLI sensor. This process is facilitated by
immobilizing one interacting partner (ligand) onto the surface of the BLI sensor
and supplying the analyte partner (receptor) from solution. In this way, the
association and dissociation phases of the ligand-receptor complex are optically
measured in real time using alterations in the interference pattern between reflected
light waves at the surface of the BLI sensor. The N-terminus of each SET1Win was
biotinylated and their C-terminus was amidated (Table 1). A 9-residue Gly/Serrich peptide spacer was inserted between the biotinylated site and the SET1Win
sequence. This 3 nm-long spacer ensures that there is a satisfactory distance
between the BLI sensor and SET1Win for WDR5 to interact without steric
hinderance from the sensor surface.

The association binding curves were acquired through a 3-fold serial dilution
of WDR5 (Figure 2). After the BLI response reached a saturation level, individual
dissociation binding curves were recorded when sensors were placed in a WDR5free buffer. The association and dissociation BLI phases underwent a timedependent single-exponential increase and decrease, respectively. The binding
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curves were fitted using the Octet Data Analysis software (Materials and
Methods; eqns. (1)-(3)). The equilibrium dissociation constants using BLI, KD-BLI,
were indirectly determined using kon and koff.

Figure 2: Label-free optical BLI sensorgrams of WDR5-SET1Win interactions.
5 nM biotin-tagged SET1Win peptides were loaded onto streptavidin (SA) sensors
for 15 minutes. Titration series of WDR5 were injected as analytes and the
corresponding association and dissociation curves are shown for the six SET1Win
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peptides.

Table 2: Kinetic rate constants of association, kon, and dissociation, koff, and
equilibrium dissociation constants, KD-BLI, of WDR5 with SET1Win peptides
using BLI. Numbers represent mean ± s.d. determined from three independent
experiments.
KD-BLI
Peptide sequence
𝒌on
𝒌off
-1 -1
-4
-1
3
(nM)
(M s )  10
(s )  10
Biotinyl-(GGS)3MLL1Win-NH2
ND*
ND**
ND***
Biotinyl-(GGS)3MLL2Win-NH2

4.4 ± 0.4

7.7 ± 0.2

170 ± 20

Biotinyl-(GGS)3MLL3Win-NH2

5.4 ± 0.6

5.3 ± 0.1

100 ± 5

Biotinyl-(GGS)3MLL4Win-NH2

2.3 ± 0.2

39 ± 2

1,700 ± 200

Biotinyl-(GGS)3SETd1AWin-NH2

8.2 ± 0.8

51 ± 6

620 ± 20

Biotinyl-(GGS)3SETd1BWin-NH2

7.1 ± 0.5

17 ± 1

250 ± 30

ND* kon was not quantitatively determined. Although WDR5-MLL1Win
interactions were detectable using a BLI measurement (Fig. 2), no accurate
quantitative determination was made due to the limited time resolution of this
approach. In this case, we assume that the kon was in thesame order of magnitude
with the kon of the other SET1Win peptides (~104 M-1s-1).
ND** koff was not quantitatively determined due to a fast dissociation rate constant.
The upper- limit value for the detection of koff is 1 s-1 according to instrument
specifications.
ND*** KD-BLI was not quantitatively determined due to the limited time resolution
of the approach. In this case, KD-BLI determined by BLI for WDR5-MLL1Win
interactions should be greater than ~105 nM. This value results from dividing the
upper-limit value of detection of koff (ND**) by the value of the kon approximation
(ND*).
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Figure 3: Label-free optoelectronic SPR sensorgrams of the WDR5-SET1Win
interactions. Titration series of the respective SET1Win peptides were injected as
analytes and the corresponding association and dissociation curves are shown for
the six SET1Win peptides.

Association rate constants
The BLI-determined kon values were in the order of 104 M-1s-1, clearly
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indicating slow association kinetics for a protein-peptide system (Table 2). It is
likely that this outcome resulted from two distinct physical restrictions: (i)
tethering SET1Win onto the surface of the BLI sensor, thus reducing its local
mobility, and (ii) partitioning of SET1Win into the WDR5 cavity. The latter
physical process was illustrated in early crystallographic studies [21], which
revealed that an MLL1Win peptide penetrates into the WDR5 cavity to undergo a
bimolecular association process. Here, we were unable to acquire an accurate
mean value of kon for the WDR5-MLL1Win interaction due to its relatively fast koff
constant, whose binding time constant was shorter than the time-resolution limit
of this approach (~1 s). Furthermore, kon measured by BLI for various SET1Win
peptides were within the same order of magnitude, suggesting a similar insertion
mechanism of the 6-residue Win motif peptide into the Win binding site (Table
1; Supplementary Figures S1-S2) [24, 65].

Dissociation rate constants
In contrast, koff values spanned between two and three orders of
magnitude (Table 2), highlighting significant distinctions in the WDR5-SET1Win
interactions. This assumes that the koff of the WDR5-MLL1 interactions is faster
than 1 s-1, showing that MLL1Win has the weakest interaction with WDR5 among
all SET1Win peptides. On the other hand, the strongest WDR5-SET1Win
interactions were monitored with MLL2Win and MLL3Win, which had average koff
values of (7.7  0.2)  10-3 s-1 and (5.3  0.1)  10-3 s-1, respectively. This finding
provides unusually long binding times of ~130 s and ~190 s, respectively.
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It was previously demonstrated that WDR5-SET1Win interactions have a
common archetype: a highly conserved Arg residue at P0 (Table 1) [22]. This Arg
residue is the pivotal player of WDR5-SET1Win interactions, contributing to most
of the binding affinity through a complex network of contacts with neighboring
residues (Supplementary Table S1, Figure S3) [22, 24]. To test this hypothesis,
we conducted BLI measurements using a control MLL3Win peptide, whose native
form exhibited the longest binding time with WDR5. The key Arg residue at P0
was replaced by an Ala residue, resulting in the R4710A MLL3Win mutant. No
interaction was detected with this R4710A MLL3Win mutant (Supplementary
Figure S4), confirming the critical role of Arg at P0 for the strength of WDR5SET1Win interactions. In addition, this finding validates the efficacy of our BLI
measurements for examining the kinetic landscape of the Win binding site of
WDR5.
Table 3: Kinetic and affinity determinations of WDR5-SET1Win interactions
using SPR. Values represent mean ± s.d. acquired from at least three independent
experimental determinations (separate receptor immobilizations). For MLL2Win, n
= 4 independent experimental determinations were used.

Sulforhodamine B-(GGS)3MLL1Win-NH2

koff
KD-SPR
𝒌on
-1 -1
-5
(M s )  10 (s-1)  103 (nM)
ND*
ND**
16,000 ± 3,000***

Sulforhodamine B-(GGS)3MLL2Win-NH2

3.7 ± 0.3

12 ± 1

33 ± 2

Sulforhodamine B-(GGS)3MLL3Win-NH2

4.9 ± 0.4

9±1

19 ± 1

Sulforhodamine B-(GGS)3MLL4Win-NH2

2.1 ± 0.3

41 ± 3

190 ± 20

Peptide sequence

Sulforhodamine B-(GGS)3SETd1AWin-NH2 3.1 ± 0.2

110 ± 10 350 ± 10

Sulforhodamine B-(GGS)3SET1dBWin-NH2 3.4 ± 0.3

24 ± 1
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69 ± 6

ND* kon was not quantitatively determined. Although the WDR5-MLL1Win
interactions were detectable using an SPR measurement (Fig. 3), no accurate
quantitative determination was made due to the limited time resolution of the
approach. In this case, we assume that the kon was in the same order of magnitude
with the kon of other SET1Win peptides (~105 M-1s-1).
ND** koff was not quantitatively determined due to a fast dissociation rate constant.
The upper-limit value for the detection of koff is 0.5 s-1 according to instrument
specifications. The Biacore 8K+ cannot measure rate constants of dissociation, koff,
faster than 0.5 s-1.
***Here, KD-SPR was determined using a steady-state SPR measurement
(Supplementary Figure S6).

Does the tethering restriction of SET1Win onto the surface of the BLI sensor
impact the kinetic rate constants?
Association rate constants
We postulated above that the slow association kinetics of WDR5-SET1Win
interactions were caused at least in part by the immobilization of SET1Win onto the
surface of the BLI sensor. To assess this hypothesis, we next employed SPR [7779] as an orthogonal, label-free approach for examining these interactions of
SET1Win peptides with WDR5. SPR is an optoelectronic technique that monitors
accumulation of bimolecular ligand-receptor complexes onto the surface of the SPR
sensor by changes in the refractive index. In this case, SET1Win analyte is supplied
by using a flow-driven fluidic device. WDR5 was immobilized onto the surface of
the SPR chips as the "receptor" (Materials and Methods). In this way, we recorded
the association and dissociation phases in real time when SET1Win was not
immobilized onto a surface (Figure 3). BiacoreTM Software was used to analyze
and fit the SPR sensorgrams using a 1:1 binding interaction model to provide the
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kon and koff rate constants (Supplementary Figure S5). In accord with our
expectation, kon values obtained by SPR were significantly increased by almost an
order of magnitude to quantities greater than 105 M-1s-1 (Table 3; Supplementary
Figure S6, Figure S7A). Again, kon measured by SPR for various SET1Win peptides
were within the same order of magnitude, potentially indicating an identical
insertion mechanism of the 6-residue Win motif peptide into the Win binding site
(Table 1; Supplementary Figures S1-S2) [24, 65]. In addition, this insertion
mechanism prevails no matter whether SET1Win is in either physically restricted
(e.g., BLI) or unrestricted (e.g., SPR) conditions.

Dissociation rate constants
Interestingly, with the exception of SETd1A, the koff values acquired by the
SPR measurement of WDR5-SET1Win interactions closely resembled those
measured by BLI (Table 3; Supplementary Figure S7B). Moreover, this finding
provides indirect evidence that WDR5 did not undergo denaturation upon its
immobilization onto the surface of the SPR sensor. Tethering SET1Win onto the
surface of the BLI sensor via its C-terminus was considered inconvenient, because
prior crystallographic information indicated the interaction of the C-terminus
residues (Table 1) with the WDR5 surface [24]. However, does the SET1Win
tethering onto the surface of the BLI sensor via its N-terminus impose an additional
physical restriction on the binding mechanism? Since the koff measured by BLI and
SPR are almost identical, we conclude that the SET1Win tethering onto the surface
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of the BLI sensor via its N-terminus did not produce any additional restrain on the
detachment mechanism of SET1Win from the high-affinity Win binding site.

Figure 4: Steady-state FP curves of the WDR5-SET1Win interactions. The N
terminus of the SET1Win peptides was tagged with sulforhodamine B, whereas the C
terminus was amidated.The final concentration of labeled SET1Win peptides in each well
was 10 nM. Three independent experiments were conducted to obtain the WDR5 dose
response.
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Figure 5: Quantitative comparisons of dissociation equilibrium constants of
WDR5-SET1Win interactions using BLI, SPR, and steady-state FP
measurements. "*" is the upper-limit value for the detection of KD-BLI. This value
results from dividing the upper-limit value of the detection of koff by the value of
the kon approximation (Table 2).
Comparisons of binding affinities of WDR5-SET1Win interactions in
restricted and unrestricted conditions
Next, we asked how immobilization-free (i.e., unrestricted) conditions
influence the binding affinities. It is expected that the equilibrium dissociation
constant slightly decreases if both WDR5 and SET1Win move freely in solution.
Hence, we determined equilibrium dissociation constant values using steady-state
FP measurements, KD-FP (Materials and Methods) [80-82]. This fluorescence
technique monitors changes in the polarity of the emitted light due to modifications
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in the rotational diffusion coefficient of a fluorescently labeled ligand. For example,
the formation of the ligand-receptor complex is accompanied by a decline in the
rotational mobility of the ligand, increasing the polarity of the emitted light. Here,
Sulforhodamine B, an optically stable and bright fluorophore [83], was chemically
attached to the N terminus of SET1Win via a 9-residue Gly/Ser-rich flexible spacer,
whereas their C terminus was amidated. WDR5 concentration-dependent, steadystate FP binding curves were collected using a plate reader in a high-throughput
setting (Fig. 4). In this way, we determined the immobilization-free KD-FP
(Supplementary Table S2). In accord with our anticipation, KD-FP values were
slightly lower than those acquired by SPR, KD-SPR, meaning that WDR5-SET1Win
interactions appeared somewhat stronger when probed in unrestricted conditions.

The KD-FP values are also in agreement with results of prior ITC measurements
(e.g., in immobilization-free conditions) at either lower [65] or higher salt
concentrations [24]. It is worth mentioning that we preferred replacing Arg by Ser
at the C terminus of MLL1Win and MLL4Win to avoid potential rebinding events of
the native Arg at P6 to the WDR5 cavity (Table 1). Regardless, we employed
similar peptide sequences and identical buffer conditions to obtain meaningful
comparisons among the three approaches. Then, we have discovered the following
relationship for each WDR5-SET1Win interaction:
KD-BLI > KD-SPR > KD-FP (Fig. 5; Supplementary Table S2). In addition, numerical
values of
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KD-FP replicated similar trends noted with different SET1Win peptides using both
BLI and SPR.

Tentative interpretations
The kinetics and affinity measurements of the WDR5-SET1Win interactions
were conducted with no significant variation among independently recorded BLI
sensorgrams. The precision of this technique allowed us to quantitatively compare
kinetics that were within the same order of magnitude. The SET1Win motif is located
about 60 residues N-terminal to the SET domain, both of which are at the Cterminal end of the large SET1 proteins. These proteins range between ~1,700 –
5,500 amino acids in length. The rotational and diffusional rates of SET1 proteins
relative to WDR5 are slow enough that these proteins can be considered as
stationary compared to WDR5. Therefore, a more physiologically-relevant
approach that recapitulates the binding of the full-length SET1 is that in which the
14-residue SET1Win peptide is attached onto a surface, whereas WDR5 is free in
solution. In this way, the actual kon measured by BLI would be conceivably closer
to that value in physiological conditions. In addition, it should be mentioned that
SET1Win is physically restrained at both ends when it is part of the SET1 subunit,
suggesting an even lower kon value. However, SET1Win may have stabilized
conformations that promote binding within the context of the large SET1 subunit.
In other words, the unrestricted SET1Win may undergo significantly greater degrees
of freedom to adopt numerous non-productive conformations. Furthermore,
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binding of SET1 proteins to WDR5 may be coupled with additional interaction
pockets that can amplify the binding strength either by increasing kon or by
decreasing koff or both. For example, prior sedimentation velocity experiments have
shown that a 225-residue MLL1Win-containing polypeptide exhibits a binding
affinity of ~120 nM to WDR5 [22].

kon values measured by SPR are yet at least an order of magnitude lower than
those predicted for a protein-peptide interaction system (107 - 108 M-1s-1) [84-88].
Here, WDR5-SET1Win interactions require a precise insertion of the 6-residue, Argcontaining SET1Win peptide into the WDR5 cavity. Therefore, we interpret that kon
values are limited by the entropic penalty determined by the SET1Win partitioning
into the Win binding site. The high-affinity Win binding site features a conical
geometry with a maximum internal diameter of ~1.5 nm, as measured from side
chain to side chain. For example, MLL1Win partitions ~1.0 nm into the Win binding
site (Fig. 1) [24]. In support to this interpretation, previous single-molecule studies
have shown that kon values of the interactions of peptides, up to 25 residues in
length, with a narrow 2 nm-wide nanopore are in the order of 105 M-1s-1 [89, 90].
This is the same order of magnitude with kon values that we determined by SPR.

However, the kon is a composite parameter, which includes contributions of the
diffusion-limited rate factor, kon0, and electrostatic free energy of the WDR5SET1Win complex, G*el. Zhou and coworkers have demonstrated that the rate
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constant of association of two proteins can be accurately computed using the
following expression: kon = kon0 exp(-G*el/kBT), where kB and T are Boltzmann's
constant and the absolute temperature, respectively [91, 92]. For this equation, they
employed kinetic-rate theory of rigid-body docking and Poisson-Boltzmann
formalism [93-95]. Using the same approach [93] and crystallographic information
of the WDR5-SET1Win complex [24], we found kon values of several SET1Win
peptides (Supplementary Table S3). For example, computed kon values for
MLL2Win and MLL3Win were 2.9  105 M-1s-1 and
1.2  105 M-1s-1, respectively. These values compare well with our corresponding
experimental data determined by SPR, which were (3.7  0.3)  105 M-1s-1 and (4.9
 0.4)  105 M-1s-1, respectively. Yet, computed kon values for MLL1Win and
MLL4Win were in the order of 104 M-1s-1. The TransComp server: Web Server for
Predicting Protein Association Rate Constants [91, 93] was not able to produce
computed kon values for SETd1AWin and SETd1BWin, likely because these WDR5SET1Win complex formations do not undergo a single-step association mechanism.
This outcome suggests that the WDR5-SET1Win interactions of SETd1AWin and
SETd1BWin exhibit some subtle structural distinctions with respect to MLL1Win,
MLL2Win, MLL3 Win, and MLL4 Win, which is in accord with prior crystallographic
data [24, 65].
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2.5 Concluding remarks, practical implications, and future prospects
In summary, we present a detailed kinetic fingerprint of the multitasking highaffinity Win binding site of WDR5, a protein with major regulatory implications in
the methylation of H3K4 and in multiple physical associations with other proteins.
This study reveals slow kinetics of association and dissociation of the SET1Win
peptides with WDR5. It is known that WDR5 bridges the interaction between the
SET domain of large SET1 subunits and other WRAD2 constituents. A longbinding time of WDR5-SET1Win interaction, meaning slow dissociation kinetics of
the high-affinity Win binding site, is a pivotal mechanism by which WDR5 assists
the functional integrity of the multisubunit WRAD2 complex. Furthermore, slow
dissociation rates detected in this study point out a fundamental consideration for
future therapeutics aimed at targeting interactions of the Win binding site with other
proteins. The stability of these multisubunit complexes would decrease the
opportunities for inhibitors to interfere in WDR5-SET1/MLL interactions.
Consequently, this stresses the need for both fast association rates and slow
dissociation rates when designing potential inhibitors to modulate WDR5 function.
Newly designed small-molecule drugs would need to bind strongly to the WDR5
cavity and stave off other binding partners. Slow dissociation rate constants also
reiterate the efficacy of SET1win peptidomimetics as a fundamental platform for
such drugs. Modifications of these sequences that enhance the association rates,
while maintaining the disassociation rates, could be very effective at inhibiting Win
binding site interactions. A good place to start would be the alteration of either the
net charge or charge distribution of these peptides for amplifying the rate constants
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of association. Any approach employed in this work can be used in the highthroughput screening of libraries of small-molecule compounds against WDR5SET1Win interactions. However, WDR5 is a more relevant target for drug discovery
when immobilized onto the SPR sensor, where the free inhibitor in solution would
better mimic in vivo function. This experimental design enables determinations of
kinetic rate constants, contrasting the steady-state FP measurements. Our results
also indicate that WDR5 did not undergo denaturation upon its immobilization onto
the SPR sensor. In the future, it would be desirable to extend these kinetic studies
to full-length WRAD2 subunits, because of the suitability of these high-throughput
approaches for examining long-lived protein-protein interactions. For instance, it
would be interesting to conduct SPR measurements, in which a full-length SET1
subunit is immobilized on the chip surface and use WDR5 as analyte in solution.

50

ABBREVIATIONS
AUC,

analytical

ultracentrifugation;

BLI,

Biolayer

Interferometry;

FP,

Fluorescence polarization anisotropy; H3K4, histone 3 lysine 4; ITC, isothermal
titration calorimetry; KMT, lysine methyltransferases of histones; kon, the
association rate constant; koff, the dissociation rate constant; KD, the equilibrium
dissociation constant; KD-BLI, the equilibrium dissociation constant obtained by
biolayer interferometry; KD-SPR, the equilibrium dissociation constant obtained by
surface plasmon resonance; KD-FP, the equilibrium dissociation constant obtained
by steady-state fluorescence polarization; MLL, Mixed lineage leukemia; MYC,
transcription factor oncoprotein; PDPK1, 3- phosphoinositide-dependent protein
kinase 1; PI3K, phosphatidylinositol 3-kinase; SET1, Suppressor of Variegation,
Enhancer of Zeste, and Trithorax 1 lysine methyltransferases of histones; SET1Win,
14-residue WDR5 interaction (Win) motif peptides of each SET1 protein; SPR,
Surface plasmon resonance; WDR5, WD40 repeat protein 5; Win, evolutionarily
conserved WDR5-interaction motif found in all SET1 family members; WRAD2,
subcomplex consisting of WDR5, retinoblastoma binding protein-5 (RbBP5),
absent-small-homeotic-2-like protein (Ash2L), and dumpy-30 (DPY-30
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1. Complex formation of WDR5 with SET1Win peptides.

A

1
7

2
6
3
4

5

B

Figure S1: Structures of WDR5 (green) complexed with MLL1Win peptide
(magenta). (A) The insertion of MLL1Win into the WDR5 cavity is shown from
the top. (B) The same interaction is shown from the side. These graphic
representations were made using the pdb code 4ESG [1].
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MLL1Win

MLL2Win

MLL3Win

MLL4Win

SET1aWin

SET1bWin

Figure S2: Structures of WDR5 complexed with SET1Win peptides. MLL1Win,
MLL2Win, MLL3Win, MLL4Win, SETd1AWin, and SETd1BWin are inserted into the
WDR5 cavity. Structures correspond to protein data bank codes: 3EG6, 4ESG,
4ERQ, 4ERY, 4ERZ, 4EWR and 4ES0 [1, 2].
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2. List of hydrogen bonds at the WDR5-SET1Win protein interface.
Table S1: Comprehensive mapping of hydrogen bonding at the WDR5SET1Win interface. These results were obtained using previously published cocrystallization data of Dharmarajan and coworkers [1]. The structures were not
always able to model the whole sequence of the peptides, so these hydrogen bonds
are not comprehensive. The first residue in each bond belongs to the SET1Win
peptide, whereas the second one belongs to WDR5. Only peptide sequences of the
segments that were able to model these interactions are listed below. Entries with
two distances represent two different hydrogen bonds formed by the same residues.
The cut-off distance for identifying these hydrogen bonds was 3.2 Å. Here, BB and
SC denote backbone and side chain, respectively.

Peptide
MLL1Win
LNPHGSARAEVHL

Hydrogen Bonds
H3761 – D107
G3762 – G89
A3764 – D107
R3765 – S91
R3765 – C261
R3765 – F133
MLL2Win
G5337 – G89
INPTGCARSEPKI
A5339 – D107
R5340 – S91
R5340 – C261
R5340 – F133
K5344 – K259
MLL3Win
A4709 – D107
VNPTGCARSEPKMS R4710 – S91
R4710 – C261
R4710 – F133
K4714 – K259
MLL4Win
A2510 – D107
LNPHGAARAEVY
R2511 – S91
R2511 – C261
R2511 – F133
SETd1AWin
A1494 – D107
QTGSARSEGY
R1495 – S91
R1495 – C261
R1495 – F133
Y1499 – K259
SETd1BWin
A1704 – D107
GCARSEG
R1705 – S91
R1705 – C261
R1705 – F133

Distance (Å)

Type

2.7
3.0
3.0
3.0, 2.8
2.9
3.0
3.1
2.9
3.1, 2.8
2.9
3.0
2.9
2.9
3.1, 2.8
2.9
2.9
2.9
3.0
3.0, 2.8
2.9
3.0
3.0
3.0, 2.8
2.9
3.1
2.8
3.0
3.2, 2.8
2.8
3.1

SC-SC
BB-BB
BB-SC
BB-SC, SC-BB
SC-BB
SC-BB
BB-BB
BB-SC
BB-SC, SC-BB
SC-BB
SC-BB
BB-BB
BB-SC
BB-SC, SC-BB
SC-BB
SC-BB
BB-BB
BB-SC
BB-SC, SC-BB
SC-BB
SC-BB
BB-SC
BB-SC, SC-BB
SC-BB
SC-BB
BB-BB
BB-SC
BB-SC, SC-BB
SC-BB
SC-BB
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Figure S3: Structure of the binding cavity of WDR5. It illustrates its key residues
involved in hydrogen bonding with the evolutionarily conserved Arg residue of
MLL1Win at position P0. The Arg residue is marked in magenta. The hydrogen
bonds are indicated by thick dashed lines marked in yellow. The cut-off distance
for identifying these hydrogen bonds was 4.0 Å. This graphic representation was
made using the pdb code 4ESG [1].
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3. Negative control of BLI measurements using an arginine-replaced
MLL3Win derivative.

Response (nm)

0.1 µM
0.3 µM
0.9 µM
3.0 µM
9.0 µM

Time (s)
Figure S4: Arginine is a key side chain in trapping the MLL3Win peptide within
the WDR5 cavity. This figure shows the BLI sensorgram, which includes the
association and disassociation curves for the negative-control MLL3Win peptide
interacting with WDR5. The sequence of this control peptide was
(GGS)3VNPTGCAASEPKMS, where Arg was substituted by Ala at P0 of MLL3Win
(Table 1). For pursuing BLI measurements, this control peptide was biotinylated
at the N terminus and amidated at the C terminus. 5 nM negative-control MLL3Winmutated peptide was loaded onto streptavidin (SA) sensors and allowed to associate
with WRD5, whose concentrations ranged from 0.1 µM to 9 µM. Then, a
dissociation process followed. The figure provides compelling evidence that no
association phase was detected, illustrating that no binding interactions occurred in
this case.
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4. Quantitative kinetic determinations of WDR5-SET1Win interactions using
SPR.
Relative Response (RU)
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Figure S5: Representative SPR sensorgrams and their kinetic fits for the
interactions of SET1Win peptides with WDR5. WDR5 was immobilized onto
CM5 chips and allowed to associate with SET1Win peptides. Each panel indicates
the peptide concentrations, the association and disassociation curves, as well as the
fits of data to obtain kon and koff. While these are single runs for each peptide, at
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500

least three independent runs were conducted to obtain the average kinetic values.
(A) MLL2Win, (B) MLL3Win, (C) MLL4Win, (D) SETd1AWin,
and (E) SETd1BWin.

Relative Response (RU)

5. Determination of the equilibrium dissociation constant of WDR5 MLL1Win interactions using SPR.

MLL1Win Concentration (M)
Figure S6: Steady-state SPR measurements for the quantification of the
interactions between MLL1Win peptide and WDR5. WDR5 was immobilized
onto CM5 chips and allowed to associate with MLL1Win peptide, whose
concentration was varied in the range of 4  10-8 through 4  10-5 M (the horizontal
axis). The resultant maximum relative responses were plotted and fitted to obtain
the KD of the interaction. Although this set of illustrated data resulted from a single
experiment, three independent data acquisitions were employed to obtain the
average value of KD
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6. Quantitative comparisons of kinetic rate constants of WDR5-SET1Win
interactions between BLI and SPR measurements.

Figure S7: Comparisons of kinetic rate constants of association and
dissociation between restricted BLI and unrestricted SPR conditions. (A)
Association rate constants. (B) Dissociation rate constants. All experimental details
are provided in Materials and Methods.
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7. Quantitative comparisons of the binding affinities of WDR5-SET1Win
interactions among BLI, SPR, and steady-state FP.
Table S2: Quantitative comparisons of KD obtained via BLI, SPR, and steadystate FP. KD-BLI, KD-SPR, and KD-FP are the equilibrium dissociation constants
measured via BLI, SPR, and steady-state FP, respectively.
Peptide
KD-BLI
KD-SPR
KD-FP
(nM)
(nM)
(nM)
MLL1Win
16,000 ± 3,000** 9,000 ± 5,500***
≳100,000*
MLL2Win

170 ± 20

33 ± 2

23 ± 5

MLL3Win

100 ± 5

19 ± 1

15 ± 4

MLL4Win

1,700 ± 200

190 ± 20

130 ± 20

SETd1AWin 620 ± 20

350 ± 10

72 ± 5

SETd1BWin 250 ± 30

69 ± 6

18 ± 2

*This is the upper-limit value for the detection of KD-BLI. It results from dividing
the upper-limit value of detection of koff by the value of the kon approximation.
**KD-SPR was determined using a steady-state SPR measurement.
***Prior ITC measurements at a slightly increased salt concentration show that data
are consistent with the steady-state FP measurements [1].
8. Computational predictions of the association rate constants of WDR5SET1Win interactions using the basal rate constants and electrostatic free
energies of the transient WDR5-SET1Win complex.
Table S3: Determination of the association rate constants using the basal rate
constants, kon0, and electrostatic free energies, ΔG*el, of the transient WDR5SET1Win complex.

MLL1Win

kon0
(M-1  s-1)
1.27  105

ΔG*el
(kcal/mol)
1.412

kon
(M-1  s-1)
1.17  104

MLL2Win

2.79  105

-0.027

2.92  105

MLL3Win

2.07  105

0.323

1.20  105

MLL4Win

2.64  104

0.122

2.15  104

SETd1AWin

ND*

ND*

ND*

SETd1BWin

ND*

ND*

ND*

Peptide sequence

These values were determined using The “TransComp: Web Server for Predicting
Protein Association Rate Constants” (https://pipe.rcc.fsu.edu/transcomp/) [3-7].
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ND* Computational predictions could not be made for these interactions, because
the association process of the WDR5-SET1Win complex may not undergo a singlestep mechanism.
The calculation of the kon was based on the following equation:
kon = kon0 exp(-ΔG*el/kBT)
(S1)
Here, kon0 is the basal rate constant for attaining the transient WDR5-SET1Win
complex. ΔG*el indicates the electrostatic energy of the transient WDR5-SET1Win
complex. The computational process encompasses three components: (i) the
generation of the transient WDR5-SET1Win complex, (ii) the calculation of the
basal rate constant kon0, and (iii) the determination of the electrostatic interaction
energy, ΔG*el, which is associated with the WDR5-SET1Win transient complex.

9. Accession codes.
WDR5 protein:
MLL1Win motif :
MLL2Win motif:
MLL3Win motif:
MLL4Win motif:
SETd1AWin motif:
SETd1BWin motif:

UniProtKB - P61964 (WDR5_HUMAN)
UniProtKB - Q03164 (KMT2A_HUMAN)
UniProtKB - O14686 (KMT2D_HUMAN)
UniProtKB - Q8NEZ4 (KMT2C_HUMAN)
UniProtKB - Q9UMN6 (KMT2B_HUMAN)
UniProtKB - O15047 (SET1A_HUMAN)
UniProtKB - Q9UPS6 (SET1B_HUMAN)

10. Supporting references.
1
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3.1 Abstract
Progress in tumor sequencing and cancer databases has created an enormous
amount of information that scientists struggle to sift through. While several
research groups have created computational methods to analyze large databases,
much work still remains in distinguishing key implications of pathogenic
mutations. Here, we describe an approach to identify and evaluate clinically
significant mutations of WD40 repeat protein 5 (WDR5), a chromatin-associated
protein hub. This multitasking protein maintains the functional integrity of large
multi-subunit enzymatic complexes of the six human SET1 methyltransferases.
Remarkably, the somatic cancer mutations of WDR5 preferentially distribute
within and around an essential cavity, which hosts the WDR5 interaction (Win)
binding site. Hence, we assessed the real-time binding kinetics of the interactions
of key clustered WDR5 mutants with the Win motif peptide ligands of the SET1
family members (SET1Win). Our measurements highlight that this subset of cancer
mutants not only exhibits divergent perturbations in the kinetics and strength of
interactions relative to those of the native WDR5, but also among the SET1Win
ligands. The immediate outcomes of this study could be used further for accelerated
discoveries in precision medicine.
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3.2 Introduction
WD40 repeat proteins (WDRs) are among the most abundant protein-protein
interaction (PPI) domains in the human proteome (1-3). WDRs are either
implicated in numerous cell signaling pathways (4,5) or in scaffolding large multisubunit enzymatic complexes (6,7). Notably, WD40 repeat protein 5 (WDR5) is a
highly conserved nuclear hub, which is primarily known for its regulatory role in
histone 3 lysine 4 (H3K4) mono- and di-methylation (8-13). In this process, WDR5
bridges the interaction between the catalytic domain of mixed lineage leukemia
MLL/SET1 family proteins and other subunits of the large methyltransferase
complex. The assembly and stability of this enzymatic complex is necessary for
optimal methyltransferase activity (14-16). In addition, WDR5 interacts with other
protein partners, such as transcription factor MYC (17-20) and 3-phosphoinositidedependent protein kinase 1 (PDPK1) (21). Two highly conserved motifs of these
protein binders, the WDR5 interaction (Win) motif (22-24) and WDR5-binding
motif (WBM) (18,25,26), are deemed responsible for the vast majority of their
interactions with WDR5. Interactions corresponding to these motifs are mediated
by the Win and WBM sites, respectively (Fig. 1a).
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Figure 1: The two binding sites of WDR5 and the structure of the WDR5MLL3Win complex. (a) Representations of the Win and WBM binding sites of
WDR5. Orientations of WDR5 in the two cartoons are 180 with respect to each
other. (b) The top view of the WDR5-MLL3Win complex. (c) The side view of the
WDR5-MLL3Win complex. (d) The side view of the interaction sites between
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MLL3Win (green) and WDR5 (gray). All presented residues are within 5 Å of the
other binding partner. The residues corresponding to the WDR5 mutations explored
in this study are marked in dark gray. MLL3Win residues are labelled as well.
Potential hydrogen bonds between the two binding partners are shown as yellow
dotted lines. (e) Key residues of the WDR5 binding cavity involved in hydrogen
bonding with the evolutionarily conserved Arg residue (R4710) of MLL3Win at
position P0 (Supplementary Table S1). The hydrogen bonds are indicated by thick
dashed lines marked in yellow. The cut-off distance for identifying these hydrogen
bonds was 4.0 Å. WDR5 was represented using pdb entry 4ERY (35).
For oncoproteins, the driver cancer mutations preferentially populate either
within an active site or on their binding surface (27,28). Based upon this argument,
we postulated that missense somatic cancer mutations of WDR5 form a dense
cluster either within one or both binding sites. Databases, such as Catalogue of
Somatic Mutations in Cancer (COSMIC) (29,30), have become instrumental
resources for unraveling the influential roles of specific proteins in different cancers
(31-33). However, by determining the density and location of known mutations,
their important subsets under disease-like conditions can potentially be identified.
Using the clustering of mutations in protein structures (CLUMPS) method (34), we
were able to identify, in accord with our hypothesis, that the high-density
distribution of WDR5 cancer missense alterations occurs within and around the
Win binding site.

The Win binding site is located within a central cavity and facilitates highaffinity interactions of WDR5 with each of the six human histone
methyltransferases (HMTs; MLL1-4 and SETd1A-B), participating in the
formation

of

corresponding

six

SET1

enzymatic

complexes

(35,36).

Rearrangements in the MLL1 gene lead to solid tumors and aggressive lymphocytic
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leukemias in humans (37). Moreover, WDR5 is overexpressed under various
oncogenic conditions and its upregulation catalyzes cancer development (38-42).
In recent years, the multitasking Win binding site has received a lot of interest
(21,43-45), because it is a promising target for anti-cancer drug discovery (46-53).
Therefore, a quantitative understanding of the WDR5 interactions with other Win
motif partners has wide-ranging fundamental and clinical significance (50,54-57).
For example, the kinetic fingerprints and affinities of the interactions of WDR5
with Win motif peptides of SET1 family members (SET1Win) have been previously
reported (22,35,36,44,45).

Stimulated by our finding using the CLUMPS method (34), we explored the
impact of somatic cancer mutations of WDR5 on its interactions with 14-residue
SET1Win peptide ligands of the six SET1 proteins (Fig. 1b-c; Supplementary
Table S1). The WDR5-SET1 interaction requires the precise insertion of a highlyconserved Arg residue of SET1 proteins into the Win binding site (Fig. 1d-e) (23).
This key interaction is a prerequisite for the structural and functional integrity of
the C-terminal catalytic domain of SET1 proteins (15,22,23). SET1Win ligands
recapitulate the native interactions of the six SET1 proteins with WDR5 through
the Win binding site (35,36). Therefore, we utilized the benefit of biolayer
interferometry (BLI) (58,59) for high-throughput settings and immobilized these
SET1Win ligands onto the sensor surface. In this way, we probed the real-time
kinetics and dynamics of their interactions with a subset of WDR5 cancer mutants,
whose missense alterations are located within and around the Win binding site.
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Remarkably, while these clustered mutations feature spatial proximity, they exhibit
divergent effects on interactions with each of the six SET1Win ligands. Finally, the
results of this scalable kinetic platform were confirmed by orthogonal
determinations of affinity constants of these interactions using steady-state
fluorescence polarization (FP) spectroscopy (60,61).

3.3 Materials and Methods
Clustering of Mutations in Protein Structures (CLUMPS). This approach
was used as previously reported (34). WDR5 mutations were obtained using the
COSMIC database (29,30,62) and available X-ray crystallographic information
(PDB code 4ERY) (35). A weighted average proximity (WAP) score was generated
for the distribution of mutations using the following equation:
𝑊𝐴𝑃 = ∑ 𝑖,𝑗 𝑠𝑖 𝑠𝑗

𝑑2
𝑖,𝑗

−
𝑒 2𝑟2

𝑖≠𝑗

(1)
where i and j iterated over all residues of WDR5. Here, di,j is the Euclidean distance
between residues i and j in Angstroms, and r denotes the distance threshold set to a
constant value of 6 Å (34). si represents the normalized number of samples, in
which the residue i was mutated. This parameter is given by:
𝑠𝑖 =

𝑛𝑖3
23 + 𝑛𝑖3

(2)
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where ni represents the number of samples, in which the residue i was mutated. The
P-value was determined by calculating the WAP score for 106 random distributions
of mutations, and then by comparing it with that value of the known distribution.

Protein Expression and Purification. All expression plasmids were
synthesized, codon optimized, and sequence verified by GenScript (Piscataway,
NJ). Human WDR5 (UniProtKB - P61964; WDR5_HUMAN) and its mutants were
expressed and purified as described previously (22,23,44).

Peptide synthesis, labeling, purification, and

analysis.

For BLI

measurements, 14-residue SET1Win peptide ligands were biotinylated at their N
terminus and amidated at their C terminus. They were synthesized and purified to
≥ 95% purity by GenScript (Piscataway, NJ). Purity confirmation, amino acid
analysis, and solubility testing were conducted and provided by GenScript. For
steady-state FP measurements, details on peptide synthesis, labeling, purification,
and analysis were previously published (44). In brief, peptides were synthesized
using a Biotage Syro I peptide synthesizer (Biotage, Charlotte, NC). Then, the
peptides were purified using reversed-phase chromatography in two steps: (i) flash
chromatography using a Biotage Isolera One (Biotage AB, Uppsala, Sweden), and
(ii) semi-preparative HPLC using a Waters 2695 separations module equipped with
a Waters 2996 photodiode array detector (PDA). A Sulforhodamine B fluorophore
was chemically attached at the N terminus of the 14-residue SET1Win peptides,
whereas their C terminus was amidated. A 9-residue Gly/Ser-rich peptide sequence
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was

introduced

between

the

fluorophore

and

the

SET1Win

sequence

(Supplementary Methods). Fluorophore-containing peptide fractions were
analyzed by MALDI-TOF mass spectroscopy for the identity and purity tests.

Biolayer interferometry (BLI). Octet RED384 (FortéBio, Fremont, CA) was
employed for the BLI studies (58,59). The assay buffer contained 150 mM NaCl,
20 mM Tris-HCl, 1 mM TCEP, 1 mg/mL bovine serum albumin (BSA), pH 7.5.
Streptavidin-coated biosensors were incubated for 15 minutes with 5 nM biotintagged SET1Win peptide to specifically immobilize an optimal level of peptide.
Sensors were then rinsed briefly in assay buffer to remove unbound peptides. Next,
sensors were exposed to 3-fold serial dilutions of WDR5 for the association
process. The dissociation phase was initiated by transferring the BLI sensors into
WDR5-free buffer. For all WDR5 concentrations, binding curves were recorded by
subtracting the baseline and the drift in the sensorgrams acquired with unloaded
sensors. These BLI measurements were conducted at 24ºC. For various WDR5
concentrations, [C], the association phases were fitted using the following equation
(63):
𝑌 = 𝑌∞ − (𝑌∞ − 𝑌0 )𝑒 −𝑘obs 𝑡
(3)
where Y0 and Y are the response signals at the initial time and infinity, respectively.
t is the cumulative time of the association phase, whereas kobs denotes the apparent
first-order reaction rate constant of the association phase. The dissociation phases
were fitted using the following equation:
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𝑌 = 𝑌∞ + (𝑌0 − 𝑌 )𝑒 −𝑘off 𝑡
(4)
where Y0 and Y denote the responses at the initial time and infinity, respectively.
koff is the dissociation rate constant. The association rate constant, kon, was
determined using the slope of the linear curve (61,64):
𝑘obs = 𝑘on [𝐶] + 𝑘off
(5)
Using several WDR5 concentrations, we also conducted global fittings, which
provided the corresponding kon and koff values. The equilibrium dissociation
constants, KD, were indirectly determined using the kon and koff values (KD =
koff/kon). In each case, three independent BLI recordings were acquired for further
determinations of the kinetics and dynamics of WDR5-SET1Win interactions.

Steady-state fluorescence polarization (steady-state FP) measurements.
Steady-state fluorescence polarization (FP) recordings were performed using a
SpectraMax i3x plate reader (Molecular Devices, San Jose, CA) (60,65). All
steady-state FP measurements were conducted using a buffer that contained 20 mM
Tris-HCl (pH 7.5), 150mM NaCl, 1 mM TCEP, 0.005% Tween 20, and 96-well
black untreated polystyrene microplates (Corning Inc., Corning, NY). Other details
of steady-state FP measurements were previously reported (44). 100 µL of each 20
nM labeled SET1Win peptide was added to individual wells at a final concentration
of 10 nM. The steady-state FP anisotropy was measured on the plates after a 1 h
incubation at room temperature in the dark. WDR5-dependent dose-response data
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were averaged and then fitted using a four-parameter logistic function to acquire
the binding affinity (KD) for each interaction pairs.

Molecular graphics. In this study, molecular graphics was conducted using the
PyMOL Molecular Graphics System (Version 2.4.0 Schrödinger, LLC).

3.4 Results and Discussion
The use of CLUMPS for the identification of mutation clustering in WDR5.
We employed the CLUMPS method (34) to investigate the 3D clustering of 68
WDR5 mutations identified in 68 tumors. The missense mutations were
comprehensively compiled using the COSMIC database (29,30,62). Information
collected for each mutation included the residue number, the number of tumor
samples, in which a certain mutation was noted, and the total number of mutations,
N, in a tumor sample. N was used as a measure of the accumulation of genetic
damage in a tumor sample, in which a certain mutation was sequenced. Four
overlapping subsets of mutations were created from the total set of known
mutations with the following conditions: N < 10,000, N < 5,000, N < 1,000, and N
< 500 (Table 1). For each subset, we calculated the WAP score and the
corresponding P-value (Materials and Methods; Supplementary Fig. S1). We
found that a subset of WDR5 mutations with a relatively low N (N < 500) is more
likely to show mutation clustering, because P-value was smaller than 0.03. Notably,
the low-N subset also showed a substantial presence of mutations within and around
the Win binding site (Supplementary Tables S2-S3). Therefore, a subset of seven
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mutations were selected from all known WDR5 cancer mutations within and around
the Win binding site (Supplementary Table S4). This approach allowed us to
study the effects of these somatic cancer mutations on the kinetics and dynamics of
WDR5-SET1Win interactions.
Table 1: Results of mutation clustering of WDR5 for different subsets of N.
WAP scores were calculated using 4 different subsets of mutations divided on the
basis of the genetic damage, N, in their corresponding tumors. The P-values were
calculated by comparison to configurations with random permutations of the
distribution of mutations. 106 configurations were used for each subset. N is the
total number of mutations in a given tumor sample. m is the total number of
mutations that met the condition N  Nmax, where Nmax is the upper limit of the
number of mutations in a given tumor sample. Nmax values are listed below for four
data subsets on the first column. m was kept constant for all configurations of a
subset.
N

m

WAP Score

P-value

< 10,000

51

2.258

0.403

< 5,000

33

0.931

0.206

< 1,000

11

0.095

0.111

< 500

8

0.072

0.025
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Figure 2: Label-free optical BLI sensorgrams of the WDR5 mutant-MLL3Win
interactions. (a) Locations of the surface and cavity WDR5 mutations are shown
in blue using surface and cross-sectional views of WDR5, respectively. (b) BLI
sensorgrams showing the association and dissociation phases. For each WDR5
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mutation, sensors with immobilized MLL3Win ligand were immersed in buffers
containing different WDR5 concentrations (listed on sensorgrams) to monitor
association kinetics. Sensors were then transferred to buffer alone to monitor
dissociation kinetics.

Biolayer interferometry (BLI) measurements. In this study, targeted
mutations have locations either within the WDR5 cavity (F133L, S175L, S218F,
and D92N) or on the external surface and near the cavity (D172A, Y260H, and
P216L) (Fig. 2a; Supplementary Table S4). These mutants were chosen based on
their proximal locations to residues deemed to play roles in SET1Win interactions
with the native WDR5 protein (Supplementary Fig. S2 Tables S5-S6)
(22,23,35,36). BLI measurements were used to determine the association (kon) and
dissociation (koff) rate constants of WDR5-SET1Win interactions (58,59). 14-residue
SET1Win peptide ligands, namely MLL1Win, MLL2Win, MLL3Win, MLL4Win,
SETd1AWin, and SETd1BWin, were biotinylated at the N terminus and amidated at
the C-terminus (Supplementary Table S1). A 9-residue Gly/Ser-rich peptide
spacer was inserted between the biotinylated site and the SET1Win sequence to
avoid any steric hindrance of WDR5-SET1Win interactions from the sensor surface.
Biotinylated SET1Win peptides were then tethered to the surface of streptavidincoated sensors. Binding interactions of WDR5 with SET1Win ligands attached to
the sensor surface were monitored through changes in the optical interference
pattern generated by reflected light waves at the sensor surface (Fig. 2b). The
association binding curves were acquired by placing the BLI sensors in distinct
wells of varying WDR5 concentration. The dissociation binding curves were
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collected by placing the BLI sensors in wells containing WDR5-free buffer. It
should be mentioned that all association and dissociation phases obeyed singleexponential fits, suggesting bimolecular association processes and unimolecular
dissociation mechanisms of these binding phases, respectively.

Interestingly, we noted very weak binding interactions of all SET1Win peptides
with D92N, a cavity WDR5 mutant (Fig. 2a; Supplementary Fig. S3). While these
interactions are detectable, they cannot be accurately quantified using BLI likely
due to either a very low kon or a very high koff, or both. A couple of possibilities
could explain this interesting outcome. First, Asn-92 might interfere with the two
hydrogen bonds between the Arg residue at the P0 position of the SET1Win ligand
(Supplementary Table S1) and S91, a neighboring residue of WDR5
(Supplementary Table S5). Second, the positively charged guanidinium group of
Arg at P0 of SET1Win might make an N-O salt bridge with the negatively charged
carboxyl group of Asp-92 (Supplementary Table S6) (66). In addition, Asp-92
forms a salt bridge with Lys-52 located between  strands. Therefore, the absence
of Asp-92 might alter the local conformation of the binding pocket.
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Figure 3: Normalized dissociation rate constants of the WDR5 mutantSET1Win interactions using BLI sensorgrams. The koff values for each SET1Win
ligand’s interaction with mutants have been divided by the koff of that SET1Win
ligand’s interaction with the native WDR5 protein. (a) MLL2Win, (b) MLL3Win, (c)
MLL4Win, (d) SETd1AWin, and (e) SETd1BWin. ND stands for “Not Determined.”
Using a BLI measurement, the interaction between F133L and MLL4Win was
detectable, but not quantifiable.
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Figure 4: Normalized KD of the WDR5 mutant-SET1Win interactions using
BLI sensorgrams. The KD values for each SET1Win ligand’s interaction with
WDR5 mutants have been divided by the KD of that SET1Win ligand’s interaction
with the native WDR5 protein.
(a) MLL2Win, (b) MLL3Win, (c) MLL4Win, (d) SETd1AWin, and (e) SETd1BWin. ND
stands for “Not Determined.” Using a BLI measurement, the interaction between
F133L and MLL4Win was detectable, but not quantifiable.
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Surface mutants. We first looked at surface mutants and the effects of these
mutations on the WDR5-SET1Win interaction. The normalized values of kon
(Supplementary Fig. S4), koff (Fig. 3), and dissociation constant KD-BLI (Fig. 4) for
these WDR5 mutants are the values of these parameters of the SET1Win-WDR5
mutant pair interactions divided by those values corresponding to the SET1Winnative WDR5 pair interactions. In general, surface mutants D172A, P216L, and
Y260H exhibited closely similar values of kon, koff, and KD-BLI to those obtained for
the native WDR5 protein (Supplementary Tables S7-S9) (44). Again, we were
not able to obtain a quantifiable kon for the MLL1Win-WDR5 mutant pair
interactions due to limited time resolution of BLI. Interestingly, kon followed the
same trend with respect to SET1Win peptides, as established in our previous study
(44), with the lowest values for the neutrally charged MLL4Win, the highest values
for the acidic SETd1AWin and SETd1BWin, and the intermediate values for the
positively charged MLL2Win and MLL3Win. For example, for P216L-MLL4Win
interactions, kon was (1.9  0.3)  104 M-1s-1. Yet, for the interactions of P216 L
with MLL2Win, MLL3Win, SETd1AWin, and SETd1BWin kon was (5.6  0.8)  104 Ms , (5.3  0.7)  104 M-1s-1, (8.6  0.8)  104 M-1s-1, (8.0  0.8)  104 M-1s-1,

1 -1

respectively. We conclude that kon (0)  kon (+1)  kon (-1) for surface mutants,
where the number between parentheses is the overall charge of the SET1Win
peptides (Supplementary Table S1). In other words, kon (MLL1Win, MLL4Win) 
kon (MLL2Win, MLL3Win)  kon (SETd1AWin, SETd1BWin) for surface mutants. This
kon rule is likely determined by an asymmetric charge distribution in SET1Win with
respect to the highly conserved 6-residue Win motif peptide segment (P-3 through
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P2). Specifically, this is because of a positive charge located on the C-terminal
flanking side in P4 (MLL2Win and MLL3Win) and a negative charge located on the
N-terminal flanking side in P-7 (SETd1AWin and SETd1BWin). Asp-172 is located
within the A pocket of WDR5. SET1Win ligands show no difference in their
interactions with D172A as compared to the native WDR5 protein. We did not see
any significant changes in the kon and koff for this pocket mutant. In addition, we
noted a significantly weakened interaction of P216L with MLL4Win. Pro-216 is
located within the B pocket.

Cavity mutants. In addition to D92N, we examined three WDR5 cancer
mutations within the WDR5 cavity, such as F133L, S175L, and S218F (Fig. 2b). It
has been previously reported that F133A significantly deteriorates the strength of
the interactions of the MLL1 subunit with the WDR5-RbBP5-Ash2L subcomplex
in vitro (23). Phe-133 is a critical neighboring WDR5 residue of the evolutionarily
conserved Arg at P0 of SET1Win ligands, contributing to a potentially strong cation interaction. Very weak interactions of F133L with MLL1Win and MLL4Win were
not quantifiable using BLI. Here, F133L showed a decreased normalized kon with
MLL2Win, MLL3Win, SETd1AWin, and SETd1BWin (Supplementary Fig. S4). As
expected, F133L exhibited a noteworthy change in the koff with respect to the native
WDR5 protein (Fig. 3), leading to a significant increase in the KD-BLI. For MLL2Win,
MLL3Win, SETd1AWin, and SETd1BWin, these increased values spanned a range
between one and two orders of magnitude (Fig. 4; Supplementary Table S9). This
outcome indirectly confirms their close similarity in sequence and interaction
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mechanisms with WDR5 (35,36). Their distinctions in binding affinities with
respect to the other SET1Win ligands can be attributed to the interaction of their
flanking sides with the WDR5 surface.

However, the most interesting mutational effect is that of S175L, which has a
more divergent impact on interactions of the SET1Win peptides with respect to the
native WDR5 protein. For example, S175L selectively weakens the interactions
with MLL3Win, MLL4Win, and SETd1AWin, while substantially strengthening the
interactions with SETd1BWin (Fig. 3, Fig. 4; Supplementary Table S9). Moreover,
this change is primarily associated with a change in the koff. Ser-175 is part of a
cluster of neighboring residues that co-participate in an array of hydrogen bonds,
-, cation-, and hydrophobic interactions with the conserved Arg in P0. These
include Ser-91, Phe-133, Ser-175, Ser-218, Cys-261, Phe-263, and Ile-305 (35).
For example, Arg at P0 makes a water-mediated hydrogen bond with the Ser-175
backbone carbonyl group (36).

Known SETd1B-WDR5 crystal structures suggest that replacing Ser-175 with
Leu creates steric clashes that affect the structure of the B pocket (Supplementary
Fig. S5) (35,36). Specifically, it could displace Tyr-191 and make the pocket more
hydrophobic, which would explain the increased affinity with SETd1B. It is worth
mentioning that SETd1B is unique, because it has a Phe residue at P4
(Supplementary Table S1) that inserts into the hydrophobic B-pocket, while the
other B-pocket binders have a more polar residue (Lys or Tyr) in that position.
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Interestingly, the increased affinity is made possible through a 4-fold decrease in
the dissociation rate constant with no change in the association rate constant. Given
the importance of slow dissociation rates for effective therapeutics (50), we predict
molecules designed to take advantage of this interaction will improve dwell times
and make more effective inhibitors (21).

In agreement with prior crystallographic studies (35,36), S218F exhibited
weakened interactions with MLL2Win, MLL3Win, and MLL4Win. However, its
interactions with SETd1AWin and SETd1BWin were closely similar to those with the
native WDR5 protein (Figs. 3-4; Supplementary Table S9). This finding is in
accordance with a different mechanism of binding interactions of SETd1A Win and
SETd1BWin with respect to the other SET1Win ligands, likely due to an intermediate
orientation of the C-terminal ends of SETd1AWin and SETd1BWin on the surface of
blades 4 and 5.
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Figure 5: Normalized KD of the WDR5 mutant-SET1Win interactions using
steady-state FP spectroscopy. The KD values for each SET1Win ligand’s
interaction with WDR5 mutants have been divided by the KD of that SET1Win
ligand’s interaction with the native WDR5 protein.
(a) MLL1Win, (b) MLL2Win, (c) MLL3Win, (d) MLL4Win, (e) SETd1AWin, and (f)
SETd1BWin. For vertical bars marked by "*", the KD of those interactions could not
be determined. Those values represent the lower-limit of the KD based on the
highest WDR5 mutant concentrations used in this study.
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Validations of BLI data and qualitative comparisons between competing
techniques. To validate the outcomes of BLI measurements, we next used steadystate FP spectroscopy as an orthogonal technique (Supplementary Fig. S6) to
determine binding affinities, KD-FP, of the interactions of SET1Win ligands with
WDR5 cancer mutants (Fig. 5; Supplementary Table S10). 14-residue SET1Win
peptide ligands were fluorescently labeled with Sulforhodamine B at the N terminus
and amidated at the C terminus. A 3 nm-long Gly/Ser-rich peptide spacer was
inserted between the fluorophore site and the SET1Win sequence. Then, steady-state
FP anisotropy, r, values were collected at increasing WDR5 concentrations. Doseresponse FP measurements enabled determinations of the KD-FP. Remarkably, the
FP experiments validated all qualitative findings acquired by BLI. These include
the confirmation of very weak binding interactions of D92N with all SET1Win
peptides (Supplementary Fig. S7). In addition, we always found that the absolute
KD values (i.e., not normalized) obeyed the following inequality: KD-BLI  KD-FP.
This outcome validates our previous results, indicating that measured interactions
are stronger in unrestricted conditions than those corresponding to restrained
conditions (Supplementary Tables S11-S12) (44). Because these WDR5 mutants
have been examined using BLI and FP, we can compare these approaches
quantitatively and qualitatively (67). For example, using BLI we can determine the
kinetic fingerprint of these interactions. Yet, this cannot be inferred using steadystate FP spectroscopy. BLI is an immobilization-based technique, whereas FP is a
method that probes binding affinity in solution under unrestricted conditions. This
is likely the reason why the KD-BLI is always about one order of magnitude greater
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than the KD-FP (Supplementary Tables S9-S10). In addition, FP measurements
enabled us to measure some weaker interactions, which had kinetics that were too
fast for the BLI time resolution (e.g., for MLL1Win). Furthermore, these approaches
probe distinctive physical processes. On one hand, BLI is a real-time technique that
samples both the association and dissociation phases based on alterations in the
interference pattern of white light reflected on the sensor surface. On the other hand,
steady-state FP is a time-independent technique that monitors changes in the
rotational diffusion of a fluorescently labeled molecule upon its binding to another
molecule. We calculated the ratio KD-BLI/KD-FP (Supplementary Fig. S8).

Figure 6: Quantitative comparison between affinity data resulting from BLI
and FP measurements. (a) A 3D graph of the ratio of the normalized KD-BLI to the
normalized KD-FP. (b) A 2D heat map of the ratio of the normalized KD-BLI to the
normalized KD-FP. Normalized KD values are the KD measured for a specific WDR5
mutant-SET1Win interaction pair divided by the KD value corresponding to the
native WDR5 protein.

The variability of the KD-BLI/KD-FP ratio for different interacting pairs was likely
caused by two determinants: (i) the difference in mobility of each SET1Win ligand
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with respect to WDR5 mutants, and (ii) the distinction in physical processes probed
by the two methods. To cancel the effect of these two determinants, we determined
another dimensionless parameter, the ratio of normalized KD-BLI/normalized KD-FP,
which spanned a much narrower spectrum, between 0.36 and 2.15 (Fig. 6;
Supplementary Table S12). This finding illuminates the qualitative agreement of
data resulting from BLI and FP measurements, fortifying our conclusions on the
effect of introducing these missense mutations on SET1Win - WDR5 interactions.
Moreover, these BLI and FP data are in accordance with a recent single-molecule
study using an engineered protein nanopore (45), which indicated unaffected
D172A-MLL4Win interactions and weak D92N-MLL4Win interactions with respect
to those of the native WDR5 protein. Taken together, these findings demonstrate
the critical role of a negative charge located within the acidic WDR5 cavity for the
strength of WDR5-SET1Win interactions.

Oncogenic potential of Win binding site mutants. While the impact of the
WDR5 cancer mutations on WDR5-SET1Win interactions is readily distinguishable,
their effect on the overall assembly of the SET1 complexes and their functional
features is a bit more nuanced. Given our understanding of SET1 family complex
behavior (16,48), we can say that these inspected WDR5 mutations have a
divergent impact. The absence of WDR5 (16) and/or the inhibition of SET1WinWDR5 interactions (48) downregulates the H3K4 di-methylation function of
MLL1 and SETd1A, while this upregulates the H3K4 mono-methylation function
of MLL3 (16,68). Therefore, mutations that significantly disrupt SET1Win-WDR5
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interactions are likely to have similar effects. Consequently, F133L and D92N
should disrupt di-methylation by MLL1 and SETd1A. Furthermore, monomethylation function of MLL3 would be upregulated in the case of F133L, S218F,
S175L and D92N. Moreover, our results show that even within the Win binding
site, given their effect on SET1win-WDR5 interactions, cavity mutations are more
likely to be driver mutations instead of passenger mutations. This holds especially
true for D92N, F133L, and S175L. For example, Ali and coworkers (2014) found
that F133L disrupts the mitotic progression in the cell cycle process (69).

The information that concerns the KD values of mutations within the B pocket
is critical for future drug development. Precision medicine depends on
understanding the unique biophysical impacts of each missense mutation on the
structure and function of putative oncogene proteins. Our data suggests that this
knowledge would help researchers and eventually clinicians in deciding which
inhibitors to use as potential therapeutic approaches. For example, this work
suggests that individuals harboring a breast cancer S175L mutation in WDR5
(Table S4) are more likely to respond to inhibitors targeting the hydrophobic
interactions in the B pocket than other inhibitors. Furthermore, the unique impacts
of S175L in SETd1b suggests that those cancers are due to perturbations in the
SETd1B-catalyzed H3K4 methylation pathway. This type of information would
greatly enhance our ability to prioritize cellular and animal-based follow-up studies
that can address more specific hypotheses.
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3.5 Concluding remarks. In this study, we evaluated key somatic cancer
mutations of WDR5. Specifically, we used the CLUMPS approach to identify that
cancer mutations accumulate within the Win binding site and extracted a
representative subset of WDR5 mutants for determining the real-time kinetics of
their interactions using high-throughput techniques. Our work shows that the total
number of mutations in a tumor sample can be used as a parameter to filter out
mutations more likely to be driver mutations. Furthermore, we noted that the Win
site shows a substantial presence of low-N mutations, while the WBM site shows
none. This helped us to exclusively focus on Win binding site mutants for further
biophysical measurements. Therefore, we explored the effect of mutations in this
binding site by presenting a detailed kinetic fingerprint of the interactions of these
mutants with various SET1Win ligands. We provide experimental evidence for
influential roles of the residues within the WDR5 cavity on the strength of these
interactions. Steady-state FP spectroscopy measurements also confirmed outcomes
resulting from BLI experiments. Finally, the interactions of WDR5 cavity mutants
depended on the nature of the SET1Win peptides. These divergent effects have
distinctive impacts on H3K4 methylation, and therefore for the downstream
expression of genes. This is a finding that can reconfigure future strategies for the
design, development, and optimization of inhibitors that are aimed at targeting the
multitasking high-affinity Win binding site under oncogenic conditions. In the
future, it would be interesting to examine the impact of the Win binding site cancer
mutations on the kinetics and strength of the interactions of WDR with other protein
partners and Win motif ligands.
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18. Supporting references.
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1. Sequence of 14-residue SET1Win peptide ligands
Table S1: Amino acid sequences of SET1Win motif peptide ligands. Here,
MLL1Win, MLL2Win, MLL3Win, MLL4Win, SETd1AWin and SETd1BWin are the
following 14-residue SET1 Win motif ligands: MLL13758-3771, MLL25333-5346,
MLL34703-4716, MLL42504-2517, SETd1A1488-1501, and SETd1B1698-1711 (1-3).
SET1Win

P-7

P-6

P-5

P-4

P-3

P-2

P-1

MLL1Win

L

N

P

H

G

S

A

MLL2Win

I

N

P

T

G

C

MLL3Win

V

N

P

T

G

MLL4Win

L

N

P

H

SETd1AWin E

H

Q

E

H

V

SETd1BWin

P0

P1

P2

P3

P4

P5

P6 Charge

R

A

E

V

H

L

S* 0

A

R

S

E

P

K

I

L

+1

C

A

R

S

E

P

K

M

S

+1

G

A

A

T

G

S

A

R

S

E

G

Y

Y

P

-1

T

G

C

A

R

S

E

G

F

Y

T

-1

R

A

E

V

Y

L

S** 0

S* This is an R3771S-substituted MLL1Win peptide ligand.
S** This is an R2517S-substituted MLL4Win peptide ligand.

2. Location of somatic cancer mutations from tumor samples with N < 500
and their distributions with a well-defined upper limit of mutations
Table S2: Location of mutations from tumor samples with N < 500. The
mutation distribution from tumor samples with low N values is shown below. Out
of 8 such somatic cancer mutations, 5 were within or around the Win binding site,
while 3 were found elsewhere. Mutated residues are either inside the WDR5 cavity
(■), have established interactions with SET1Win (□), or sequentially are one residue
away from residues with established interactions with SET1Win (○) (1,4).
Mutations within and around Independent Mutations
the Win binding site
F133L ■ □
S54N
S175L ■ □
G254D
■
A264V
L282P
N130Y ○
D150G ○
102

Table S3: Distributions of somatic cancer mutations in tumors with a welldefined upper limit of mutations. Diverse mutation clusters correspond to
different maximum number of mutations, Nmax. The mutations highlighted in
yellow were studied further using BLI and steady-state FP spectroscopy. S218F
and D92N mutations, which are located within the WDR5 cavity, were found in
tumors with N  10,000. For compiling these mutations, the COSMIC database was
used (5-7).
Condition

Mutations

N < 10,000

N130Y
L185F
P311Q
L143F
V275L
S278L
L102F
N130Y
L185F
P311Q
L143F
V275L
N130Y
L185F
N130Y

N < 5,000

N < 1,000
N < 500

S54N
R181C
S223Y
R181C
G226V
K245N
L230P
S54N
R181C
S223Y
R181C

S175L
E292Q
S202L
Y260H
G299C
H255N
G147E
S175L
E292Q
S202L
Y260H

G254D A264V
S184F D333Y
D213N P139H
P224S A201T
D172N E279K
G277D I274F

D150G
S148F
Y75H
D172A
L206P
S91F

F133L
I327V
V217M
L102V
D302E
S171L

L282P
S318P
T253A
R196C
Q289E
P216L

G254D
S184F
D213N
P224S

D150G F133L
S148F I327V
Y75H V217M
D172A L102V

L282P
S318P
T253A
R196C

A264V
D333Y
P139H
A201T

S54N S175L G254D A264V D150G F133L L282P
R181C E292Q
S54N S175L G254D A264V D150G F133L L282P

3. Results of mutation clustering for different Nmax-based mutation subsets
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N < 10,000

N < 5,000
Counts (× 10 )
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A

P = 0.206

P = 0.403
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N < 1,000

P = 0.111
WAP

P = 0.025
WAP
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Figure S1: Results of mutation clustering for different Nmax-based mutation
subsets. (A) WAP scores were calculated using 4 different subsets of mutations
divided on the basis of the genetic damage, N, in their corresponding tumors. The
P-values were calculated by comparing to the calculated WAP scores to those
corresponding to random permutations of the mutation distribution. 106
configurations were used for N < 10,000 (A), N < 5,000 (B), N < 1,000 (C), and N
< 500 (D). (E) The top and side views of WDR5 shown in red, on the left and right
sides, respectively. The locations of low-N mutations are marked in cyan. The
shaded region in dark grey represents the Win binding site of WDR5. These
representations were made using pdb entry code 4ERY (1).
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4. List of tumor locations associated with missense WDR5 cancer mutations
within and around the Win binding site
Table S4: Tumor locations associated with missense WDR5 cancer mutations.
The table shows the location of the tumors in which the mutations were found.
Mutation
D172A***
P216L
Y260H
S218F
D92N***
F133L*
S175L*
A264V
N130Y
D150G
S54N
G254D
L282P
S91F**

Tumor Location
Other information
Kidney
Skin
Large Intestine
Studied experimentally by BLI
Skin
and steady-state FP
Endometrium
Kidney
Breast
Soft Tissue
Breast
Stomach
Clustering with
Biliary Tract
Haematopoietic and Lymphoid N < 500
Tissue
Kidney
Skin
This mutant disrupts known
Win binding site interactions

*F133L and S175L also meet the clustering with N < 500 condition. It was found
that F133L disrupts the mitotic progression in the cell cycle process (8).
**S91F was not studied experimentally. It does not meet the clustering with the N
< 500 condition, yet it can disrupt known Win site interactions (Supplementary
Table S5). For example, a related mutant, S91K, is not able to make interactions
with a minimal C-terminal SET catalytic domain of MLL1 (9).
***D172A and D92N were experimentally studied using single-molecule electrical
recordings and an MLL4Win-containing engineered nanopore (3). In addition,
D172A was recently studied using pull-down assays, showing declined interactions
with histone H3 peptides with respect to the native WDR5 protein (10).

5. List of noncovalent bonds at the WDR5-SET1Win protein interface
Table S5: Mapping of hydrogen bonds at the WDR5-SET1Win interface. These
results were obtained using previously published co-crystallization data of
Dharmarajan and co-workers (1). The cut-off distance for identifying these
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hydrogen bonds was 4.0 Å. Here, BB and SC denote backbone and side chain,
respectively. These interactions were determined using protein interactions
calculator (PIC) (11). The structures were not always able to model the whole
sequence of the peptides, so the list of these hydrogen bonds is not comprehensive.
The first residue in each bond belongs to the SET1Win ligand, whereas the second
one belongs to WDR5. Only peptide sequences of the segments that were able to
model these interactions are listed below. Entries with multiple distances represent
multiple different hydrogen bonds formed by the same residues.
Peptide
MLL1Win
LNPHGSARAEVHL

Hydrogen Bonds
G3762-G89
H3761-K46
S3763-I90
A3764-S91
A3764-D107
R3765-S91
R3765-F133
R3765-C261
H3761-D107
MLL2Win
G5337 – G89
INPTGCARSEPKI
K5344 – K259
C5338-I90
A5339 – D107
R5340 – S91
R5340 – F133
R5340 – C261
C5338-S91
N5334-D107
MLL3Win
G4707-G89
VNPTGCARSEPKMS K4714 – K259
C4708-I90
A4709 – D107
R4710 – S91
R4710 – F133
R4710 – C261
C4708-S91
N4704-D107
MLL4Win
G2508-G89
LNPHGAARAEVY
A2510-S91
A2510 – D107
R2511 – S91
R2511 – F133
R2511 – C261
N2505-D107
Y2515-D172
SETd1AWin
G1492-G89

Distance (Å)
3.0
3.3
3.2
3.3,
3.0, 3.3
3.0, 2.8
3.0
2.9
2.7
3.1
2.9
3.7
2.9
3.1, 2.8
3.0
2.9
3.7
2.8
3.3
2.9
3.5
2.9, 3.5
3.1, 2.8
2.9
2.9
3.7
2.8
3.3
3.4
3.0
3.0, 2.8
3.0
2.9
2.7
3.2
3.3

Type
BB-BB
BB-SC
BB-SC
BB-SC
BB-SC
BB-SC
BB-SC
BB-SC
SC-SC
BB-BB
BB-BB
BB-SC
BB-SC
BB-SC
BB-SC
BB-SC
SC-SC
SC-SC
BB-BB
BB-BB
BB-SC
BB-SC
BB-SC
BB-SC
BB-SC
SC-SC
SC-SC
BB-BB
BB-SC
BB-SC
BB-SC
BB-SC
BB-SC
SC-SC
SC-SC
BB-BB
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Y1499 – K259
T1491-G322
A1494-S91
A1494 – D107
R1495 – S91
R1495 – F133
R1495 – C261
G1702-G89
C1703-I90
A1704-S91
A1704 – D107
R1705 – S91
R1705 – F133
R1705 – C261
C1703-S91

QTGSARSEGY

SETd1BWin
GCARSEG

2.8
3.5
3.4
3.0, 3.4
3.0, 2.8
3.1
2.9
3.3
3.4
3.5
3.0, 3.3
3.2, 2.8
3.1
2.8
3.7

BB-BB
BB-SC
BB-SC
BB-SC
BB-SC
BB-SC
BB-SC
BB-BB
BB-SC
BB-SC
BB-SC
BB-SC
BB-SC
BB-SC
SC-SC

Table S6: List of all known noncovalent interactions. These results were
obtained in a similar method as that for Table S5. For each interaction, the first
residue corresponds to the SET1Win ligand, while the second residue corresponds to
WDR5. The cut-off radii for the ionic and cation-pi interactions were 6 Å. Also,
the cut-off radii for the hydrophobic and aromatic-aromatic interactions were 5 and
7 Å, respectively.
Peptide

Ionic

MLL1Win
LNPHGSARAEVHL

R3765-D92
R3765-F133
H3761-D107 R3765-F263
H3769-D172

MLL2Win
INPTGCARSEPKI

R5340-D92

R5340-F133
R5340-F263
K5344-Y191

MLL3Win
R4710-D92
VNPTGCARSEPKMS

R4710-F133
R4710-F263
K4714-Y191

MLL4Win
LNPHGAARAEVY

Cation-Pi

R2511-D92
R2511-F133
H2507-Q322 R2511-F263

Hydrophobic
A3766-A47
A3766-A65
A3764-Y131
A3764-F133
A3764-D149
V3768-Y260
A3766-K321
A5339-Y131
A5339-F133
A5339-F149
P5343-Y260
A4709-Y131
A4709-F133
A4709-F149
P4713-Y260
A2512-A47
A2509-A65
A2512-A65
A2510-Y131

AromaticAromatic

Y2515-F149
Y2515-Y191
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SETd1AWin
QTGSARSEGY

R1495-D92

R1495-F133
R1495-F263

SETd1BWin
GCARSEG

R1705-D92

R1705-F133
R1705-F263

A2510-F133
A2510-F149
Y2515-F149
Y2515-P173
Y2515-Y191
V2514-Y260
A2512-L321
A1494-Y131
A1494-F133
A1494-F149
Y1499-Y191
Y1499-P216
Y1499-L234
A1704-Y131
A1704-F133
A1704-F149

Y1499-Y191

6. Location of surface WDR5 mutations within the A and B pockets
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Figure S2: Cartoon illustrating the location of key residues present in the A
and B pockets of the WDR5 protein.
7. Very weak interactions of D92N with SET1Win ligands are detected by BLI
measurements

MLL1Win

B

Response (nm)

0.1 µM
0.3 µM
0.9 µM
3.0 µM
9.0 µM

0.1 µM
0.3 µM
0.9 µM
3.0 µM
9.0 µM
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Time (s)

D

MLL3Win

Response (nm)
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0.9 µM
3.0 µM
9.0 µM
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3.0 µM
9.0 µM

Time (s)

Time (s)

F
0.1 µM
0.3 µM
0.9 µM
3.0 µM
9.0 µM

Time (s)

SETd1BWin
0.1 µM
0.3 µM
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9.0 µM

Response (nm)

SETd1AWin

Response (nm)

E

MLL4Win

Response (nm)

C

MLL2Win

Response (nm)

A
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Figure S3: BLI sensorgrams show either nondetectable or weakly detectable
interactions of D92N with SET1Win ligands. 5 nM biotin-tagged peptides were
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loaded onto streptavidin (SA) sensors for 15 minutes. A 3-fold serial dilution of
D92N ranging from 0.1 µM to 9 µM was used to obtain individual binding curves.
These sensorgrams show no binding interactions for MLL1Win and MLL4Win. For
the other SET1Win ligands, the binding interactions were visible, yet quantitative
kinetic determinations were not possible.
(A) MLL1Win, (B) MLL2Win, (C) MLL3Win, (D) MLL4Win, (E) SETd1AWin, and (F)
SETd1BWin.
8. Kinetic rate constants of association of WDR5 mutants with SET1Win
ligands using BLI measurements
Table S7: Kinetic rate constants of association, kon, of WDR5 mutants with the
SETd1AWin ligands using BLI measurements. kon values were provided in 104
M-1s-1. Results for WDR5 mutants were obtained the same way as those for the
native WDR5 protein. For F133L, 3-fold serial dilutions ranging from 0.3 µM to
27 µM were used. Numbers represent mean ± s.d. determined from three
independent experimental observations. D92N did not show any measurable
binding interactions using BLI, so it was not included in this table.
Ligand

WDR5*

D172A

P216L

Y260H

F133L

S175L

S218F

MLL1Win

~ 1**

~ 1**

~ 1**

~ 1**

NO***

~ 1**

~ 1**

MLL2Win

4.4 ± 0.4

5.7 ± 0.6

5.6 ± 0.8

6.6 ± 0.9

1.6 ± 0.1

4.9 ± 0.4

4.0 ± 0.2

MLL3Win

5.4 ± 0.6

6.5 ± 1.3

5.3 ± 0.7

6.4 ± 0.2

3.6 ± 2.1

4.9 ± 0.3

3.9 ± 0.5

MLL4Win

2.3 ± 0.2

3.7 ± 0.4

1.9 ± 0.3

2.4 ± 0.3

~1

3.0 ± 0.1

2.0 ± 0.2

SETd1AWin

8.2 ± 0.8

13 ± 1

8.6 ± 0.8

8.8 ± 1.3

2.6 ± 0.3

6.1 ± 0.7

5.6 ± 0.4

SETd1BWin

7.1 ± 0.5

8.9 ± 1.4

8.0 ± 0.8

10 ± 1

4.3 ± 1.2

8.4 ± 0.6

6.3 ± 0.6

*This data are from Imran and co-workers (2021) (2).
**In this case, kon was in the order of 104 M-1s-1 assuming that the association
process is in the range of values determined with the other SET1Win ligands.
***NO stands for “Not Observed.”

9. Kinetic rate constants of dissociation of WDR5 mutants with SET1Win
ligands using BLI measurements.
Table S8: Kinetic rate constants of dissociation, koff, of WDR5 mutants with
the SET1Win ligands using BLI measurements. koff values were provided in 10-3
s-1. Numbers represent mean ± s.d. determined from three independent
experimental observations. D92N did not show any measurable binding
interactions using BLI, so it was not included in this table.
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Ligand

WDR5*

D172A

P216L

Y260H

F133L

S175L

S218F

MLL1Win

> 1000**

> 1000**

> 1000**

> 1000**

NO***

> 1000**

> 1000**

MLL2Win

7.7 ± 0.2

14 ± 1

11 ± 2

13 ± 1

140 ± 20

6.3 ± 0.1

25 ± 2

MLL3Win

5.3 ± 0.1

9.3 ± 1.9

11 ± 3

7.7 ± 0.6

100 ± 10

16 ± 2

21 ± 3

MLL4Win

39 ± 2

51 ± 10

220 ± 50

47 ± 28

> 1000*

130 ± 4

71 ± 1

SETd1AWin

51 ± 6

110 ± 30

33 ± 4

98 ± 29

690 ± 40

89 ± 30

46 ± 7

SETd1BWin

17 ± 1

23 ± 3

30 ± 5

23 ± 3

240 ± 20

4.9 ± 0.3

23 ± 2

*This data are from Imran and co-workers (2021) (2).
**This upper-limit value for the detection of koff is set according to instrument
specifications.
***NO stands for “Not Observed.”
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10. Normalized kinetic rate constants of association of WDR5 mutants with
SET1Win ligands using BLI measurements

Figure S4: Normalized association rate constants of the WDR5-SET1Win
interactions using BLI sensorgrams. The kon values for each SET1Win ligand’s
interaction with WDR5 mutants have been divided by the kon of that SET1Win
ligand’s interaction with the native WDR5 protein. ND stands for “Not
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Determined.” Interaction between F133L and MLL4 was detectable, but not
quantifiable, using a BLI measurement.
11. Equilibrium dissociation constants of WDR5 mutants with SET1Win
ligands using BLI measurements.

Table S9: Equilibrium dissociation constants, KD-BLI, of the WDR5 mutants
with the SET1Win ligands determined from BLI measurements. KD-BLI values
are provided in nM. Numbers represent mean ± s.d. determined from three
independent experimental determinations. D92N did not show any measurable
binding interactions using the BLI, so it was not included in this table.

Ligand

WDR5#

D172A

P216L

Y260H

F133L

S175L

S218F

MLL1Win

≳100,000*

≳ 100,000*

≳ 100,000*

≳ 100,000*

NO**

≳ 100,000*

≳ 100,000*

MLL2Win

170 ± 20

240 ± 10

200 ± 50

200 ± 20

8,300 ± 1,000

130 ± 10

640 ± 20

MLL3Win

100 ± 5

140 ± 10

200 ± 30

110 ± 20

3,700 ± 1,600

330 ± 20

530 ± 20

MLL4Win

1,700 ± 200

1,400 ± 200

9,900 ± 1,400

3,400 ± 1,200

≳ 100,000*

4,200 ± 100

3,400 ± 300

SETd1AWin

620 ± 20

900 ± 240

380 ± 20

1,100 ± 200

30,000 ± 5,000

1,400 ± 300

830 ± 110

SETd1BWin

250 ± 30

260 ± 10

370 ± 40

230 ± 10

6,000 ± 1,900

56 ± 3

360 ± 20

#

These data are from the reference (2).
*This upper-limit value for the detection of KD-BLI results from dividing the upperlimit value of the detection of koff by the value of the kon approximation.
**NO stands for “Not Observed.”
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12. Structural information on the effect of the S175L mutation.

SETd1AWin P4

MLL4Win P4

Tyr 191

S175L

Figure S5: The effect of the S175L mutation on the SETd1AWin-S175L
interaction. The figure shows the effect of the S175L mutation on neighboring
residues. It shows superimposed structures from PDB 4es0, 4ewr and 4erz.
SETd1AWin is marked in cyan, while MLL4Win is marked in light blue. The red
circles show the steric clashes created by replacing Ser-175 with Leu-175 (green).
Superimposed Tyr-191 side chains from the three PDB files are shown. SETd1AWin
was used, instead of SETd1BWin, to show the B-pocket interactions, because the P6
residue in the SETd1BWin structure is disordered (1).
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13. Steady-state FP spectroscopy curves for the interactions of WDR5
mutants with SET1win ligands
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Figure S6: Steady-state FP anisotropy curves for WDR5-SET1Win ligand
interactions. The N terminus of the SET1Win ligands was tagged with
Sulforhodamine B, whereas the C terminus was amidated. The final concentration
of the labeled SET1Win ligands in each well was 10 nM. Each SET1Win ligand –
WDR5 run involved a 2-fold serial dilution of WDR5 over 24 wells. Three
independent experiments were conducted to obtain the dose response, which was
fitted using a four-parameter logistic model to get the KD.
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Fraction Bound

14. Very weak interactions of D92N with SET1Win ligands are detected by
steady-state FP spectroscopy measurements
1.2
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MLL4Win
SET1aWin
SETd1A
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Win
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Figure S7: Fraction bound of SET1Win ligands to D92N using steady-state FP
spectroscopy experiments. These experiments showed either nondetectable or
very weak interactions of D92N with all SET1Win ligands. The final SET1Win ligand
concentration was 10 nM. The WDR5 concentration (horizontal axis) spanned from
low µM to low pM. No FP signal was detectable for MLL1Win, MLL4Win, and
SETd1AWin. Very weak interactions with D92N were detected in the case of
MLL2Win, MLL3Win, and SETd1BWin. For these SET1Win ligands, Kd was greater
than 10 µM.
15. Equilibrium dissociation constants of WDR5 mutants with SET1Win
ligands using FP measurements
Table S10: Equilibrium dissociation constants, KD-FP, of WDR5 mutants with
SET1Win ligands determined from steady-state FP measurements. Three
independent experiments were conducted to obtain the dose response, which was
fitted using a four-parameter logistic model. KD-FP values are provided in nM. For
D92N, the KD values were greater than 17,000 nM. Numbers represent mean ±
s.e.m. from three individual experimental determinations.
Ligand

WDR5#

D172A

P216L

Y260H

F133L

S175L

S218F

MLL1Win

9,000 ± 5,500

5,600 ± 800

> 14,650*

9,700 ± 1,200

> 53,000*

4,800 ± 2,800

8,100 ± 3,400

MLL2Win

23 ± 5

25 ± 4

18 ± 3

34 ± 4

2,100 ± 300

11 ± 1

94 ± 7

MLL3Win

15 ± 4

12 ± 1

19 ± 1

22 ± 2

1,000 ± 100

23 ± 1

80 ± 7

MLL4Win

130 ± 20

78 ± 3

690 ± 60

130 ± 10

8,800 ± 3,900

280 ± 30

420 ± 40

SETd1AWin

72 ± 5

61 ± 2

39 ± 2

140 ± 20

5,700 ± 300

92 ± 7

100 ± 10

SETd1BWin

18 ± 2

18 ± 1

28 ± 2

23 ± 2

820 ± 30

11 ± 1

37 ± 1

#

These data are from the reference (2).
*These low-value limits are based on the highest concentrations of WDR5 mutants
employed in this study.
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16. Quantitative comparisons of affinity data acquired with BLI and FP.

Figure S8: Quantitative comparison between affinity data resulting from BLI
and FP measurements. (A) A 3D graph of the ratio of the KD-BLI to the KD-FP. (B)
A 2D heat map of the ratio of the KD-BLI to the KD-FP.
Table S11: Quantitative comparisons between affinity data resulting from BLI
and FP measurements in terms of the ratio of the KD-BLI to the KD-FP.
Protein MLL2Win MLL3Win MLL4Win SETd1AWin SETd1BWin
WDR5
7.43
6.68
12.7
8.60
13.8
D172A
9.51
11.7
17.5
14.7
14.4
P216L
10.9
10.5
14.3
9.73
12.9
Y260H
5.81
5.15
26.4
7.68
10.1
F133L
3.90
3.62
ND*
5.28
7.40
S175L
10.9
14.4
14.9
15.6
4.97
S218F
6.83
6.63
8.25
8.05
9.92
ND* stands for not determined.

Table S12: Quantitative comparisons between affinity data resulting from BLI
and FP measurements in terms of the ratio of the normalized KD-BLI to the
normalized KD-FP. A normalized KD of the binding interactions of a SET1Win ligand
with a WDR5 mutant is the KD measured for this interaction pair divided by the KD
value measured with the same SET1Win ligand interacting with the native WDR5
protein.
Protein
MLL2Win MLL3Win MLL4Win SETd1AWin SETd1BWin
D172A
1.28
1.76
1.37
1.71
1.04
P216L
1.47
1.57
1.13
1.13
0.94
Y260H
0.78
0.77
2.09
0.89
0.73
117

F133L
0.52
0.54
S175L
1.47
2.15
S218F
0.92
0.99
ND* stands for not determined.

ND*
1.18
0.65

0.61
1.82
0.94

0.54
0.36
0.72

17. Supporting methods.
Table S13: List of fluorescently labeled SET1Win ligands for steady-state FP
studies. All ligands were fluorescently labeled at the N terminus and amidated at
the C terminus. A 9-residue Gly-Ser-based peptide spacer was inserted between
Sulforhodamine B and SET1Win ligand.
1
2
3
4
5
6

Ligand

Sequence

MLL1Win
MLL2Win
MLL3Win
MLL4Win
SETd1AWin
SETd1BWin

Sulforhodamine B-(GGS)3LNPHGSARAEVHLS-NH2
Sulforhodamine B -(GGS)3INPTGCARSEPKIL-NH2
Sulforhodamine B -(GGS)3VNPTGCARSEPKMS-NH2
Sulforhodamine B -(GGS)3LNPHGAARAEVYLS-NH2
Sulforhodamine B -(GGS)3EHQTGSARSEGYYP-NH2
Sulforhodamine B -(GGS)3EHVTGCARSEGFYT-NH2
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4.1 Abstract

Surface-tethered ligand-receptor complexes are key components in biological
signaling and adhesion. They also find increasing utility in single-molecule assays and
biotechnological applications. Here, we study the real-time binding kinetics between
various surface-immobilized peptide ligands and their unrestrained receptors. A long
peptide tether increases the association of ligand-receptor complexes, experimentally
proving the fly-casting mechanism where the disorder accelerates protein recognition. On
the other hand, a short peptide tether enhances the complex dissociation. Notably, the rate
constants measured for the same receptor, but under different spatial constraints, are
strongly correlated with one another. Furthermore, this correlation can be used to predict
how surface tethering on a ligand-receptor complex alters its binding kinetics. Our results
have immediate implications in the broad areas of biomolecular recognition, intrinsically
disordered proteins, and biosensor technology.
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4.2 Introduction

Tethered ligand-receptor complexes are common in protein recognition1,2 and
cellular adhesion.3 Surface-bound ligand-protein complexes are also the basis for
biotechnological applications, such as biosensors4-9 and cell-targeted therapeutic
proteins,10,11 as well as for single-molecule techniques that probe the dynamics
and thermodynamics of protein binding.12-16 Yet, how the presence of spatial
constraints imposed by the surface and/or the tether affects the thermodynamics
and, especially, kinetics of binding is largely an open experimental question. Most
of the current insight in this topic comes from theoretical17-21 and
computational10,22-24 studies. However, experimental examinations of tethered
ligand-protein interactions are mostly limited to measuring macroscopic
intermolecular forces,25-28 equilibrium dissociation constants,29 and effective
protein concentrations.29,30
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Figure 1: WDR5 protein interacting with the SET1Win peptide ligands under
different conditions. WDR5 is shown in orange, while SET1Win ligands are
shown in magenta. Bound interacting partners are shown in blue. Lightly colored
receptors and ligands indicate interacting partners in the background. (a)
Biotinylated ST-SET1Win ligands were chemically attached onto a streptavidincoated biolayer interferometry (BLI) sensor surface. Either WDR5 proteins or one
of its mutants were freely movable in solution. (b) The same system as in (a), but
with LT-SET1Win ligands. (c) Either WDR5 proteins or one of its mutants were
immobilized onto a surface plasmon resonance (SPR) chip surface, whereas the
NT-SET1Win ligands were freely movable in solution.
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In contrast to the earlier experimental work, this study focuses on the question
of how the kinetics of binding and unbinding is altered by the tethering of one of
the binding partners to a surface. To this end, we measure the real-time kinetics of
tethered ligand-receptor complexes using surface immobilization-based sensing
approaches. In our case, the receptor is WD40 repeat protein 5 (WDR5),31,32 a
chromatin-associated hub that is primarily known for its regulatory role in histone
methylation.33,34 The 334-residue WDR5 features a seven-bladed  propeller
circular structure and a central cavity. The WDR5 cavity hosts the binding site for
the WDR5-interaction (Win) motif of human mixed lineage leukemia
(MLL/SET1) methyltransferases, also named the Win binding site. We examined
details of the interactions of five 14-residue Win motif peptide ligands of SET1
proteins (SET1Win ligands; Supplementary Table 1 and Supplemental
Methods)35,36 with WDR5 via its Win binding site. SET1Win ligands were
chemically attached to a streptavidin-coated surface. Either a 3-residue short
peptide tether (ST-SET1Win ligands; Fig. 1a) or a 9-residue long peptide tether
(LT-SET1Win ligands; Fig. 1b) was inserted between the biotinylated attachment
site of the SET1Win ligand to the surface and the SET1Win sequence. In this way,
the binding kinetics of the WDR5-SET1Win complex were probed using biolayer
interferometry (BLI).37 The association and dissociation phases of the tethered
ligand-receptor complex were discriminated optically using changes in the
interference pattern of reflected light waves at the sensor surface. Hence, these
interactions were monitored using WDR5-containing and WDR5-free assay
buffers, respectively. Tethered ligand-receptor interactions were also evaluated
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using Win binding site-directed WDR5 mutants (Supplementary Table 2 and
Supplemental Methods). To further examine the binding kinetics in the absence
of restraining tethers, WDR5 proteins were immobilized on the surface plasmon
resonance (SPR) sensors 38 (no tether, NT-SET1Win ligands; Fig. 1c).

4.3 Results and Discussion
We obtained the real-time kinetics of five SET1Win peptide ligands (MLL2Win,
MLL3Win, MLL4Win, SETd1AWin, and SETd1BWin) with four WDR5 proteins
(wild-type and 3 mutants of the Win binding site, P216L, F133L, and S218F)
using ST and LT constraints (Supplementary Figs. 1-2 Tables 3-5). Later, we
validated the outcomes of this study using S175L, a fourth WDR5 mutant of
unknown affinity. Interestingly, the association rate constants, ka, acquired with
LT-SET1Win ligands (ka-LT) were on average higher than those corresponding
values recorded with ST-SET1Win ligands (ka-ST) (Fig. 2a; Supplementary Table
6). To explain this observation, we considered the general framework of
diffusion-controlled reactions,39-41 which gives the following association rate
constant:
𝑘a = (𝑘D−1 + 𝑘R−1 )−1
(1)
where 𝑘R is the reaction-controlled rate constant and
𝑘D = 4π𝐷rel 𝑎
(2)
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is the diffusion-controlled rate constant that depends on the relative diffusion
coefficient of the two reacting species, 𝐷rel , and on a “geometric” parameter, 𝑎. In
the limit 𝑘R ≫ 𝑘D , the association is purely diffusion controlled and 𝑘a ≈ 𝑘D .42
Eq. 2 may be loosely interpreted as the rate constant of the association process
happening instantaneously upon the reactants diffusing into a favorable relative
configuration. This configuration is characterized by a linear length scale, 𝑎.
Notably, simple dimensionality arguments require that the diffusion-controlled
rate constant, 𝑘D , must be of the form of Eq. 2. Hence, Eq. 2 can be viewed as the
definition of the effective “target” size of the diffusion-controlled reaction.
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Figure 2: Scatter plots of kinetic and equilibrium constants for ST-SET1Win
and LT-SET1Win ligands. (a) Association rate constants ka-ST of ST-SET1WinWDR5 complexes plotted against association rate constants ka-LT of LT-SET1WinWDR5 complexes. Points above the blue line correspond to complexes with faster
association rate constants for ST-SET1Win ligands, while points below correspond
to interactions with slower association rate constants for ST-SET1Win ligands. (b)
Dissociation rate constants kd-ST of ST-SET1Win-WDR5 complexes plotted against
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dissociation rate constants kd-LT of LT-SET1Win-WDR5 complexes. Points above
the blue line correspond to complexes with faster dissociation rate constants for
ST-SET1Win ligands. (c) Equilibrium dissociation constants KD-ST of ST-SET1WinWDR5 complexes plotted against equilibrium dissociation constants KD-LT of LTSET1Win-WDR5 complexes. Points above the blue line correspond to less stable
complexes with ST-SET1Win ligands. m indicate the slopes of linear fits in panels
(b) and (c). Data represent mean ± s.d. that resulted from three independent BLI
sensorgrams.

There are two notable examples of this equation. First, Smoluchowski (1917)
has obtained a formula for the diffusion-controlled rate constant, where the
association process between two spherically symmetrical reactants takes place
whenever their distance reaches the “capture radius” value a.43,44 Second, Berg
and Purcell (1977) derived a formula for the rate constant of the process where a
freely diffusing particle hits a patch on a planar wall, with 𝑎 being the linear size
of the patch.45 The Berg and Purcell's scenario can be viewed as a prototype for
the system studied here, as one of the reactants is surface immobilized. It should
be noted that the length parameter, a, generally depends on the interaction
between the reactants.39,41 For example, the electrostatic attraction between them
leads to a larger “capture radius”.

Equipped with these ideas, we consider the difference between the cases of
ST- and LT-SET1Win ligands. The much smaller, surface-attached SET1Win ligand
diffuses rapidly, with a diffusion coefficient 𝐷SET1Win ≫ 𝐷WDR5 . Diffusion of the
SET1Win ligand occurs around its attachment point within a certain volume, which
depends on the tether length. This suggests a simple model of association, as
follows. Like in Berg and Purcell’s model,45 the surface-attached SET1Win ligand
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appears as target with a characteristic size, a, to a freely diffusing WDR5.
Because of the complicated geometry of the system, it is challenging to derive a
simple expression for 𝑎. LT-SET1Win can deviate further from the attachment
point than ST-SET1Win. Therefore, LT-SET1Win is a bigger “target” for the WDR5
than ST-SET1Win (i.e., 𝑎LT > 𝑎ST ), so the association rate constant for LTSET1Win, 𝑘a−LT , is higher than that for ST-SET1Win, 𝑘a−ST , as observed in Fig.
2a. Note, however, that this picture is expected to break down in the limit of long
tethers where further increase of the tether length results in a larger search volume
that has to be explored by the binding partners, reducing the overall association
rate. Indeed, as recently discussed by Misiura and Kolomeisky,46 the dependence
of the association rate constant on the tether length is non-monotonic, with the
maximum association speedup occurring at an intermediate tether length.

The association speedup induced by a longer tether found here is an
experimental validation of the “fly-casting association mechanism,” which was
proposed earlier by Wolynes and coworkers on theoretical grounds and
computational analysis47-49 and discussed later by others.13,46,50-54 This mechanism
explains how intrinsically disordered proteins with random-coil conformations
can bind faster to their targets.12,55 Because of the geometric nature of the
parameter 𝑎, it is expectable that the ratio of a values for LT-SET1Win and STSET1Win, 𝑎LT /𝑎ST , is nearly the same for all SET1Win ligands. Indeed, we observe
a linear correlation between the association rate constants for LT-SET1Win and
ST-SET1Win, 𝑘a−LT and 𝑘a−ST, respectively (Fig. 2a). But recalling that the

136

parameter 𝑎 also depends on the energetics of the interactions, deviations from a
perfectly linear correlation are not surprising.

In contrast to the association rate constants, the dissociation rate constants for
ST-SET1Win ligands, kd-ST, were consistently higher than those for LT-SET1Win
ligands, kd-LT (Fig. 2b; Supplementary Tables 7-8). Furthermore, kd-ST and kd-LT
values closely followed a proportionality relationship. To explain these
observations, we start with the Arrhenius law for the unimolecular dissociation
process:42
Δ𝐺

𝑘d = 𝜈 exp(− 𝑘 𝑇a ) ,
𝐵

(3)
where 𝜈 is a prefactor, and Δ𝐺a is the activation free energy, which is determined
by the strength of cohesive interactions between SET1Win and WDR5. It is known
that a microscopic object (e.g., a Brownian particle) attached to a surface via a
flexible polymer tether experiences a repulsive net force that pushes it away from
the surface even when the surface is perfectly neutral. This force is "entropic" in
its nature, originating from the fact that the object has more space available when
it is further away from the surface. The properties of this force have been
theoretically studied by Segall and coworkers,56 who showed that it is roughly
inversely proportional to the distance from the surface.

Based on the above argument, as the force pushes WDR5 away from the
surface, and thus from SET1Win, it enhances dissociation by lowering the
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dissociation barrier. The simplest approximate description of this
mechanochemical effect for the dissociation rate constant, 𝑘d , is the EyringZhurkov-Bell formula:57
𝑘d = 𝜈 exp (−

Δ𝐺a −𝑓Δ𝑥
𝑘𝐵 𝑇

𝑓Δx

) = 𝑘𝑑0 exp( k 𝑇),
B

(4)
where 𝑘𝑑0 is 𝑘𝑑 at 𝑓 = 0. Here, 𝑓 is the magnitude of the force, and Δ𝑥 is an
activation length. Hence, 𝑘𝑑0 is the dissociation rate constant in the absence of the
surface. Clearly, the force 𝑓 for ST-SET1Win, 𝑓ST , is higher than that for LTSET1Win, 𝑓LT . Therefore, the dissociation rate constant for ST-SET1Win, 𝑘d−ST, is
greater than that for LT-SET1Win, 𝑘d−LT, as observed in Fig. 2b. Assuming that
the activation length Δ𝑥, being again a geometric parameter, is approximately the
same for different constructs, the ratio of the two dissociation rate constants
should be close to a constant. This should happen even though the rate constants
themselves may vary considerably owing to the variation of the activation free
energy, Δ𝐺a , and to exponential sensitivity of the dissociation rate constant to the
energetics of interaction. Indeed, this is what we observe in Fig. 2b. Despite
almost two orders of magnitude variation between the individual 𝑘d constants for
each construct, 𝑘d−ST and 𝑘d−LT remain proportional to each other. Note that the
𝑘a constants for the same constructs vary within a much narrower range, within a
maximum factor of ~4, supporting the above proposal that the association process
is near the diffusion-controlled limit and thus less sensitive to energetics.
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These results suggest that the length of the tether plays a significant role in
modulating the interactions of the SET1Win-WDR5 complex. An increased
physical constraint as a result of a decreased tether length not only reduces the
rate constant of complex formation, as established earlier, but also substantially
decreases the stability of the complex. Consequently, the overall impact of
reducing the tether length is an increase in KD (Fig. 2c; Supplementary Tables 910). Changes observed for 𝑘a should normally be independent from those noted
for 𝑘d , because the mechanisms of changing the corresponding activation free
energies are different. Indeed, we observed no correlation between the 𝑘a and 𝑘d
values (Supplementary Figs. 3-4).
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Figure 3: Scatter plots of kinetic and equilibrium constants for NT-SET1Win
and LT-SET1Win ligands. (a) Association rate constants ka-NT of NT-SET1WinWDR5 complexes plotted against association rate constants ka-LT of LT-SET1WinWDR5 complexes. Points above the blue line correspond to interactions with
faster association rate constants for NT-SET1Win ligands.
(b) Dissociation rate constants kd-NT of NT-SET1Win-WDR5 complexes plotted
against dissociation rate constants kd-LT of LT-SET1Win-WDR5 complexes. Points
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above the blue line correspond to interactions with faster dissociation rate
constants for NT-SET1Win ligands.
(c) Equilibrium dissociation constants KD-NT values of NT-SET1Win-WDR5
complexes plotted against equilibrium dissociation constants KD-LT of LTSET1Win-WDR5 complexes. Points below the blue line correspond to more stable
complexes with LT-SET1Win ligands. m indicate the slopes of linear fits in all
panels. Data represent mean ± s.d. that resulted from three independent BLI
sensorgrams.
We then measured the kinetic rate constants for 20 ligand-receptor complexes
using unrestricted conditions (no tether, NT-SET1Win ligands) (Supplementary
Fig. 5 Tables 11-13). In this case, BLI was not used, because it does not have a
satisfactory sensitivity to reliably detect a short-peptide binding to the surface.
The SPR,38 with its greater sensitivity, was a more effective choice for this case.
Accumulation of ligand-receptor complexes onto the surface of the SPR sensor
was monitored by changes in the refractive index. Therefore, WDR5 was
immobilized onto the surface of the SPR chips (Fig. 1c), and the association and
dissociation phases were probed in real time. As established by our previous
work,58 the 𝑘a values for NT-SET1Win ligands were substantially greater than
those for LT-SET1Win ligands (Fig. 3a; Supplementary Table 14). This
significant difference is due to the increased translational and rotational diffusion
coefficients of NT-SET1Win ligands relative to WDR5 and its derivatives.
Moreover, our previous work58 also showed, by comparison with values obtained
from fluorescence polarization (FP) spectroscopy, that immobilizing WDR5 onto
the sensor surface does not impact its functional integrity. Let's assume that
𝐷NT−SET1Win and 𝐷WDR5 are the translational diffusion coefficients of NTSET1Win and WDR5, respectively. For applying Eq. 2 to this problem, one now
has to consider that 𝐷NT−SET1Win ≫ 𝐷WDR5 , since either WDR5 or one of its
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derivatives was immobilized on the sensor surface. Therefore, the unrestrained
NT-SET1Win was responsible for the diffusion-mediated mutual approach of the
reacting species, so 𝐷rel ≈ 𝐷NT−SET1Win . Again, Eq. 2 predicts proportionality
between 𝑘a−NT and 𝑘a−LT , as noted in Fig. 3a, with the ratio of the two roughly
equal to the ratio of SET1Win’s and WDR5’s diffusion coefficients.

Remarkably, the 𝑘d values using NT-SET1Win and LT-SET1Win ligands were
closely similar (Fig. 3b; Supplementary Table 15). Our interpretation of this
finding is in terms of Eq. 4. In the case of LT-SET1Win ligands, but not for STSET1Win ligands, the repulsive force 𝑓 is negligible as the complex is far enough
from the surface. Hence, the dissociation rate constant is near that value
corresponding to the zero-force limit, 𝑘𝑑0 , which is the dissociation rate constant
for NT-SET1Win ligands, 𝑘d−NT . In other words, at long enough tether lengths, the
experimental system approaches that of NT-SET1Win ligands in terms of the
dissociation rate constant, 𝑘d . Therefore, the equilibrium dissociation constant,
KD, of the ligand-receptor complex becomes larger as we go from NT-SET1Win
ligands to LT-SET1Win ligands (Fig. 3c; Supplementary Tables 16-17).
Moreover, the differential free energy of the ligand-receptor complex formation,
ΔΔG, for NT-SET1Win ligands with respect to LT-SET1Win ligands is in the range
-0.3 through -1.5 kcal/mol. The primary contribution to this change results from
the considerable increase in the 𝑘a in the absence of the tether. This shows how
the attachment of a binding partner to a surface influences the overall dynamic
equilibrium of the interaction. In our case, the effect is substantial given the large
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difference in size between the two binding partners. Even though for NT-SET1Win
ligands the WDR5 is restricted to the surface, the comparison between similar
restriction and steady-state fluorescence polarization (FP) data of freely
interacting SET1Win and WDR5 in solution shows that this condition can be
thought as that of an unrestricted interaction.58
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Figure 4: 3D plots and contour maps of normalized KD constants. (a)
Qualitative free energy landscapes of SET1Win-WDR5 interactions when NTSET1Win (NT), ST-SET1Win (ST), and LT-SET1Win (LT) peptide ligands were
used. Vertical lines 1, 2, and 3, which are marked in cyan, indicate the differential
free energy barriers due to unrestrained diffusion of the ligand, fly-casting
mechanism, and repulsion entropic forces of the receptor from the sensor surface,
respectively. (b) Bar graph and (c) contour map of KD-ST values for the interaction
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of ST-SET1Win ligands, with WDR5 and its mutants, divided by their
corresponding KD-NT values measured with the corresponding NT-SET1Win
ligands. (d) Bar graph and (e) contour map of
KD-LT values for the interaction of LT-SET1Win ligands, with WDR5 and its
mutants, divided by their corresponding KD-NT values measured with the
corresponding NT-SET1Win ligands. KD-ST and KD-LT for MLL4Win-F133L
interactions could not be quantitatively determined using BLI measurements.
These data points are colored in black.

In Fig. 4a, we illustrate a qualitative comparison of the free energy landscapes
that correspond to NT-SET1Win, ST-SET1Win, and LT-SET1Win ligands. For short
and long tethers, the presence of the flexible tether reduces the association rate
constant of the SET1Win-WDR5 complex with respect to that in the absence of the
tether (Supplementary Fig. 6). Further increase in the kd-ST with respect to kd-LT
(Supplementary Fig. 7) due to repulsion forces of WDR5 proteins from the
sensor surface explains the relative increase in the normalized values (KD-ST/KDNT)

 (KD-LT/KD-NT) (Fig. 4b-e). Because there are linear correlations between

measured affinities of various SET1Win-WDR5 pairs with specified constraints,
we can advantageously utilize these findings to predict the kd and KD for a given
tethered ligand-receptor complex. To demonstrate this, we examined the
interactions of SET1Win ligands with S175L, a WDR5 derivative, whose singlesite mutation is located within the Win binding site. Using the kinetic and
equilibrium parameters measured for NT-SET1Win-S175L interactions via SPR
(Supplementary Tables 12-13), we established the proportionality relationships
with their corresponding parameters for ST-SET1Win ligands (Supplementary
Fig. 8). Remarkably, our experimental determinations of kd-ST for S175L against 5
ST-SET1Win ligands are closely similar to corresponding anticipated values
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(Table 1). Furthermore, using the same method we demonstrate the predictive
power of this approach for the KD-ST values (Table 2). Therefore, the binding
affinity of tethered ligand-receptor interactions can be precisely modulated by
changing the tether length (Supplementary Fig. 9).
Table 1: Table showing the predicted and experimental values of the kd-ST for
S175L interacting with ST-SET1Win. kd-ST are the dissociation rate constants
corresponding to ST-SET1Win ligands. Predicted values of kd-ST were obtained
using the proportionality relationship between kd-ST and kd-NT (Supplementary
Fig. 8) and the experimentally determined values of kd-NT (Supplementary Table
12). Triplicate kd-NT values were used to calculate corresponding kd-ST values by
linear interpolation. Values indicate mean  s.d., which were calculated using
these triplicates.
Parameter

SET1Win

Predicted values
 103 (s-1)

kd-ST

MLL2Win
MLL3Win
MLL4Win
SETd1AWin
SETd1BWin

14 ± 1
36 ± 1
190 ± 10
300 ± 10
13 ± 1

Experimental
values
 103 (s-1)
12 ± 1
28 ± 1
180 ± 10
160 ± 10
5.4 ± 0.2

Table 2: Table showing the predicted and experimental values of the KD-ST
for S175L interacting with ST-SET1Win. KD-ST are the equilibrium dissociation
constants corresponding to ST-SET1Win ligands. Predicted values of KD-ST were
obtained using the proportionality relationship between KD-ST and KD-NT
(Supplementary Fig. 8) and the experimentally determined values of KD-NT
(Supplementary Table 13). Triplicate KD-NT values were used to calculate
corresponding KD-ST values by linear interpolation. Values indicate mean  s.d.,
which were calculated using these triplicates.
Parameter

SET1Win

Predicted values
 109 (M)

KD-ST

MLL2Win
MLL3Win
MLL4Win
SETd1AWin
SETd1BWin

150 ± 10
270 ± 10
2,800 ± 100
5,500 ± 200
110 ± 10

Experimental
values
 109 (M)
360 ± 30
810 ± 90
8,500 ± 300
2,900 ± 100
110 ± 6
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4.4 Conclusion
In summary, we provide compelling experimental evidence for the fly-casting
mechanism of association between surface-attached peptide ligands and their
receptors. The observed speedup in the association rate ka when using a longer
tether is rather modest for the tether lengths employed here, which agrees with
previous computational work.47 We also found that the dissociation rate constant
was greater in the case of a short tether length as a result of entropic repulsion
forces acting on the receptor pulling it away from the surface. Accordingly, this
resulted in a weakened interaction of the tethered ligand-protein complex. As a
longer tether accelerates the association but decelerates the dissociation, the
binding affinity of the ligand-receptor complex is greater at increased tether
lengths. Our experimental approach can be used to predict dissociation rate
constants and binding affinities of ligand-protein interactions for specified
physicochemical properties of the tether. Therefore, our method can be employed
in biosensor technology to modulate the interaction strength of a ligand-protein
complex on a sensing surface by modifying the tether length. Finally, this result
has been successfully validated using a test WDR5 mutant of unknown
dissociation constant for five ST-SET1Win ligands.
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1. Materials and Methods
1.1. Peptide synthesis, purification, and analysis. For BLI measurements,
14-residue SET1Win peptide ligands were synthesized and purified to ≥ 95%
purity by GenScript (Piscataway, NJ). These peptide ligands were biotinylated at
their N terminus and amidated at their C terminus. Their sequence is provided in
Table S1, which is displayed below.
Table S1: List of 14-residue SET1Win peptide ligands used in biolayer
interferometry (BLI) measurements. An either a 3-residue short tether (ST) or a
9-residue long tether (LT) was inserted between the biotinylated attachment site
and SET1Win sequence. The tether sequence is marked in blue. The SET1Win
sequence is marked in red.
#
SET1Win
Tether length
Ligand sequence
1
ST-MLL2Win
ST
Biotinyl-(GGS)INPTGCARSEPKILNH2
2
ST-MLL3Win
ST
Biotinyl-(GGS)VNPTGCARSEPKMSNH2
3
ST-MLL4Win
ST
Biotinyl-(GGS)LNPHGAARAEVYLSNH2
4
ST-SETd1AWin
ST
Biotinyl-(GGS)EHQTGSARSEGYYPNH2
5
ST-SETd1BWin
ST
Biotinyl-(GGS)EHVTGCARSEGFYTNH2
6
LT-MLL2Win
LT
Biotinyl-(GGS)3INPTGCARSEPKILNH2
7
LT-MLL3Win
LT
Biotinyl-(GGS)3VNPTGCARSEPKMSNH2
8
LT-MLL4Win
LT
Biotinyl-(GGS)3LNPHGAARAEVYLSNH2
9
LT-SETd1AWin
LT
Biotinyl-(GGS)3EHQTGSARSEGYYPNH2
10 LT-SETd1BWin
LT
Biotinyl-(GGS)3EHVTGCARSEGFYTNH2
Purity confirmation, amino acid analysis, and solubility testing were conducted
and provided by GenScript. For SPR measurements, SET1Win peptide ligands
were synthesized, purified, and analyzed in-house at Ichor Life Sciences
(LaFayette, NY). Details on these procedures and protocols were previously
provided 1. Peptide synthesis was performed using a Biotage Syro I peptide
synthesizer (Biotage, Charlotte, NC). Peptide purification was achieved using
reversed-phase chromatography in two steps: (1) flash chromatography
employing a Biotage Isolera One (Biotage AB, Uppsala, Sweden), and (2) semipreparative high-performance liquid chromatography (HPLC) using a Waters
2695 separations module, which was coupled with a Waters 2996 photodiode
array detector (PDA).
1.2. Protein expression and purification. In this study, all expression
plasmids were synthesized, codon optimized, and sequence verified by GenScript
(Piscataway, NJ). Human WDR5 (UniProtKB - P61964; WDR5_HUMAN) and
its mutants were expressed and purified as described previously.1-3 WDR5
construct design has the following sequence:
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6H-TEV-WDR5 in pET3aTr vector (Addgene, Watertown, MA). The detailed
WDR5 sequence (sequence fragments marked in yellow are linkers) is the
following:
MHHHHHHSSGVDLGTENLYFQSNGATEEKKPETEAARAQPTPSSSATQ
SKPTPVKPNYALKFTLAGHTKAVSSVKFSPNGEWLASSSADKLIKIWG
AYDGKFEKTISGHKLGISDVAWSSDSNLLVSASDDKTLKIWDVSSGKC
LKTLKGHSNYVFCCNFNPQSNLIVSGSFDESVRIWDVKTGKCLKTLPA
HSDPVSAVHFNRDGSLIVSSSYDGLCRIWDTASGQCLKTLIDDDNPPVS
FVKFSPNGKYILAATLDNTLKLWDYSKGKCLKTYTGHKNEKYCIFAN
FSVTGGKWIVSGSEDNLVYIWNLQTKEIVQKLQGHTDVVISTACHPT
ENIIASAALENDKTIKLWKSDC
Table S2: This table shows WDR5 mutants used in this study. These WDR5
mutants involve amino acid side chains within the Win binding site of WDR5.4-6
Entry
WDR5 Mutant
1
P216L
2
F133L
3
S218F
4
S175L
1.3. Biolayer interferometry (BLI). These measurements were conducted
using an Octet RED384 instrument (FortéBio, Fremont, CA) at 24ºC.7 The assay
buffer included 150 mM NaCl, 20 mM Tris-HCl, 1 mM TCEP, 1 mg/mL bovine
serum albumin (BSA), pH 7.5. Streptavidin-coated biosensors were incubated
with 5 nM biotinylated SET1Win for 15 minutes. Then, the unbound peptides were
washed out by rinsing the sensors in assay buffer. These experimental conditions
were optimized to amplify the signal-to-noise ratio while preventing potential
artifacts. These include the rebinding of receptors to the surface-immobilized
peptide ligands during the dissociation phase. Prior crystallographic studies
demonstrated that these ligand-receptor interactions follow a 1:1 binding model.8-9
The association process was monitored by exposing the sensors to 3-fold serial
dilutions of WDR5 proteins. The dissociation phase was probed by transferring
the sensors into WDR5-free assay buffer. The association phases were fitted using
the equation:10
𝑌 = 𝑌∞ − (𝑌∞ − 𝑌0 )𝑒 −𝑘obs 𝑡
(S1)
Here, Y0 and Y denote the responses at the initial time and infinity, respectively.
kobs is the apparent first-order reaction rate constant of the association phase. t
represents the cumulative time of the association reaction. The dissociation phases
were fitted using the equation:
𝑌 = 𝑌∞ + (𝑌0 − 𝑌 )𝑒 −𝑘off 𝑡
(S2)
Here, koff indicates the dissociation rate constant. Y0 and Y  are the responses at
the initial time and infinity, respectively. Finally, the association rate constant, kon,
was determined using the slope of the linear curve:11-12
𝑘obs = 𝑘on [𝐶] + 𝑘off
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(S3)
Then, global fittings were achieved using several WDR5 (or WDR5 mutant)
concentrations. These fittings provided the corresponding kon and koff values.
Equilibrium dissociation constant values, KD, were indirectly determined using the
kon and koff values (KD = koff/kon). Three independent BLI measurements were
conducted for all conditions in this study.
1.4. Surface plasmon resonance (SPR). In this study, all SPR measurements
were conducted using a Cytiva Biacore 8K instrument (Cytiva Life Sciences,
Marlborough, MA), as previously reported.1 WDR5 proteins were immobilized
onto the active flow cell of each channel of a Cytiva Series S Sensor Chip CM5
(Cytiva Life Sciences). The sensor surface was then activated using an injection
of 1:1 N-hydroxysuccinimide (NHS)/1-ethyl-3-(3dimethylaminopropyl)carbodiimide (EDC) (Cytiva Amine Coupling Kit, Cytiva
Life Sciences). The protein sample was then injected across the active flow cell.
Finally, both active and passive flow cells were chemically deactivated.
Multicycle kinetic analyses were conducted at a flow cell temperature of 25C
and a sample compartment temperature of 20C in a running buffer composed of
20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM TCEP, 0.05% Tween 20.
BiacoreTM Insight Evaluation Software v3 (Cytiva Life Sciences) was employed
to analyze and fit the sensorgrams using a 1:1 binding interaction model to
provide the association (ka) and dissociation (kd) rate constants. The KD were
calculated indirectly using KD = kd/ka.
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2. Examples of BLI sensorgrams and fittings for probing the real-time
kinetics of SET1Win-WDR5 interactions.

Figure S1: BLI sensorgrams of ST-MLL2Win interacting with WDR5 and its
mutants. 5 nM biotinylated ST-MLL2Win was loaded onto streptavidin-coated
sensors for 15 minutes. 3-fold serial dilutions of WDR5 and its mutants were used
to obtain individual binding curves. These sensorgrams were fitted to obtain ka-ST,
kd-ST, and KD-ST (eqns. (S1)-S3)). The fits are shown in black.
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Figure S2: BLI sensorgrams of LT-MLL2Win interacting with WDR5 and its
mutants. 5 nM biotinylated LT-MLL2Win was loaded onto streptavidin-coated
sensors for 15 minutes. 3-fold serial dilutions of WDR5 and its mutants were used
to obtain individual binding curves. These sensorgrams were fitted to obtain ka-LT,
kd-LT, and KD-LT (eqns. (S1)-S3)). The fits are shown in black.
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3. Determinations of the kinetic and equilibrium constants of the
interactions of ST-SET1Win ligands with WDR5 receptors using BLI
measurements.
Table S3: Kinetic rate constants of association, ka-ST, of WDR5 and its
mutants with ST-SET1Win ligands using BLI measurements. 5 nM biotinylated
ST-SET1Win were loaded onto streptavidin-coated sensors for 15 minutes. 3-fold
serial dilutions of WDR5 and its mutants, ranging from 0.1 µM to 9 µM, were
used to obtain individual binding curves. The buffer solution contained 150 mM
NaCl, 20 mM Tris-HCl, 1 mM TCEP, 1 mg/ml bovine serum albumin (BSA), pH
7.5. The binding curves were fitted using the Octet Data Analysis software. ka-ST
values were provided in (M-1 s-1) × 10-4. For F133L, 3-fold serial dilutions ranging
from 0.3 µM to 27 µM were used. Numbers represent mean ± s.d. determined
from three independent BLI experimental determinations.
Peptide
WDR5
P216L
F133L*
S175L**
S218F
MLL2

4.0 ± 0.2

4.2 ± 0.5

1.7 ± 0.1

3.4 ± 0.3

4.0 ± 0.2

MLL3

6.6 ± 1.8

4.5 ± 0.3

2.1 ± 0.1

3.5 ± 0.3

4.2 ± 0.2

MLL4

2.6 ± 0.3

1.8 ± 0.3

~1

2.0 ± 0.1

2.1 ± 0.1

SETd1A

6.9 ± 0.4

5.9 ± 0.2

2.7 ± 0.4

5.7 ± 0.4

7.4 ± 0.3

SETd1B

4.8 ± 0.1

4.4 ± 0.1

3.0 ± 0.2

4.8 ± 0.1

5.3 ± 0.2

*In this case, ka-ST was in the order of 104 M-1s-1 assuming that the association
process is in the range of values determined with the other MLL peptides.
**Experimental values of the test mutant of WDR5.
Table S4: Kinetic rate constants of dissociation, kd-ST, of WDR5 and its
mutants with ST-MLL ligands using BLI measurements. The N terminus of
ST-SET1Win ligands were tagged with biotin and their C-terminus were amidated.
5 nM biotinylated ST-SET1Win ligands were loaded onto streptavidin-coated
sensors for 15 minutes. 3-fold serial dilutions of WDR5 and its mutants, ranging
from 0.1 µM to 9 µM, were used to obtain individual binding curves. The buffer
solution contained 150 mM NaCl, 20 mM Tris-HCl, 1 mM TCEP, 1 mg/ml
bovine serum albumin (BSA), pH 7.5. The binding curves were fitted using the
Fortebio Octet Data Analysis software. kd-ST values were provided in (s-1) × 103.
For F133L, 3-fold serial dilutions ranging from 0.3 µM to 27 µM were used.
Numbers represent mean ± s.d. determined from three independent BLI
experimental determinations.
Peptide
WDR5
P216L
F133L
S175L**
S218F
MLL2

16 ± 1

21 ± 3

240 ± 10

12 ± 1

53 ± 3

MLL3

12 ± 2

23 ± 2

170 ± 10

28 ± 1

47 ± 1

MLL4

62 ± 7

350 ± 50

> 1000*

180 ± 10

120 ± 10
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SETd1A

130 ± 10

79 ± 7

760 ± 120

160 ± 10

130 ± 10

SETd1B

29 ± 1

42 ± 3

320 ± 10

5.4 ± 0.2

37 ± 3

*This upper-limit value for the detection of kd-ST is set according to instrument
specifications.
**Experimental values of the test mutant of WDR5.

Table S5: Equilibrium dissociation constants, KD-ST, of WDR5 and its
mutants with ST-SET1Win ligands determined from BLI measurements. The
N terminus of ST-SET1Win ligands were tagged with biotin and their C-terminus
were amidated. 5 nM biotinylated ST-SET1Win ligands were loaded onto
streptavidin-coated sensors for 15 minutes. 3-fold serial dilutions of WDR5 and
its mutants, ranging from 0.1 µM to 9 µM, were used to obtain individual binding
curves. The buffer solution contained 150 mM NaCl, 20 mM Tris-HCl, 1 mM
TCEP, 1 mg/ml bovine serum albumin (BSA), pH 7.5. The binding curves were
fitted using the Fortebio Octet Data Analysis software. For F133L, 3-fold serial
dilutions ranging from 0.3 µM to 27 µM were used. KD-ST values were provided in
nM. Numbers represent mean ± s.d. determined from three independent BLI
experimental determinations.
Peptide
MLL2
MLL3
MLL4
SETd1A
SETd1B

WDR5
410 ± 22
190 ± 57
2500 ± 400
1800 ± 200
600 ± 30

P216L
510 ± 50
530 ± 30
20000 ± 5200
1300 ± 100
960 ± 100

F133L
14,000 ± 2,000
7,900 ± 400
≳ 100,000*
29,000 ± 10,000
10,000 ± 1,000

S175L**
360 ± 30
810 ± 90
8,500 ± 300
2,900 ± 100
110 ± 6

S218F
1,300 ± 10
1,100 ± 100
5,800 ± 500
1,700 ± 100
720 ± 80

*This upper-limit value for the detection of KD-ST results from dividing the upperlimit value of the detection of kd-ST by the value of the ka-ST approximation.
**Experimental values of the test mutant of WDR5.

4. The kinetic and equilibrium constants of the interactions of ST-SET1Win
ligands with WDR5 receptors normalized to those values corresponding to LTSET1Win ligands.
Table S6: Kinetic rate constant of association, ka-ST, of WDR5 and its
mutants, for ST-SET1Win ligands divided by the corresponding ka-LT for LTSET1Win ligands. Numbers represent mean ± s.d. determined from three
independent BLI experimental determinations.
Peptide
MLL2
MLL3
MLL4
SETd1A
SETd1B

WDR5
0.89 ± 0.04
1.2 ± 0.4
1.1 ± 0.2
0.83 ± 0.06
0.68 ± 0.01

P216L
0.74 ± 0.10
0.84 ± 0.08
0.96 ± 0.17
0.69 ± 0.02
0.55 ± 0.02

F133L
1.0 ± 0.1
0.59 ± 0.02
ND*
1.07 ± 0.19
0.70 ± 0.05

S175L**
0.69 ± 0.07
0.71 ± 0.08
0.68 ± 0.03
0.93 ± 0.07
0.57 ± 0.01

S218F
1.0 ± 0.1
1.0 ± 0.1
1.1 ± 0.1
1.3 ± 0.1
0.85 ± 0.04
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*ND stands for “Not Determined.” Interaction between F133L and MLL4 was
detectable using a BLI measurement. However, no statistically significant
accurate determinations were made due to limited resolution of the approach.
**Experimental values of the test mutant of WDR5.

Table S7: Kinetic rate constant of disassociation, kd-ST, of WDR5 and its
mutants interacting with ST-SET1Win ligands divided by the corresponding
kd-LT for LT-SET1Win ligands. Numbers represent mean ± s.d. determined from
three independent BLI experimental determinations.
Peptide
MLL2
MLL3
MLL4
SETd1A

WDR5
2.1 ± 0.1
2.2 ± 0.4
1.6 ± 0.2
2.5 ± 0.3

P216L
1.9 ± 0.4
2.1 ± 0.2
1.6 ± 0.2
2.4 ± 0.3

F133L
1.7 ± 0.1
1.6 ± 0.1
ND*
1.1 ± 0.2

S175L**
2.0 ± 0.1
1.7 ± 0.1
1.4 ± 0.1
1.8 ± 0.1

S218F
2.2 ± 0.1
2.2 ± 0.1
1.7 ± 0.1
2.7 ± 0.2

SETd1B

1.7 ± 0.1

1.4 ± 0.1

1.3 ± 0.1

1.1 ± 0.1

1.6 ± 0.1

*ND stands for “Not Determined.” Interaction between F133L and MLL4 was
detectable using a BLI measurement. However, no statistically significant
accurate determinations were made due to limited resolution of the approach.
**Experimental values of the test mutant of WDR5.

Table S8: Calculations of the differential activation free energies of the
dissociation processes, ΔΔGd, of the interactions of ST-SET1Win ligands with
respect to those of LT-SET1Win ligands. Calculated values of ΔΔGd are given in
kcal/mol. Data are provided as mean  s.d. from three independent BLI
experimental determinations.
Peptide

WDR5

P216L

F133L

S175L**

S218F

MLL2

-0.45 ± 0.01

-0.38 ± 0.12

-0.33 ± 0.04

-0.40 ± 0.02

-0.45 ± 0.04

MLL3

-0.45 ± 0.10

-0.43 ± 0.07

-0.30 ± 0.03

-0.32 ± 0.02

-0.47 ± 0.01

MLL4

-0.28 ± 0.08

-0.28 ± 0.10

ND*

-0.19 ± 0.01

-0.33 ± 0.04

SETd1A

-0.53 ± 0.06

-1.88 ± 0.06

-0.04 ± 0.11

-0.36 ± 0.03

-0.59 ± 0.04

SETd1B

-0.30 ± 0.03

-0.21 ± 0.06

-0.16 ± 0.02

-0.06 ± 0.03

-0.28 ± 0.05

*ND stands for “Not Determined.” Interaction between F133L and MLL4 was
detectable using a BLI measurement. However, no quantitative determinations
were made due to limited time resolution of the approach. **Experimental values
of the test mutant of WDR5.
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Table S9: KD-ST measured with ST-SET1Win ligands normalized to the
corresponding KD-LT values measured with LT-SET1Win ligands. Numbers
represent mean ± s.d. determined from three independent BLI experimental
determinations.
Peptide
MLL2
MLL3
MLL4
SETd1A
SETd1B

WDR5
2.4 ± 0.2
1.9 ± 0.7
1.5 ± 0.3
3.0 ± 0.4
2.4 ± 0.1

P216L
2.5 ± 0.3
2.6 ± 0.2
2.0 ± 0.6
3.5 ± 0.4
2.6 ± 0.3

F133L
1.7 ± 0.2
2.1 ± 0.1
ND*
0.96 ± 0.39
1.7 ± 0.1

S175L**
2.8 ± 0.3
2.5 ± 0.3
2.0 ± 0.1
2.0 ± 0.1
2.0 ± 0.1

S218F
2.1 ± 0.1
2.2 ± 0.2
1.7 ± 0.2
2.0 ± 0.1
2.0 ± 0.3

*ND stands for “Not Determined.” Interaction between F133L and MLL4 was
detectable using a BLI measurement. However, no quantitative determinations
were made due to limited time resolution of the approach. **Experimental values
of the test mutant of WDR5.

Table S10: Calculations of the differential activation free energies of the
ligand-receptor complex formation, ΔΔG, of WDR5-SET1Win interactions of
ST-SET1Win ligands with respect to those of LT-SET1Win ligands. Calculated
values of ΔΔG are given in kcal/mol. Data are provided as mean  s.d. from three
independent BLI experimental determinations.
Peptide
MLL2
MLL3
MLL4
SETd1A
SETd1B

WDR5
0.51 ± 0.04
0.37 ± 0.21
0.22 ± 0.13
0.64 ± 0.07
0.53 ± 0.03

P216L
0.54 ± 0.07
0.57 ± 0.05
0.40 ± 0.20
0.74 ± 0.07
0.57 ± 0.08

F133L
0.32 ± 0.08
0.45 ± 0.04
ND*
-0.05 ± 0.22
0.32 ± 0.05

S175L**
0.61 ± 0.06
0.53 ± 0.08
0.42 ± 0.02
0.42 ± 0.02
0.40 ± 0.04

S218F
0.43 ± 0.01
0.45 ± 0.05
0.30 ± 0.06
0.42 ± 0.03
0.40 ± 0.08

*ND stands for “Not Determined.” Interaction between F133L and MLL4 was
detectable using a BLI measurement. However, no quantitative determinations
were made due to limited time resolution of the approach. **Experimental values
of the test mutant of WDR5.

158

5. Scatter plots of the association rate constants versus the dissociation rate
constants using linear- and logarithm-scale representations.

Figure S3: Scatter plots of the association rate constants versus the
dissociation rate constants using a linear-scale representation. (a) Data
resulted from short-tether (ST) experiments. (b) Data resulted from long-tether
(LT) experiments. (c) Data resulted from no tether (NT) experiments. For ST and
LT experiments, MLL4Win-F133L interactions were not quantitatively determined.
Hence, they only have four points each for MLL4 (for WDR5, P216L, S218F and
S175L). For NT experiments, SETd1AWin-F133L interactions were not
quantitatively determined. Therefore, they only have four points for SETd1A (for
WDR5, P216L, S218F and S175L). Data are provided as mean  s.d. from three
independent experimental determinations.
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Figure 4: Scatter plots of the association rate constants versus the
dissociation rate constants using a logarithm-scale representation. (a) Data
resulted from short-tether (ST) experiments. (b) Data resulted from long-tether
(LT) experiments. (c) Data resulted from no tether (NT; SPR) experiments. For
ST and LT experiments, MLL4Win-F133L interactions were not quantitatively
determined. Hence, they only have four points each for MLL4 (for WDR5,
P216L, S218F and S175L). For NT experiments, SETd1AWin-F133L interactions
were not quantitatively determined. Therefore, they only have four points for
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SETd1A (for WDR5, P216L, S218F and S175L). Data are provided as mean 
s.d. from three independent experimental determinations.
6. Examples of SPR sensorgrams and fittings for probing the real-time
kinetics of NT-SET1Win-WDR5 interactions.

Figure S5: SPR sensorgrams of NT-MLL2Win interacting with immobilized
WDR5 proteins. WDR5 and its mutants were immobilized onto Cytiva Series S
CM5 chips using EDC/NHS amine coupling chemistry in separate experiments.
Titration series of no-tether MLL2Win (NT-MLL2Win) was injected as analyte and
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the corresponding association (120 sec.) and dissociation (360 sec.) curves are
shown. Data for WDR5 is taken from Imran and co-workers (2021).1 These
sensorgrams were fitted to obtain ka-NT, kd-NT, and KD-NT (eqns. (S1)-S3)). The fits
are shown in black.
7. Determinations of the kinetic and equilibrium constants of the
interactions of NT-SET1Win ligands with WDR5 receptors using SPR
measurements.
Table S11: Kinetic rate constants of association, ka-NT, of immobilized WDR5
receptor and its mutants with NT-SET1Win ligands using SPR measurements.
WDR5 and its mutants were immobilized onto Cytiva Series S CM5 chips using
EDC/NHS amine coupling chemistry. Titration series of the respective NTSET1Win ligands were injected as analytes. In the case of the SETd1A-F133L
binding interaction, the kinetic constants were outside the limits that could be
measured by the instrument. ka-NT values were provided in
(M-1s-1) × 10-4. Values represent mean ± s.d. acquired from three independent
SPR experimental determinations.
Peptide WDR5*
P216L
F133L
S175L***
S218F
MLL2
37 ± 3
48 ± 4
10 ± 1
56 ± 1
48 ± 2
MLL3
49 ± 4
63 ± 4
14 ± 1
78 ± 1
46 ± 1
MLL4
21 ± 2
24 ± 1
8.6 ± 0.3
41 ± 2
27 ± 1
SETd1A
31 ± 2
30 ± 1
~ 10**
33 ± 1
40 ± 2
SETd1B
34 ± 3
34 ± 2
13 ± 1
69 ± 1
39 ± 1
1
*Data from Imran and co-workers. **Interaction between wild-type F133L
and SETd1A was detectable using a SPR measurement. However, no quantitative
determinations were made due to limited time resolution of the approach. In this
case, ka-NT was in the order of 105 M-1s-1 assuming that the association process is
in the range of values determined with the other NT-SET1Win ligands. ***The test
mutant of WDR5.
Table S12: Kinetic rate constants of dissociation, kd-NT, of WDR5 and its
mutants with the NT-SET1Win ligands using SPR measurements. WDR5
proteins were immobilized onto Cytiva Series S CM5 chips using EDC/NHS
amine coupling chemistry. Titration series of the respective SET1Win peptide
ligands were injected as analytes. In the case of the SETd1A-F133L binding
interaction, the kinetic constants were outside the limits that could be measured
by the instrument. kd-NT values were provided in (s-1) × 103. Values represent
mean ± s.d. acquired from three independent SPR experimental determinations.
Peptide
WDR5*
P216L
F133L
S175L***
S218F
MLL2

12 ± 1

15 ± 1

170 ± 10

11 ± 1

41 ± 1

MLL3

9.2 ± 0.1

19 ± 1

150 ± 10

27 ± 1

47 ± 1

MLL4

41 ± 3

200 ± 10

340 ± 10

140 ± 10

86 ± 2
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SETd1A

110 ± 10

43 ± 1

> 500**

230 ± 10

100 ± 10

SETd1B

24 ± 1

35 ± 1

280 ± 10

9.6 ± 0.3

41 ± 1

*Data from Imran and co-workers.1 **The upper-limit value for the detection
of kd-NT using SPR experiments is explicitly specified by the instrument
manufacturer. The Biacore 8K+ cannot measure rate constants of dissociation, kd-1
NT, faster than 0.5 s . ***The test mutant of WDR5.
Table S13: Equilibrium dissociation constants, KD-NT, of WDR5 and its
mutants with the NT-SET1Win ligands using SPR measurements. Either
WDR5 or its derivatives was immobilized onto Cytiva Series S CM5 chips using
EDC/NHS amine coupling chemistry. Titration series of the respective NTSET1Win ligands were injected as analytes. KD-NT was calculated directly from
these kinetic rate constants using KD = kd/ka. In the case of the SETd1A-F133L
binding interaction, the kinetic constants were outside the limits that could be
measured by the instrument. Therefore, an affinity analysis (relative response vs.
concentration dose-response curve) was used to calculate the KD-NT. KD-NT values
were provided in nM. Values represent mean ± s.d. acquired from three
independent SPR experimental determinations.
Peptide
MLL2
MLL3
MLL4
SETd1A
SETd1B

WDR5*
33 ± 2
19 ± 1
190 ± 20
350 ± 10
69 ± 6

P216L
31 ± 1
30 ± 1
860 ± 20
140 ± 10
110 ± 10

F133L
1,700 ± 100
1,000 ± 100
4,000 ± 100
11,000 ± 1,000**
2,200 ± 100

S175L***
20 ± 1
35 ± 1
350 ± 10
710 ± 20
14 ± 1

S218F
87 ± 5
100 ± 10
320 ± 10
250 ± 10
100 ± 10

*Data from Imran and co-workers.1 **Here, KD-NT was determined using a steadystate SPR measurement. ***The test mutant of WDR5.

8. The kinetic and equilibrium constants of the interactions of NT-SET1Win
ligands with WDR5 receptors normalized to the corresponding of LT-SET1Win
ligands.
Table S14: Kinetic rate constant of association, ka-NT, of WDR5 and its
mutants, determined by SPR measurements divided by the corresponding k aLT determined by BLI sensorgrams. Data are provided as mean  s.d. from three
independent experiments.
Peptide
WDR5
P216L
F133L
S175L***
S218F
MLL2
8.4 ± 0.7
8.5 ± 0.7
6.2 ± 0.1
11 ± 1
12 ± 1
MLL3
9.2 ± 0.7
12 ± 1
3.9 ± 0.1
16 ± 1
12 ± 1
MLL4
9.0 ± 1.1
12 ± 1
ND*
14 ± 1
13 ± 1
SETd1A 3.7 ± 0.2
3.5 ± 0.1
ND**
5.4 ± 0.2
7.2 ± 0.4
SETd1B 4.8 ± 0.4
4.3 ± 0.2
3.0 ± 0.1
8.2 ± 0.1
6.2 ± 0.1
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*ND stands for “Not Determined.” Interaction between F133L and MLL4 was
detectable using a BLI measurement. However, this interaction was not
quantitatively determined using BLI due to the limited time resolution of the
approach. ** Interaction between F133L and SETd1A was detectable using a SPR
measurement. However, this interaction was not quantitatively determined using
SPR due to the limited resolution of the approach. ***The test mutant of WDR5.

Table S15: Kinetic rate constants of dissociation, kd-NT, of WDR5 and its
mutants, determined by SPR, normalized to the corresponding kd-LT values.
Data are provided as mean  s.d. from three independent experiments.
Peptide
WDR5
P216L
F133L
S175L***
S218F
MLL2
1.6 ± 0.1
1.3 ± 0.1
1.3 ± 0.1
1.7 ± 0.1
1.7 ± 0.1
MLL3
1.7 ± 0.1
1.7 ± 0.1
1.4 ± 0.1
1.7 ± 0.1
2.2 ± 0.1
MLL4
1.1 ± 0.1 0.94 ± 0.01
ND*
1.2 ± 0.1
1.2 ± 0.1
SETd1A 2.1 ± 0.1
1.3 ± 0.1
ND**
2.6 ± 0.1
2.2 ± 0.1
SETd1B 1.3 ± 0.1
1.2 ± 0.1
1.2 ± 0.1
2.0 ± 0.1
1.8 ± 0.1
*ND stands for “Not Determined.” **The interaction between F133L and
SETd1A was detectable using an SPR measurement. Yet, this interaction was not
quantitatively determined using BLI due to the limited time resolution of the
approach. ***The test mutant of WDR5.

Table S16: KD-NT values determined by SPR measurements, which were
normalized to the corresponding KD-LT values determined by BLI
measurements. Data are provided as mean  s.d. from three independent
experiments.
Peptide
MLL2
MLL3
MLL4
SETd1A
SETd1B

WDR5
0.19 ± 0.01
0.19 ± 0.01
0.12 ± 0.01
0.56 ± 0.02
0.27 ± 0.02

P216L
0.15 ± 0.01
0.15 ± 0.01
0.087 ± 0.002
0.38 ± 0.01
0.29 ± 0.01

F133L
0.20 ± 0.01
0.28 ± 0.01
ND*
0.37 ± 0.01
0.36 ± 0.01

S175L**
S218F
0.15 ± 0.01
0.13 ± 0.01
0.11 ± 0.01
0.19 ± 0.01
0.085 ± 0.001 0.093 ± 0.002
0.49 ± 0.02
0.30 ± 0.02
0.25 ± 0.01
0.28 ± 0.01

ND stands for “Not Determined.” The interaction between F133L and MLL4 was
detectable, but not quantifiable using BLI. **The test mutant of WDR5.

164

Table S17: Differential activation free energies of the ligand-receptor
complex formation, ΔΔG (kcal/mol), determined for NT conditions with
respect to LT conditions. Data are provided as mean  s.d. using three
independent experiments.
Peptide

WDR5

P216L

F133L

S175L**

S218F

MLL2

-0.98 ± 0.03

-1.1 ± 0.1

-0.94 ± 0.01

-1.1 ± 0.1

-1.2 ± 0.1

MLL3

-0.99 ± 0.02

-1.1 ± 0.1

-0.75 ± 0.01

-1.3 ± 0.1

-0.97 ± 0.02

MLL4

-1.3 ± 0.1

-1.4 ± 0.1

ND*

-1.5 ± 0.1

-1.4 ± 0.1

SETd1A
SETd1B

-0.34 ± 0.02
-0.76 ± 0.05

-0.57 ± 0.01
-0.73 ± 0.02

-0.58 ± 0.01 -0.42 ± 0.02
-0.60 ± 0.01 -0.83 ± 0.02

-0.70 ± 0.03
-0.74 ± 0.01

*ND stands for “Not Determined.” The interaction between F133L and MLL4
was detectable, but not quantifiable using BLI. **The test mutant of WDR5.
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9. The 3D plots and contour maps of the association rate constants under
ST and LT conditions normalized to those recorded under NT conditions.

Figure S6: 3D plots and contour maps of the normalized association rate
constants. (a) Bar graph and (b) contour map of ka-ST values for the interaction of
ST-SET1Win ligands, with WDR5 and its mutants, divided by their corresponding
ka-NT values. (c) Bar graph and (d) contour map of ka-LT values for the interaction
of LT-SET1Win ligands, with WDR5 and its mutants, divided by their
corresponding ka-NT values. ka-ST for the MLL4Win-F133L interactions could not
be determined using BLI, while ka-NT of the SETd1AWin-F133L interactions could
not be determined using SPR. Therefore, those values are colored in black.
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10. The 3D plots and contour maps of the dissociation rate constants under
ST and LT conditions normalized to those recorded under NT conditions.

Figure S7: 3D plots and contour maps of the normalized association rate
constants. (a) Bar graph and (b) contour map of kd-ST values for the interaction of
ST-SET1Win ligands, with WDR5 and its mutants, divided by their corresponding
kd-NT values. (c) Bar graph and (d) contour map of kd-LT values for the interaction
of LT-SET1Win ligands, with WDR5 and its mutants, divided by their
corresponding kd-NT values. kd-ST for the MLL4Win-F133L interactions could not be
determined using BLI, while kd-NT of the SETd1AWin-F133L interactions could
not be determined using SPR. Therefore, those values are colored in black.
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11. Scatter plots of kinetic and equilibrium constants for the ST, LT, and
NT experiments.

Figure S8: Scatter plots of the ka, kd, and KD for the ST and NT conditions.
(a) ka-ST values plotted against the corresponding ka-NT values. Points below this
line correspond to interactions with slower association rates for the ST
experiments. (b) kd-ST values plotted against the corresponding kd-NT values. Points
above this line correspond to interactions with faster disassociation rate constants
for the ST experiments. (c) KD-ST values plotted against the corresponding KD-NT
values. Points above this line correspond to interactions that were weaker in the
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ST experiments. Data are provided as mean  s.d. from three independent
experiments.

Figure S9: Scatter plots of the equilibrium dissociation constants of S175L
data. (a) KD-ST values plotted against the KD-LT values. The red line is the fit
resulted from interactions of WDR5, P216L, S218F and F133L with SET1Win
under ST and LT conditions. The green points represent interactions of S175L.
Points above this blue line correspond to interactions which were weakened by
reducing tether length. (b) KD-NT values plotted against the KD-LT values. The red
line is the fit resulted from interactions of WDR5, P216L, S218F and F133L with
SET1Win under NT and LT conditions. The green points represent interactions of
S175L. Points below this blue line correspond to interactions that were stronger
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under NT conditions. m indicates the slope of curves in both panels. Data are
provided as mean  s.d. from three independent experiments.
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5.1 Abstract
WD40 Repeat Protein 5 (WDR5) is a well-known epigenetic regulator which has
recognized interactions with a host of different proteins. It has a 22 residue Nterminus intrinsically disordered tail whose function is unknown. Most available
crystal structures of WDR5 use a truncated version similar to WDR523-334
(WDR5ΔN) to get around this intrinsically disordered region (IDR). Studies of
WDR5’s interactions with other proteins do not differentiate between full-length
WDR5 (WDR5FL) and WDR5ΔN, ignoring any differences between them. Here we
look at the impact of the tail on WDR5’s interactions, its effect on our Biolayer
Interferometry (BLI) measurements of WBM site kinetics and its role in aiding
WDR5 function. We also look at the significance of physiologically relevant salt
conditions for quantifying these interactions.
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5.2 Introduction
WD40 repeat protein-5 (WDR5) plays established roles in multiple protein
complexes.

1

It is crucial to the regulation of Histone-3 Lysine-4 (H3K4)

methylation by SET1 family proteins; MLL1, MLL2, MLL3, MLL4, SETd1A and
SETd1B.2-4 Not only does it interact directly with these SET1 proteins

5-7

it also

interacts with retinoblastoma binding protein-5 (RbBP5) which is an integral part
of the SET1 complex.5, 6, 8, 9 Moreover, it also has known interactions with the
transcription factor MYC,10-13 3-phosphoinositide-dependent protein kinase 1
(PDPK1)14 and other interacting partners involved in phosphatidylinositol 3-kinase
(PI3K) signaling.14 These interactions have wide ranging implications for
epigenetic regulation and complex assembly among other things.

WDR5 has two known binding sites responsible for all of its interactions: the
WDR5 Interacting (Win) site2, 3, 15-17 and the WDR5 Binding Motif (WBM) site.13,
14, 18

SET1 proteins and histone H3 have the Win sequence which allows them to

associate with the Win site.3 These interactions involve precise insertions into the
Win site cavity and thus impose an entropic penalty on the binding. The kinetics of
these interactions have been explored before and reveal a significantly slow
association rate as expected.7 On the other hand, RbBP518 and MYC13 use the
WDR5 Binding Motif to bind to the WBM site. These are primarily surface
interactions which have not been explored kinetically before.
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The N-terminus IDR present on WDR5 has no understood function. These 22
residues are largely ignored when focusing on WDR5’s functions. Most available
crystal structures work with a truncated version similar to WDR523-334 (WDR5ΔN)
to get around this region.2,15,16,17 This IDR has part of the Win motif and has been
seen interacting with the Win site cavity in at least one crystal structure
exploration.19

Figure 1: BLI Experiment of RbBP5 interacting with WDR5 in the presence
of Salt. The figure shows the RbBP5 peptide interacting with WDR5. RbBP5
(magenta) is immobilized onto the BLI sensor surface with a linker. WDR5 (red),
Na+ ions (light blue) and Cl- ions (green) are shown freely moving in solution.
Bound WDR5 is marked in blue.
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In this study we look at the role the intrinsically disordered tail plays in WDR5’s
interactions, the effect it can have on kinetics measurements of the WBM site and
its contribution to the overall function of WDR5 inside the cell. We also look at the
importance of maintaining physiologically relevant conditions when looking at
these interactions.

5.3 Results and Discussion
WDR5FL and the tale of the N-terminus. We obtained BLI sensorgrams for
the interaction of RbBP5 peptide with Full-length WDR5 (WDR5FL) which
included the N-terminus tail (Table 1). The biotinylated RbBP5 peptide was
immobilized onto Streptavidin sensors and then submerged in different
concentrations of the analyte, WDR5FL. Once the interaction reached equilibrium,
the sensors were moved to an analyte free solution. This allowed us to look at the
association and dissociation phases of the interaction in real time. WDR5FL gave us
the curves shown in figure (Figure 2a). Not only did we see large responses we
also saw that as the concentration of WDR5FL was increased, the curves did not
show faster saturation. The lower concentrations showed quick saturation while the
higher concentrations did not. This was counterintuitive to the expectations we
would have for any simple 1:1 protein-protein interaction. The results were
reproduced an additional two times to confirm that no experimental errors were
responsible for this deviation from normal expected behavior. Optimizing this
experiment, by varying loading and association steps, to decrease maximum
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response did not improve the results. Decreasing loading peptide concentration to
1 nM reduced the maximum response but did not produce results amenable to 1:1
binding analysis. Reducing the maximum concentration of analyte to 600 nM or
300 nM again did not solve this problem. We hypothesized that there could be
another interaction creating an artifact in our BLI data.
Table 1: Peptides. The table shows the peptides used for this work, their sequences
and the sites they bind onto on WDR5. The C-terminus of all peptides were
amidated. The N-terminus of RbBP5369-379 peptide and MLL34703-4716 were
Biotinylated while that of WBM Inhibitor and ARTEVY were acetylated. The
relevant sequences are in black, N-terminal and C-terminal modifications are
marked in blue, and the linkers are marked in red.
Peptide Name
Peptide Sequence
Binding Site
RbBP5369-379 Peptide

Biotinyl-GGSGGSGGSAAEDEEVDVTSVD-NH2

WBM

WBM Inhibitor

CH3CO-AAEDEEVDVTSVD-NH2

WBM

ARTEVY

CH3CO-ARTEVY-NH2

Win

MLL34703-4716

Biotinyl-GGSVNPTGCARSEPKMS-NH2

Win
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Figure 2: RbBP5 Interaction with WDR5FL. (a) This figure shows BLI
sensorgrams obtained for the interaction of RbBP5 with full length WDR5.
Biotinylated RbBP5 peptide was immobilized as ligand on to Streptavidin sensors.
The sensors were dipped into well containing different concentrations of WDR5FL
as analyte. The sensorgrams corresponding to the 5 different concentrations used
are shown below. (b) This figure shows the schematic of the interaction and the
role the N-terminus IDR plays in our results.
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Dimerization. Based on available X-ray crystallography structure, we
hypothesized that, in the case of these specific BLI experiments, WDR5 may be
binding in such a way that it leaves the Win site open to interactions with the Nterminus tail of other present WDR5s. The N-terminus tail has a Win motif
sequence given by EAARAQP that can potentially insert into the Win site cavity.19
This schematic is shown in figure (Figure 2b). Thus, the binding of WDR5 to the
immobilized RbBP5 peptide would allow even more WDR5 to bind onto the first
one and so on. To test this, we added ARTEVY (win6mer), a Win binding site
inhibitor, to the RbBP5-WDR5FL association well, to block the Win site (14).
Figure 3a shows that ARTEVY successfully brought the interaction to normal
behavior. Considering ARTEVY is a Win site binder, normally it would have no
effect whatsoever on the WBM interaction making this result very interesting.
Moreover, Figure 3b also shows that when the same experiment was performed
with WDR523-334 (WDR5ΔN), not only did ARTEVY have no effect, but the curves
seen were similar to the 10 µM ARTEVY spike curve in Figure 3a. This confirms
that the interaction between the N-terminus IDR and the Win binding site was
responsible for the unexpected results. Furthermore, when the original experiment,
shown in Figure 3a, was carried out with 20 µM ARTEVY spiked in the
association wells we got the sensorgrams shown in figure Figure S1. These curves
showed a concentration dependent responses and rates of saturation, more
amenable to 1:1 binding fitting and gave us kinetics of the interaction.
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Figure 3: Blocking the Win binding site using ARTEVY. RbBP5’s interaction
with WDR5 inhibited with different concentrations of ARTEVY peptide.
Biotinylated RbBP5 peptide was immobilized onto Streptavidin sensors. 3 µM
WDR5 association wells were spiked with different concentrations of ARTEVY
(a) WDR5FL (b) WDR5ΔN.
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Moreover, we looked at the interaction of RbBP5 with WDR5ΔN (Figure 4a). These
curves were again well behaved, readily analyzable and gave us very similar
kinetics (Table S1). Additionally, the interaction of MLL3 with WDR5ΔN
interaction showed no difference from MLL3’s interaction with WDR5FL
interaction measured by us previously (Figure S2, Table S2), showing that this
effect was limited to WBM measurements. These comprehensive results allow us
to conclude that WDR5FL dimerizes due to the interaction between the N-terminus
IDR and the Win binding site cavity. This dimerization is amplified in the case of
our BLI measurements of the RbBP5-WDR5FL complex because of the specific
configuration WDR5 ends up in after binding with the RbBP5 peptide as shown in
figure. We expect this to hold true for most WBM binding measurements through
BLI and SPR in which the WBM partner is immobilized.

Two-State Interaction. Another possibility that we explored was that the
RbBP5-WDR5FL interaction was a two-state interaction. It was possible that the
complex was going through a conformational change after the initial binding
leading to a much more stable complex. Therefore, our interaction model would
have

changed

from

A + B ⇌ AB
to
A + B ⇌ AB ⇌ AB*
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Here A and B represent the binding partners RbBP5 and WDR5 respectively,
AB represents the complex and AB* represents a more stable complex forming
after conformational change i.e the second state. The model fit our optimized
data sets really well (Figure S3). The figure shows our analysis of one of these
curves using this model (Figure S4a). It shows that as association proceeds,
we get higher and higher percentages of the more stable AB*. Consequently,
the dissociation rate constant should decrease the longer the association time
or “contact time”. Figure S4b shows the two-state test, the contact time was
increased and the corresponding dissociation curves were analyzed. Similar
tests have been performed before using the SPR (20). We saw that increasing
contact time had no effect on the dissociation rate. Therefore, even though the
model fit our data well, this interaction was not a two-state interaction. Our
results reemphasize the unreliability of picking and choosing models based
only on how well they fit the BLI data. Validating models through orthogonal
tests is crucial to extracting useful and credible information from data.

Phase Separation and WDR5. These results have significant ramifications for
understanding the behavior of WDR5. Previous work7 has shown that WDR5’s
interactions with SET1 proteins have very low association rates due in part to the
entropic cost associated with the SET1 Win motif Arginine inserting into the
WDR5 cavity. However, this exploration suggests that the intrinsically disordered
tail allows WDR5 to dimerize under certain conditions. This increased intermolecular affinity could potentially trigger phase-separation and allow WDR5 to
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form local hyper-concentrations making up for the slow association rates.
Moreover, the connection between the presence of IDRs and the ability to phase
separate has been explored extensively before (15-18). This would explain why,
despite the low association rates, WDR5 is crucial to the regulation of the histone
methylation function of some SET1 proteins.2 Phase separation would allow
WDR5 to maintain its specificity, granted by the Win binding site cavity, while not
compromising on function.

Association and dissociation rate constants. Looking at the kinetics of the
RbBP5-WDR5ΔN interaction, we see that that this WBM site interaction had a
greater association rate then most of our measured Win binding site interactions.
This was in line with our predictions as this surface interaction did not have the
same entropic limitations that the Win binding site cavity interactions have.
Furthermore, the dissociation rate constant was also in general greater than those
of the Win binding site interactions (Figure 4a, Table S1). This may be due to a
relative lack of hydrogen bonds stabilizing the RbBP5-WDR5 complex (Table S3).
The complex has several ionic and hydrophobic contributions (Table S4), but it
seems they do not make this a high-affinity complex. Consequently, the KD of the
interaction was 1.5 μM, making this interaction weaker than most SET1 protein
interactions with WDR5 (7, 16, 17).
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Figure 4: RbBP5 Interaction with WDR5ΔN. (a) This figure shows BLI
sensorgrams obtained for the interaction of RbBP5 with WDR5ΔN. Biotinylated
RbBP5 peptide was immobilized as ligand on to Streptavidin sensors. The sensors
were dipped into well containing different concentrations of WDR5FL as analyte.
The sensorgrams corresponding to the 5 different concentrations used are shown
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below. (b) RbBP5-WDR5 complex inhibited with different concentrations of
WBM inhibitor (Table 1). Biotinylated RbBP5 peptide was immobilized onto
Streptavidin sensors. 3 µM WDR5 association wells were spiked with different
concentrations of WBM inhibitor. (c) Normalized maximum responses obtained for
the inhibition of WDR5-RbBP5 interactions.

Inhibition. Additionally, our data shows that this interaction can be inhibited
by using a peptidomimetic inhibitor based on the RbBP5 WBM motif (Table 1).
We saw that formation of the RbBP5-WDR5 complex was greatly decreased, as the
concentration of WBM inhibitor was increased from 1 μM through 10 μM (Figures
4bc, Table S5). However, the effect of the inhibitor at 1 μM concentration was
insignificant and an order of magnitude higher concentration was required to
produce a strong inhibition. This suggests that the WBM inhibitor while capable of
inhibition would need some modifications to increase its effectiveness. Our results
show that this peptide can serve as the basis for the design of strongly binding
molecules.

Effect of salt concentration. The figure shows that the RbBP5-WDR5
interaction is highly aided by electrostatic effects (Figure S5). The WBM site on
WDR5 is highly positive, while the WBM motif on RbBP5 is highly negative.
Moreover, we postulated that this would make the interaction very susceptible to
shielding effects from salt.

To test this, we measured the kinetics of these

interactions in three other buffers. Tris, TCEP and BSA were kept the same while
the concentration of NaCl was varied. The three additional NaCl concentrations
used were 50 mM, 300 mM, and 600 mM. 150 mM NaCl had already been used,
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as mentioned above. Our results, in figure, show that the interaction is significantly
affected by salt concentration (Figure 5, Figure S6, Table S6). The interaction
strength decreased as NaCl was increased, as shown by the figure. The overall
change in strength was non-linear with respect to salt. Furthermore, our technique
allowed us to further break down this effect in terms of changes in association and
dissociation rates. We see that increasing salt-concentration decreases association
rate constant. This is to be expected as the higher salt concentration would decrease
the Debye screening length, decrease the effective interaction radius of the two
binding partners and lead to fewer association events occurring. Surprisingly, the
salt also affected the dissociation rate. We see that at 50 mM NaCl, the dissociation
rate is 50-fold slower that at 600 mM NaCl. Moreover at 150 mM NaCl and 300
mM NaCl the interaction is ~3 fold slower and ~2 fold slower, respectively, than
that at 600 mM NaCl. This explains the overall non-linearity of the change in
interaction strength.
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Figure 5: Effect of Salt on the RbBP5 Interaction with WDR5ΔN. The figure
shows the binding constants obtained for the RbBP5 interaction with WDR5ΔN in
different salt concentrations. (a) association rate constants (b) dissociation rate
constants (c) equilibrium dissociation constants.
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5.4 Conclusions
Our work presents the first ever thorough kinetic study of WDR5 WBM site
interactions, explores the impact of salt on WBM site kinetics, and suggests the role
the N-terminus IDR of WDR5 plays in governing its overall function. We found
that the WBM site association rate constant was higher than those of the Win site,
but this increase was countered by a simultaneous increase in the dissociation rate.
Furthermore, we see that increasing salt decreases the association rate of the
interaction and increases the dissociation rate, greatly weakening the binding
affinity. This underscores the importance of maintaining physiologically relevant
conditions for in-vitro studies, especially for WDR5 work. Additionally, we see
that the N-terminus intrinsically disordered tail contributes to the inter molecular
affinity of WDR5 increasing the likelihood of phase separation. This increased
likelihood of phase separation may explain the unique way with which WDR5 is
able to maintain a balance between specificity and function.

5.5 Materials and Methods
Protein Expression and Purification. Full-length WDR5 (WDR5FL) and was
expressed and purified in a similar way as described previously.7 N-terminus
truncated WDR5 (WDR523-334, WDR5ΔN) was purified in the same way. pET3aTr
vectors containing the 6×His-TEV-WDR5 and 6×His-TEV- WDR523-334 sequences
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were transformed into Rosetta™ 2 BL21(DE3)pLysS (Novagen, Cat #71403)
competent E. coli cells. These cells were then grown overnight on Luria-Bertani
(LB) agar carbenecillin/chloramphenicol selection plates at 37oC. Single colonies
from these transformations were used for carbenicillin and chloramphenicol
inoculated 50 mL Terrific Broth (TB) media starter cultures. This culture was
grown overnight at 30oC. Inoculated 1L TB media cultures were seeded by the
starter cultures. These expression cultures were grown at 37oC for 2.5 hours and
then left at room temperature for 30 minutes. They were induced with 100 µM
IPTG and grown at 16oC for 20 hours. Pellets were harvested and lysed using
multiple passes through a microfluidizer. The Lysis buffer contained PMSF and
EDTA-free protease inhibitor. The lysate was spun down, the supernatant was
collected and passed through a Nickel column on an FPLC. WDR5 was eluted using
buffer containing imidazole. The Hi-tag was cleaved using TEV Protease. The
Nickel column was again used to extract the His-tag and TEV Protease from the
proteins.

Peptide synthesis, labeling, purification, and analysis. All peptides for
biolayer interferometry, the Fluorescein isothiocyanate (FITC) labelled peptides for
FP spectroscopy and the label-free peptides were synthesized and purified by
GenScript (Piscataway, NJ). The peptides were purified to ≥ 95% purity. The BLI
peptides were Biotinylated at the N-terminus, the FP ones were labelled with FITC
at the N-terminus and the un-labelled ones were acetylated at the N-terminus. These
were purified to ≥ 90% purity. The label was again added at the N-terminus. All the
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peptides were amidated at the C-terminus. Amino acid analysis, purity
confirmation, and solubility testing were provided by GenScript.

Biolayer interferometry (BLI). BLI studies were carried out using
OctetRED384 (FortéBio, Fremont, CA). The assays were performed the same way
as in our previous studies7. Peptide’s biotinylated at the N-terminus were
immobilized onto Streptavidin (SA) sensors as ligands. These sensors were dipped
into analyte containing wells (Manufacturer, Town, State) to obtain association
curves and then were moved to analyte free wells to obtain dissociation curves.
Unless specified otherwise, the running buffer for most experiments contained 150
mM NaCl, 20 mM Tris, 1 mM TCEP and 1mg/ml BSA. The pH of all running
buffers was adjusted to 7.5. For the inhibition experiments, additional nonbiotinylated peptides were included with the analytes
Molecular graphics. All protein representations were prepared using PyMOL
Molecular Graphics System (Version 2.4.0 Schrödinger, LLC).
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1. Traces for RbBP5’s interaction with ARTEVY saturated WDR5

Figure S1: BLI Sensorgrams for RbBP5’s interaction with ARTEVY
saturated WDR5FL. This figure shows BLI sensorgrams obtained for the
interaction of RbBP5 with WDR5FL + ARTEVY. Biotinylated RbBP5 peptide
was immobilized as ligand on to Streptavidin sensors. The sensors were dipped
into well containing different concentrations of WDR5 as analyte as well as 20
μM ARTEVY. The sensorgrams corresponding to the 5 different WDR5
concentrations used are shown below.
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2. Kinetics measured for the RbBP5-WDR5 interaction
Table S1: WDR5FL and WDR5ΔN, kinetics and KD, with RbBP5. The table
shows kon, koff and KD values for the interaction of RbBP5 peptide with WDR5FL
and WDR5ΔN. For WDR5FL, ARTEVY was spiked in the association well to
block the Win site and prevent dimerization. Values were obtained using BLI
sensorgrams in figure S1 and figure 4 These sensorgrams were fitted to obtain
kon and koff, which were used to indirectly obtain KD. Triplicates were performed
and the resultant mean ± s.d values are shown.
kon
(×10 M-1s-1)
17 ± 2
9.4 ± 1.1
4

WDR5FL
WDR5ΔN

koff
(×10-1 s-1)
2.4 ± 0.3
1.4 ± 0.1

KD
(µM)
1.4 ± 0.4
1.5 ± 0.3
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3. Traces for the MLL3- WDR5ΔN Interaction

Figure S2: BLI sensorgrams for MLL3’s interaction with WDR5ΔN. This
figure shows BLI sensorgrams obtained for the interaction of MLL3 with
WDR5ΔN. Biotinylated MLL3 peptide was immobilized as ligand on to
Streptavidin sensors. The sensors were dipped into well containing different
concentrations of WDR5ΔN as analyte. The sensorgrams corresponding to the 5
different concentrations used are shown.
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4. Kinetics measured for the MLL3-WDR5 interactions
Table S2: WDR5FL and WDR5ΔN, kinetics and KD, with MLL3. The table
shows kon, koff and KD values for the interaction of MLL3 with WDR5FL(3) and
WDR5ΔN. WDR5FL values were taken from our previous work. WDR5ΔN values
were obtained using similarly acquired BLI sensorgrams shown in figure S2.
These sensorgrams were fitted to obtain kon and koff, which were used to indirectly
obtain KD. Triplicates were performed and the resultant mean ± s.d values are
shown.
kon
(×10 M-1s-1)
6.3 ± 2.8
6.6 ± 1.8
4

WDR5ΔN
WDR5FL

koff
(×10-2 s-1)
0.97 ± 0.04
1.2 ± 0.2

KD
(nM)
170 ± 70
190 ± 60
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5. Two state analysis of the RbBP5-WDR5FL interaction

Figure S3: Two state fitted BLI sensorgrams for RbBP5’s interaction with
WDR5Fl. This figure shows BLI sensorgrams obtained for the interaction of
RbBP5 with full length WDR5. Biotinylated RbBP5 peptide was immobilized as
ligand on to Streptavidin sensors. The sensors were dipped into well containing
different concentrations of WDR5FL as analyte. The sensorgrams corresponding to
the 5 different concentrations used are shown. Fitting was performed using
MatLab and is shown in red.
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Figure S4: Two state analysis of RbBP5-WDR5FL Interaction. (a) Raw
Response and AB vs AB* composition obtained from two-state analysis of the
RbBP-WDR5 association. The purple points show the time values chosen for the
contact-time analysis and the corresponding AB* response. Analysis was
performed using Matlab. (b) Normalized Dissociation curves obtained after
different association times. The contact time was increased and the corresponding
dissociation curves were analyzed Each curve was normalized using its starting
value.
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6. Known interactions at the RbBP5-WDR5 interface.
Table S3: Mapping of the Hydrogen bonds at the RbBP5-WDR5 interface.
These results were obtained using previously published co-crystallization data
(PDB ID: 6KIW).1 The cut-off distance for identifying these hydrogen bonds was
4.0 Å. Here, BB and SC denote backbone and side chain, respectively. These
interactions were determined using protein interactions calculator (PIC).2 The
structure was not able to model the whole sequence of RbBP5, so these hydrogen
bonds are not comprehensive. The first residue in each bond belongs to RbBP5,
whereas the second one belongs to WDR5. BB and SC denote backbone and side
chain, respectively.
Hydrogen Bonds
S379-N225
E371-L249
S379-R181
D376-N225
V377-N225

Distance (Å)
3.4
2.5
3.3
3.1
3.5

Type
BB-BB
BB-BB
BB-SC
BB-SC
BB-SC

Table S4: List of all known noncovalent interactions between RbBP5 and
WDR5. These results were obtained in a similar method as for Table S2. For
each interaction, the first residue corresponds to RbBP5 while the second residue
corresponds to WDR5. The cut-off for ionic interactions was 6 Å, while for
hydrophobic interactions it was 5 Å.
Ionic
E373-K245
E373-K247
D372-K247
E374-K272
D376-K272
E271-K291

Hydrophobic
V375-Y228
V375-L249
V377-Y228
V377-L240
V377-L249
V377-F266
V377-L288
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7. Impact of WBM Inhibitor

Table S5: Impact of WBM Inhibitor on RbBP5-WDR5 interaction. The table
shows the impact of RbBP5 based inhibitor on the BLI response. 5 nM RbBP5
peptide was immobilized onto Streptavidin sensors and its interaction with 600
nM WDR5ΔN was disrupted using the WBM inhibitor. The interaction was
allowed to reach equilibrium and the highest response values were recorded. The
normalized responses were calculated by setting the without inhibitor response to
1. Triplicates were performed and the resultant value mean ± s.d values are
shown.
Inhibitor Concentration (µM)
0
1
5
10

Normalized Response
1
1.0 ± 0.1
0.65 ± 0.06
0.21 ± 0.05
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8. Role of Charge Distribution

Figure S5: RbBP5 peptide and WDR5 charge distribution. The figures show
the charge distributions on RbBP5 and WDR5.
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9. RbBP5-WDR5ΔN interactions in different buffer conditions

Figure S6: BLI Sensorgrams for different buffer conditions. This figure shows
BLI sensorgrams obtained for the interaction of RbBP5 with WDR5ΔN.
Biotinylated RbBP5 peptide was immobilized as ligand on to Streptavidin
sensors. The sensors were dipped into well containing different concentrations of
WDR5ΔN as analyte. The sensorgrams corresponding to the 5 different
concentrations used are shown below. The NaCl concentration in the buffer was
varied. (a) 50 mM NaCl (b) 300 mM NaCl (c) 600 mM NaCl
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Table S6: Salt analysis. The table shows kon, koff and KD values for the interaction
of RbBP5 peptide with WDR5ΔN under different buffer conditions. The
concentration of NaCl in the buffer was varied while other components were kept
constant. Values were obtained using BLI. Sensorgrams were fitted to obtain kon
and koff, which were used to indirectly obtain KD. Triplicates were performed and
the resultant mean ± s.d values are shown.
Salt
(mM NaCl)
50
150
300
600

kon
(×104 M-1s-1)
14 ± 1
9.4 ± 1.1
10 ± 1
5.1 ± 1.1

koff
(×10-2 s-1)
0.82 ± 0.06
14 ± 1
19 ± 2
43± 11

KD
(nM)
60 ± 4
1500 ± 300
1900 ± 400
9300 ± 4000
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Chapter 6: Summary and Future work
In summary, we have extracted the kinetics of WDR5-SET1 interactions as well as
of WDR5’s interaction with RbBP5. We used SET1Win peptides to emulate the
binding sites of large SET1 proteins and we studied their interactions with WDR5
using BLI, SPR and FP methods. The use of multiple bulk-phase techniques
increased confidence in our findings. It shows how the use of orthogonal
approaches ensures that derived results are credible and reproduceable across
techniques. Furthermore, the exploration of the effects of restrictions on interacting
partners provides much-needed information on how to interpret the results derived
from different bulk-phase techniques.
Additionally, in the case of the Win site interactions, we have obtained association
and dissociation rates for wild-type WDR5 as well WDR5 cancer mutants. These
mutants were divided into two categories: surface mutants and cavity mutants. The
surface mutants included, D172A, P216L and Y260 H. While the cavity mutants
included F133L, S175L, S218F and D92N. We used BLI to extract kinetics and
indirectly calculate the KD, and then we validated our findings using FP. We
observed divergent impacts of Win site mutations on the kinetics of the Win site
interactions. All of the Win site binders were not always impacted the same way
due to these mutations. This study will help lay the groundwork for precision
medicine. Understanding the impacts of individual mutations in cancers sets up the
base for having tailor made drugs to counter those effects.
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Moreover, our work with varying the surface-tethering conditions for these
interactions investigated interesting experimental phenomenon. We looked at three
conditions: short tether (ST), long tether (LT) and no tether (NT). We studied the
interactions of SET1Win peptides with WDR5 under these conditions. For the ST
case, the peptides were attached to a BLI sensor surface using 3 residue (GGS)
tethers. For the LT case the tethers were elongated to 6 residues (GGS)3. While for
the NT conditions WDR5 was immobilized onto a SPR sensor and the peptides
were free in solution. Our results showed that as the conditions changed, so did the
rates of association and dissociation. The LT condition provided faster association
rates and slower dissociation rates as compared to the ST condition. However, NT
conditions exhibited even faster association rates compared to LT. The dissociation
rates under LT and NT conditions were very similar. This work provides
experimental evidence of the fly-casting mechanism of association between a
surface tethered ligand and its receptor. Furthermore, it looks at the entropic force
modulating the dissociation rate constants of these interactions, in a quantifiable
way. This approach allowed us to set up a model to predict the effects of surface
tethering and then test these using more sets of interactions.
Finally, the exploration of the interaction of RbBP5 with WDR5 showed that WBM
interactions are also amenable to study using BLI. We provide kinetics of this
interaction for WDR5FL as well as WDR5ΔN , using a peptide containing the RbBP5
WBM sequence. Moreover, we establish that the N-terminus IDR of WDR5 can
insert into the Win site cavity. This detailed work shows conclusively that this IDR
can impact BLI measurements of WBM site kinetics. Also, it confirms the self-

213

association behavior of WDR5. This result is also potentially crucial in explaining
how WDR5 is able to have a wide range of interacting partners while maintaining
specificity.
Future work on in this regard can focus on other yet to be kinetically explored
binding partners of WDR5. In this direction, we have already obtained preliminary
data for the MYC-WDR5 interaction as shown in figure 1.

Figure 1: BLI sensorgram of the MYC- WDR5ΔN interaction. This figure shows
BLI sensorgrams obtained for the interaction of MYC with WDR5ΔN. Biotinylated
MYC peptide, containing the WBM motif, was immobilized as ligand on to
Streptavidin sensors. The sensors were dipped into well containing different
concentrations of WDR5ΔN as analyte. Here, the sensorgrams corresponding to the
5 different concentrations are shown.

Furthermore, now that we understand of the kinetics of the interactions mediated
by the Win site using SET1 representative peptides, we can investigate these
kinetics with larger fragment of the SET1 proteins. For this purpose, we can use the
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truncated proteins of SET1 family members i.e., MLL13745-3969, MLL25319- 5537,
MLL34689-4911, MLL42490-2715, SETd1A1474-1708, and SETd1B1727-1966.These SET1
fragments include the Win motif, required for binding to WDR5, as well as the SET
domain, responsible for catalyzing histone methylation. Studying these larger
fragments would bring us one step closer in mimicking in vivo conditions for our
in vitro experiments. Also, we can use these proteins along with the members of
the SET1 family core complex to look at the stability of the complexes formed by
the SET1 proteins. By immobilizing SET1 fragments onto biosensors and allowing
them to interact with combinations of analytes we can study the preference for the
formations of different sub-complexes as well as their stabilities.
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